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Abstract 
Pateamine A is a cytotoxic terpenoid isolated from the marine sponge Mycale hentscheli 
that induces apoptosis in mammalian cell lines and is growth inhibitory to yeasts and fungi, 
yet shows no inhibitory action in prokaryotes. The targets of pateamine in mammalian cell 
lines were isolated and identified using a combination of affinity chromatography and mass 
spectrometry, putative targets included the DEAD-Box helicase eIF4A family of proteins, 
β-tubulin and actin. In vitro assessment of tubulin and actin polymerization showed 
pateamine was able to affect them only at high micromolar concentrations, whereas the 
effect on eIF4A in vitro was shown by others to occur at nanomolar concentrations. 
Additionally, pateamine was shown to inhibit cap-dependent protein synthesis in vivo, 
suggesting eIF4A as a primary target. The generation of a pateamine resistance-conferring 
mutation in the yeast eIF4A encoding gene TIF1, suggested further that eIF4A is a primary 
target in both mammalian and yeast cells, and allows the speculation of the position of the 
binding site for pateamine on the N-terminal lobe of eIF4A and the proposal of potential 
covalent interaction between this drug and its target. Given the size of the DEAD-Box 
helicase family, all of which share considerable homology with the eIF4As, FAL1 
especially which is essential for rRNA maturation, a chemogenomic screen was performed 
in an attempt to establish the breadth of functional interactions of pateamine. The results of 
hierarchical clustering of these screen results suggest that pateamine has a mode-of-action 
distinct from other compounds screened previously, despite its effect on protein synthesis 
it failed to cluster with any other protein synthesis inhibitors regardless of their separate 
mechanisms, though, as a class, protein synthesis inhibitors were not found to form a 
discrete cluster in any of the variations of cluster analysis performed. Functional analysis, 
by GO term enrichment, of the genes whose deletions are hypersensitive to pateamine 
indicates that deletions of genes involved in numerous aspects of RNA metabolism affect 
pateamine sensitivity, however clear results regarding the involvement of FAL1 or any 
other non-eIF4A target in pateamine’s mode-of-action were not found. 
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1 Introduction 
 
1.1 Drug mechanism and mode-of-action 
A bio-active small molecule, or drug, is a chemical entity that elicits a specific response in 
a biological system. While a vast array of chemical entities are able to elicit a response in 
biological systems only a subset of these can be considered drug-like compounds due to 
the lack of specific responses elicited by other compounds. For instance, many organic 
solvents may have effects in biological systems that are non-specific, e.g. methanol causes 
dehydration, increased permeability of the plasma membrane and non-specific 
cross-linking of cellular proteins. While this is an effect on a biological system it cannot be 
called a specific one. In the 1870’s Paul Erlich proposed that specific staining by chemical 
dyes occurs due the interaction between the dye and a cellular structure and John Newport 
Langley proposed there was some structure in nerves capable of specifically interacting 
with pilocarpin and atropine (Maehle, Prull et al. 2002). This is what is meant by a specific 
response, that is, those responses that are mediated by the physical interaction between a 
small molecule and a specific biological structure or structures. 
 
In general, drug-like compounds interact with cellular macromolecules: proteins, nucleic 
acids, carbohydrates and lipids, with the majority of characterized bio-active compounds 
targeting proteins. In the case of proteins these interactions are usually non-covalent, 
mediated by hydrogen bonds, electrostatic, hydrophobic and van der Waals interactions 
between the small molecule and the target. The interaction between a drug and its target 
(especially those that are protein targets) can be viewed in a similar way to the relationship 
between enzymes and their substrates. An initial binding event occurs between a portion of 
the compound and the target, which become a higher affinity interaction according to the 
2 
 
“induced fit” theory (Koshland 1994). That is after the initial binding, both the small 
molecule and the target protein induce a conformational change in each other that leads to 
greater complementarily between the compound and its binding site on the protein. This is 
exemplified in the case of small molecule chaperones that allow correct protein folding of 
a nascent polypeptide in situations where the protein is likely to fold incorrectly (Arakawa, 
Ejima et al. 2006). 
 
Covalent interactions between small molecules and proteins also occur but they are much 
less common and often involve nucleophilic attack by an enzyme on reactive electrophilic 
centres of the small molecule. For instance the epoxide moiety is fumagillin attacked by a 
nucleophilic amino acid side chain present at its binding site on methionine 
aminopeptidase 2 (Sin, Meng et al. 1997). Often the nucleophilic attack is an integral part 
of the mechanism by which that enzyme performs its function, for instance irreversible 
protease inhibitors (Sabido, Tarrago et al. 2009). However, covalent drug-protein adducts 
can be formed with non-enzymatic protein targets also. Bioactive molecules targeting 
lipids tend to do so via non-covalent interactions also, e.g. nystatin interacts with ergosterol 
reversibly (Bastide, Jouvert et al. 1982; Richman-Boytas and Parks 1989). However, 
irreversible interactions with DNA are common with agents that target it specifically, for 
instance DNA alkylating agents (Vanduuren 1988). While most bioactive compounds can 
be separated into those that target proteins, nucleic acids or lipids exclusively, on occasion 
a compound may target a non-protein structure through a protein that acts directly on the 
that target, as is the case with etoposide where the target could viewed as being the 
complex of topisomerase II and DNA (Liu, Hsiung et al. 1994). 
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The identity of the structure targeted by a small molecule and how the function of that 
target is perturbed by the compound constitutes that compound’s mode-of-action or 
mechanism. These terms are commonly used interchangeably however there is a subtle 
difference between them. The mode-of-action of a compound is often a broad 
categorization, for instance, DNA alkylating agents, protein synthesis inhibitors, and 
cholesterol lowering drugs. These classifications can be useful to describe what the 
compound does in broad terms, but they often do not contain enough information to say 
exactly how this effect is achieved. The mechanism of a drug on the other hand specifies 
the cellular structure targeted by the compound, how its function is changed and how that 
alters the performance or the phenotype of the biological system in the presence of the 
compound; all of the information required to describe exactly what the compound does. 
 
Understanding detailed mechanisms of a compound’s action is becoming more important 
as the search for specific drugs with high efficacy and low incidence of side effects 
increases. In the case of therapeutic drugs this knowledge may lead to the rational or semi-
rational design of new drugs that emulate the action of previous drugs while potentially 
having fewer side-effects or greater efficacy. This is especially true for antibiotic, anti-
fungal, anti-viral and anti-neoplastic drugs that are particularly prone to a loss of efficacy 
due to the development of resistance by the intended target (White, Marr et al. 1998; 
Walsh 2000; Gottesman 2002; Sarafianos, Hughes et al. 2004). Knowledge of the target 
and mechanism of a drug can aid in the understanding of how side-effects occur as well as 
the design of the drugs with fewer side effects. Side-effects, as with the desired effect of a 
drug, are also mediated by interaction with cellular structures, however it must be 
ascertained whether the side-effects noted are due to the interaction with more than one 
target, or with one target whose exact function depends on the environment in which it 
exists, e.g. difference in function in different cell types. It is becoming more apparent that 
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the function, in the context of the cell, of any one gene, or the protein or RNA it encodes, 
is dependent on the other genes that are being expressed in that cell type, therefore the 
downstream consequence of perturbing one target in different cell types may well differ.  
 
In the case of non-therapeutic compounds, e.g. toxins, mechanistic knowledge of their 
action can yield highly useful biological probes that can lead to a greater understanding of 
the function of their targets. This aspect is becoming particularly important with the rise of 
chemical genetics which, in part, attempts to understand biological phenomena by 
identifying compounds that alter the occurrence of that phenomenon. The premise of the 
chemical-genetic approach is that small molecules can emulate genetic mutations, that is, 
an inhibitor of an enzyme is functionally analogous to a loss of function mutation in the 
gene that encodes that enzyme (Piggott and Karuso 2004). The reverse also holds, where 
some mutations can cause an increase in the activity of the protein product. Small 
molecules can also be found to stimulate the function of their target; admittedly they are 
underrepresented in the literature but that may be due to the manner in which drugs have 
been sought rather than the likelihood of their existence. 
 
This is analogous to classical reverse genetics approaches, where mutants are sought with 
altered phenotypes. Once found, the mutation is identified and the role of that gene in the 
phenotype of interest is characterized. Chemical genetics can greatly accelerate the 
discovery of compounds that alter phenotypes, but linking this back to the gene/targets 
responsible for this alteration remains a significant challenge. When approaching gene 
function from a purely genetic angle the information is retained in the sequence of DNA, 
on the other hand the conditional mutation that a drug or bioactive compound emulates is 
transient and unable to be amplified, and is therefore more difficult to characterize.  
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However the advantage of using chemical mimics of genetic mutations is that they allow 
an assessment of temporal gene function; when the interaction is reversible they can be 
added, removed and titrated; and the timing of addition can be altered. Due to this 
emulation of conditional mutants, bioactive compounds allow access to essential gene 
functions that are difficult to study in a purely genetic manner. From a systems biology 
point of view the broader the phenotype that a compound induces the more can be learned 
about its target, also the more different phenotypes induced by the compound the better, as 
this allows for a more complete assessment of the targets function.  
 
Hence, small molecules can be used to study the function of their target in a complete 
biological system, and the consequence of altering that function, but this requires 
knowledge of their target. Another way in which small molecules can illuminate target 
function is by understanding the nature of the physical interaction between the small 
molecule and its target. The function of a protein is defined by its structure, which is in 
turn defined by its amino acid sequence. Biologically active small molecules physically 
interact with proteins and change their function. This must mean that small molecule 
binding alters either protein structure, for example through altering conformation or 
shifting the balance within ensembles of conformations, or its ability to associate with 
other proteins or substrates, in the case of enzyme inhibitors. Therefore, an appreciation of 
the way in which the protein structure changes upon small molecule binding should 
provide evidence of the structure-function relationship of that protein.  
 
By linking the target of a compound with phenotypes that treatment with that compound 
induces or suppresses, biologically active small molecules are potentially incredibly 
powerful tools in understanding how biological systems work from the molecular to the 
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cellular level. However, without an understanding of the nature of these effects at both a 
molecular and cellular level, their use as biological probes is limited, as are the inferences 
that can be drawn by their use. It is often the case, however, that there is a little knowledge 
concerning the action of the small molecule on its target and a little knowledge concerning 
the function of that target so while it is tempting to try and define one without the other, it 
is inevitable and advantageous that knowledge of the two will co-occur. 
 
1.2 Pateamine 
Pateamine A (pateamine) is a novel terpenoid natural product isolated in the early 1990’s 
from samples of the marine sponge Mycale hentscheli collected off the south-west coast of 
the South Island of New Zealand (Figure 1.1). The authors used a bioassay guided isolation 
approach to identify a MeOH/CH2Cl2 (19:1) fraction that was ultimately shown to contain 
pateamine A (pateamine B and C have also been isolated, however they are present in 
minor amounts, and differ from pateamine A only in the substitution of the tertiary amine 
at C17). Purified pateamine showed potent growth inhibitory effects on the fungi Candida 
albicans, Trichophyton mentagrophytes and Cladosporium resinae and cytotoxicity in the 
murine leukemic cell line P388 (IC50 = 0.15 ng/ml), but was significantly less potent in 
confluent BSC cells (IC50 ~300ng/ml) and inactive against prokaryotes tested This 
suggests that pateamine A may be a eukaryotic specific toxin with selectivity towards 
rapidly dividing cells (Northcote, Blunt et al. 1991).  
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Figure 1.1 The structure of pateamine A. 
 
The total synthesis of pateamine was reported in 1998 (Romo, Rzasa et al. 1998) and 
synthetic pateamine was used to show a potential immunosuppressive effect in a mouse 
skin graft rejection assay, where it afforded tolerance of the graft for 15 days after 
implantation, compared to 10 days for the clinically used immunosuppressive cyclosporine 
A. In culture pateamine shows at potent (IC50 = 2.6 nM) effect on T-cell activation in a 
mixed lymphocyte reaction (MLR) with negligible cytotoxicity (LCV (lymphocyte 
viability assay)/MLR ratio > 1000), suggesting that pateamine may possess 
immunosupressive properties similar to that of cyclosporine A.  
 
Further, with the use of a luciferase reporter assay, it was shown that pateamine 
specifically inhibits the transcription of the pro-inflammatory cytokine interleukin 2 (IL-2) 
in Jurkat T-cells after stimulation with phorbol-12-myristate-13-acetate (PMA) and 
ionomycin. During the total synthesis a small number of derivatives were made that 
showed both the macrocycle and the trienylamine tail were required for the inhibitory 
nature of pateamine to the IL-2 promoter but that the primary amine withstood 
derivatisation (both N-dexamethasone and N-Boc derivatives were active in the assay), 
suggesting the primary amine may be a site of tolerable modification. Later the same 
authors confirmed a specific effect on the Jurkat T-cell IL-2 promoter activity using 
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RT-PCR and expanded on the range of derivatives made (Romo, Choi et al. 2004). This 
further structure-activity relationship study reaffirmed the tolerance to C3 primary amine 
derivatisation, showing that it could also be completely removed along with the nearby C5 
methyl without a significant loss of activity. On the other hand analogues replacing the 
C19 - C20 alkene with an alkyne were inactive unless combined with a dienyl tail with 
aterminal methyl ether instead of the tertiary amine. Interestingly, the terminal methyl 
ether derivative with the original conjugated diene at C19 - C22 was not active. 
 
Further investigation of the toxic effects of pateamine to mammalian cells revealed the 
cytotoxic effects of pateamine are due to the induction of apoptosis (Hood, West et al. 
2001). In this study the sensitivities of two tumourigenic cell lines (SY5Y and H441 cells) 
were compared to that of a non-tumourigenic cell line (LLC-PK1). Contrary to the original 
discovery and isolation report by Northcote et al. where there seemed to be selective 
toxicity towards the tumourigenic cell line greater than 2000-fold compared to confluent 
cells, there was no significant difference between the IC50 values of the tumourigenic and 
non-tumourigenic cell lines in the MTT viability assay. However all cell lines tested where 
shown to undergo DNA cleavage after a 24 hour treatment of pateamine, suggesting the 
induction of an apoptotic pathway. Further experiments in the IL-3 dependant 32D cells 
confirmed the induction of apoptosis by concentration dependent DNA cleavage, and early 
Annexin V binding to the cell surface.  
 
Annexin V binds to phosphatidyl serine, normally phophatidyl serine is localized almost 
exclusively to the inner leaflet of the plasma membrane, an asymmetry maintained by 
flipase enzymes. In early apoptosis the loss of this asymmetry precedes a loss of membrane 
integrity, compared to necrotic cell death where the two occur simultaneously (Guimaraes 
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and Linden 2004). Pateamine causes a loss of phosphatidyl serine asymmetry, indicated by 
Annexin V binding to the cell, before the loss of membrane integrity, indicated by the 
entry of the fluorophore propidium iodide into the cell. The active analogue DMDA-
pateamine was also found to be approximately 1,000-fold less potent in its ability to 
significantly alter the level of intracellular ATP in IMR-90 cells that had been induced to 
enter quiescence by contact inhibition and serum deprivation (Kuznetsov, Xu et al. 2009), 
compared to the concentrations that induced cell death in actively dividing cells. This was 
interpreted by the authors as it being a specific cytotoxin in non-dividing cells, though it 
must be noted that both of the assays that suggest this specificity are performed with cells 
grown to very high density, which will alter drug sensitivity in itself. 
 
The potential selectivity of pateamine towards transformed cells was further investigated 
with use of 32D cells transfected with plasmids that express the p21
ras
 and bcr/abl 
oncogenes (Hood, West et al. 2001). The sensitivity of the transfected and non-transfected 
cells to pateamine was tested with the tetrazolium salt MTT. Respiring cells reduce the 
yellow MTT to a blue formazan product, making this a common viability assay. As seen 
previously, pateamine showed little selectivity towards the cells transfected with either of 
the oncogenes in the MTT assay. However, when cell viability was assessed with trypan 
blue (a dye that is actively effluxed from living cells), statistically significant differences 
were seen between the transfected and non-transfected cells at concentrations above 
10 nM, an effect seen with the protein synthesis inhibitors puromycin, cycloheximide and 
mycalamide as well as the DNA damaging agent Ara-C. In line with the trypan blue assay 
results the p21
ras
 and bcr/abl transfected 32D cells were more sensitive to pateamine with 
respect to Annexin V binding, suggesting these cell lines were more sensitive to apoptosis 
induction by pateamine.  
10 
 
The induction of apoptosis occurs through two major pathways, the extrinsic pathway 
involves activation of membrane bound “death receptors” and the activation of the protease 
caspase 8, which in turn activates downstream caspases ultimately leading to DNA 
cleavage and the formation of apoptotic bodies. The intrinsic pathway on the other hand 
involves the leakage of cytochrome C from the mitochondria, and the activation of caspase 
9, which then in turn activates downstream effector caspases. It has been shown the 
pateamine causes the activation of caspase 9 which peaks two hours after exposure and 
quickly declines, followed a number of hours later by the activation of caspase 8 (Miller, 
Rouwe et al. 2004). Cross talk between the intrinsic and extrinsic pathways is well 
established and is thought to be an aspect of the commitment to the completion of 
apoptosis once induced (Strasser, O'Connor et al. 2000). 
 
Miller, Rouwe et al. (2004) also readdressed the potential immunosuppressive effects of 
pateamine using both the aforementioned mixed lymphocyte reaction and also T-cells 
directly stimulated by an anti-CD3 antibody and measuring interferon γ (IFNγ), another 
indicator of T-cell activation. Where Romo et al used the trypan blue exclusion assay as a 
measure of viability Miller et al. used Annexin V binding to directly assess the early 
activation of apoptosis rather than membrane integrity, which is still maintained during 
early apoptosis. The IC50 values for 
3
H-thymidine incorporation (T-cell proliferation), 
Annexin V binding (apoptosis) and IL-2 production for pateamine treated MLR were 
indistinguishable (IC50 ~0.5 nM). Furthermore pateamine failed to selectively inhibit the 
production of IFNγ without causing an equivalent growth inhibition according to the MTT 
assay. 
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In summary, pateamine A is a novel marine natural product that is potent inducer of 
apoptosis in the majority of mammalian cell lines tested, with arguable selectivity towards 
transformed cell lines. While it seems that pateamine specifically decreases the 
transcription of the IL-2 gene in Jurkat T-cells, it does not seem to decrease the production 
of the IL-2 protein by isolated splenocytes. Despite the discrepancies that exist in the 
literature regarding the exact biological activities displayed by pateamine, and perhaps 
because of them, establishing a mechanism or mode-of-action by which these seemingly 
diverse effects occur will provide functional evidence for the role of the target of 
pateamine in apoptosis and IL-2 promoter activity. 
 
1.3 The eIF4A family of DEAD-box helicases 
The super-family of RNA DEAD-box helicases is highly conserved amongst all species 
analyzed to date. While members of this family exist in bacteria and archea they are most 
prevalent in eukaryotic organisms, where they are involved at almost every step of RNA 
metabolism including, but not limited to pre-mRNA splicing, nuclear export, translation 
initiation, mRNA decay, ribosome biogenesis and mitochondrial gene expression 
(Hernandez and Vazquez-Pianzola 2005). The S. cerevisiae and H. sapiens genomes 
encode 25 and 38 DEAD-box proteins respectively, indicating just how ubiquitous these 
proteins are. This super-family is defined by numerous distinct enzymes that share 
significant sequence and structural homology, yet are exquisitely specific to the processes 
in which they function. The name derives from the presence of a highly conserved 
D-E-A-D motif which is required for ATP binding and hydrolysis. Specifically, the eIF4A 
family of proteins are the archetypal DEAD-box RNA helicases representing the minimal 
sequence required for inclusion in the DEAD-box super-family. All DEAD-box proteins 
are ATP-dependent RNA helicases and RNA-dependent ATPases, whereby the energy 
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from ATP hydrolysis is used to unwind RNA secondary structure or separate 
complimentary RNA strands (Linder 2006).  
 
The members of eIF4A family represent the two major mechanisms by which DEAD-box 
RNA helicases function, that is, as a processive helicase, melting RNA secondary 
structure, or as a RNA anchor where ATP hydrolysis is linked to the release of RNA. They 
are essential for translation initiation in yeast (Linder and Slonimski 1989) and humans 
(Gingras, Raught et al. 1999) (yeast eIF4A also known as TIF1/2p and eIF4AI/II 
respectively), non-sense mediated mRNA decay in humans (eIF4AIII) (Ferraiuolo, Lee et 
al. 2004), and rRNA processing in yeast (Fal1p) (Kressler, de la Cruz et al. 1997). In 
humans and yeast, eIF4A has an identical role in translation initiation. It is recruited to the 
5`-untranslated region (5`-UTR) of mRNA, soon after nuclear export, by the scaffolding 
protein, eIF4G, which directly interacts with both the 5`-UTR and the 7-methyl guanine 
cap-binding protein eIF4E. It has been shown the eIF4A is able to melt mRNA secondary 
structure in the 5`-UTR facilitating the formation of the 43S pre-initiation complex and 
ultimately ribosome recruitment and scanning to the start codon (Sonenberg and 
Hinnebusch 2009), and that the translation of mRNA with a greater degree of secondary 
structure in the 5`-UTR has a higher requirement for the activity of eIF4A, both in vivo and 
in vitro (Svitkin, Pause et al. 2001). 
 
While translation initiation is essentially identical in yeast and humans subtle differences 
exist, for instance in humans eIF4A exists in two forms, free and bound to eIF4G which is 
bound to eIF4E, the three together known as the eIF4F complex, it is thought that eIF4A 
may cycle through this complex as a part of its mRNA unwinding function. In yeast only 
the free, unbound form is present, rather than a stable eIF4F complex consisting of eIF4E, 
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eIF4G and eIF4A, that is isolatable by 7-methyl guanosine affinity chromatography in 
mammalian cells, only eIF4E and eIF4G can be isolated in the way from yeast (Lanker, 
Muller et al. 1992). 
 
Figure 1.2 The role of eIF4A in cap-dependent translation initiation. The 7-methyl guanosine 
cap is bound by eIF4E which interacts with eIF4G, which in turn recruits eIF4A that unwinds mRNA 
5`-UTR structure with the aid of eIF4B. Figure adapted from McCarthy, 1998. 
 
This phenomenon may be related to the fact the human eIF4G1 contains two eIF4A 
binding sites (Korneeva, Lamphear et al. 2001), compared to the yeast eIF4G which has 
one (Li, Belsham et al. 2001), and may also be related to the observation that most yeast 
transcripts have relatively short and unstructured 5`-UTR (McCarthy 1998). In both 
organisms eIF4A is the most abundant translation initiation factor (von der Haar and 
McCarthy 2002), and its helicase function is augmented by the RNA binding protein eIF4B 
(Altmann, Wittmer et al. 1995). In isolation eIF4A is a non-processive, bi-directional RNA 
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helicase, however, as a part of the eIF4F complex it becomes processive and 
uni-directional, in the 5` - 3` direction (Rogers, Richter et al. 2001). 
 
Two distinct mechanisms of translation initiation exist, the aforementioned cap-dependent 
mechanism, which relies on the 5`-methyl guanine cap of mRNA being bound by the 
eIF4E component of the eIF4F complex and is dependent on the activity of eIF4A, and a 
cap-independent mechanism. This second mechanisms is dependent on the presence of 
internal ribosome entry sites (IRES) 3` to the cap structure, and often a considerable 
distance from the cap. These IRES allow the ribosome to being loaded onto the transcript 
independent of the 5`-UTR and cap and have a variable requirement for eIF4A (Jackson, 
Hellen et al. 2010). IRES have been found in a variety of transcripts, particularly those 
derived from viral genomes, whereby the host cell’s translation machinery is re-routed to 
translate viral mRNA by compromising the eIF4F complex, particularly through protease 
mediated partial cleavage of the eIF4G component (Holcik and Sonenberg 2005). 
However, they have also been found in mRNA encoding eIF4G itself and those encoding 
anti-apoptotic proteins such as X-linked anti-apoptotic protein (XIAP), amongst others 
(Johannes and Sarnow 1998). In yeast IRES-containing transcripts are far less prevalent 
but have been found in genes that are involved in filamentous growth induced in response 
to nutrient starvation, though it seems there are distinct mechanistic differences from their 
mammalian, insect and viral counterparts (Gilbert, Zhou et al. 2007). 
 
In contrast to the role of eIF4AI and II in mammalian translation initiation, the closely 
related protein, eIF4AIII functions in the non-sense mRNA decay (NMD) pathway, and is 
unable to compensate for eIF4AI/II in vitro or in vivo (Ferraiuolo, Lee et al. 2004). NMD 
is an mRNA decay pathway responsible for the degradation of transcripts containing a 
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premature termination codon (PTC). It is thought this mechanism has evolved to prevent 
the translation of PTC containing transcripts that would produce truncated proteins that 
could possibly have deleterious, dominant-negative function thereby compromising the 
function of the pathways they participate in. These PTCs occur as a consequence of genetic 
mutations and aberrant splicing reactions and are recognized by the exon-exon junction 
complex (EJC) and the translational machinery (Hentze and Kulozik 1999).  
 
The EJC is deposited on exon-exon junctions during splicing and are displaced by the 
translocating ribosome during the pioneer round of translation (Le Hir, Izaurralde et al. 
2000). When a PTC is present more than 50 – 55 nucleotides upstream of the final 
exon-exon junction, that transcript is marked for degradation. The EJC is composed of 
eIF4AIII, which acts as the mRNA anchoring component, and the proteins Y14, Magoh 
and MLN51 and serves as a recruitment point for other proteins involved in the 
degradation of the transcript (Shibuya, Tange et al. 2004). When a PTC is present the EJC 
signals to the ribosome via Upf3 together with Upf1 and Upf2, and the transcript is 
degraded (Figure 1.3). Although the mechanistic details concerning the deposition of the 
EJC are yet to be fully resolved it has been found to involve phosphorylation of Upf1 
(Singh, Jakob et al. 2007). eIF4AIII acts as the anchor for this complex by binding the 
mRNA at the exon-exon Junction in an ATP-dependent manner. Its intrinsic ATPase 
activity is inhibit by the binding of Y14-Magoh and MLN51 which bind to the interface of 
the two lobes of eIF4AIII locking it in a position that prevents in from hydrolyzing the 
bound ATP (Nielsen, Chamieh et al. 2009). In the absence of a PTC the translocating 
ribosome disrupts this interaction, allowing ATP hydrolysis and the dissolution of the EJC 
complex (Ishigaki, Li et al. 2001).  
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Figure 1.3 Non-sense mediated decay of mRNA. During splicing, the EJC complex (of which 
eIF4AIII is a core member) is deposited on exon-exon junctions. In the absence of a premature 
stop codon (PTC), the EJC is displaced by the ribosome during the pioneer round of translation 
and the mRNA is translated. If a PTC is present 50-55 nt upstream of the final exon-exon junction 
the EJC signals to the ribosome via Upf3 together with Up1 and Upf2, and the transcript is 
degraded. 
 
In contrast to the NMD pathway present in higher eukaryotes, the pathway in yeast does 
not involve an EJC, since the majority of yeast transcripts do not contain introns and those 
that do contain only one (Conti and Izaurralde 2005). Instead, yeast NMD involves the 
sensation of a PTC by the translation machinery itself and does not involve the closest 
yeast homologue of eIF4AIII known as Fal1p. This protein has also been shown not to 
compensate for a loss of yeast eIF4A (Tif1/2p) but functions in small ribosome subunit 
biogenesis, specifically the processing of the 35S pre-rRNA and the production of the 18S 
rRNA (Kressler, de la Cruz et al. 1997). Very little is known about the exact mechanism by 
which Fal1p is recruited to the 35S pre-rRNA transcript or any protein-protein interactions 
that it may take part in. While there are, for Fal1p, database interactions these are derived 
from large-scale studies and have not been validated. It is unclear whether the role of Fal1p 
17 
 
in 35S pre-rRNA processing involves RNA unwinding activity, as in the case of eIF4AI/II 
and Tif1/2p or simply RNA binding activity as in the case of eIF4AIII. 
 
1.4 Eukaryotic translation and protein synthesis inhibitors 
Eukaryotic protein translation can be divided into three separate and distinct phases: 1. 
Initiation; 2. Elongation; 3. Termination. Each phase is characterized by a specific 
sequence of events and small molecule inhibitors have been found that specifically inhibit 
each of initiation and elongation, and others that mimic termination. 
 
Translation initiation is the phase which involves events prior to the positioning of the 80S 
ribosome at the AUG start codon. In eukaryotic organisms there exist two separate 
mechanisms for translation initiation: cap-dependent and independent, as detailed in 
Section 1.4. In yeast the predominant mechanism is cap-dependent initiation though there 
have been some IRES controlled transcripts found (Gilbert, Zhou et al. 2007). Subsequent 
to the formation of the eIF4F complex and melting of mRNA secondary structure by 
eIF4A and eIF4B, a pre-assembled 43S pre-initiation complex, consisting of Met-tRNAi 
(initiator Met-tRNA) and eIFs 1, 1A, 2, 3 and 5, is recruited to the transcript and scans to 
the AUG start codon, where base-pairing occurs between the start codon and the anti-
codon of the Met-tRNAi component. The Met-tRNAi is anchored to the rest of the 
complex by eIF2 with GTP bound, recognition of the start codon causes the scanning to 
halt, the hydrolysis of GTP and the loss of other associated eIFs, which allows the large 
(60S) subunit to associate and form the complete 80S ribosome ready to accept the 
appropriate aminoacyl-tRNA into the A-site (Kapp and Lorsch 2004; Sonenberg and 
Hinnebusch 2009). 
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Pateamine is the first characterized specific inhibitor of cap-dependent translation 
initiation, subsequently the inhibitors silvestrol (Cencic, Carrier et al. 2009) and 
hippuristanol (Lindqvist, Oberer et al. 2008) have also been shown to inhibit eIF4A by 
stabilizing and destabilizing the eIF4A-RNA respectively, and hence inhibiting cap-
dependent translation initiation in mammalian cells. Others inhibitors of initiation have 
also been characterized, for instance 4EGI-1 binds to mammalian eIF4E preventing it from 
interacting with eIF4G (Moerke, Aktas et al. 2007), ribavirin on the other hand mimics the 
7-methyl guanosine cap structure of mRNA preventing the association of eIF4E mRNA 
(Kentsis, Topisirovic et al. 2004), it has recently been suggested that the 
apoptosis-inducing compound resveratrol may also target eIF4A (Lomenick, Hao et al. 
2009). It can be said that rapamycin also inhibits translation initiation, but it does so 
indirectly by inhibiting TOR in mammalian and yeast cells, the consequence of this is the 
phosphorylation of numerous translation initiation factors, preventing cap-dependent 
translation initiation indirectly (Brazelton and Morris 1996; Crespo and Hall 2002). There 
has been considerable interest in the use of specific cap-dependent translation inhibitors as 
anti-neoplastic drugs given the over-expression of numerous eIF4F components in a 
number of cancers (Lindqvist and Pelletier 2009), and the role of translation initiation as 
the major point of translational regulation (Sonenberg and Hinnebusch 2009). As of yet 
there are no characterized inhibitors of the translation of transcripts controlled by 
eIF4A-independent IRES. 
 
The formation of the 80S ribosome positioned over the AUG start codon marks the end of 
initiation and the beginning of elongation, where polypeptide chain elongation occurs. The 
80S ribosome has three separate sites, known as the acceptor (A) site which accepts 
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incoming aminoacylated tRNA bound by the eukaryotic elongation factor 1A (eEF1A), the 
peptidyl (P) site, which is the site of peptide bond formation a between the nascent 
polypeptide chain and the incoming amino acids, and the exit (E) site where deacylated 
tRNA are allowed to leave after the peptidyl transferase reaction (Figure 1.4). The catalysis 
of the peptide bond formation only occurs if the incoming tRNA has an anti-codon 
complementary to the mRNA codon at the A-site. Only after the tRNA and mRNA are 
translocated to the P-site is another aminoacylated-tRNA allowed to bind to the A-site. The 
release of the incoming aminoacylated tRNA by eEF1A occurs prior to the hydrolysis of 
its bound GTP, which only occurs if the anti-codon base-pairs with the codon at the A-site. 
The release of the deacylated tRNA from the E-site occurs as a result of the translocation 
of the ribosome to the next codon, this step is catalyzed by eEF2 with the hydrolysis of 
GTP. In yeasts and fungi there is an additional elongation factor (eEF3), which actively 
promotes the release of the deacylated tRNA from the E-site, it has been suggested that this 
activity is intrinsic to the ribosome of other eukaryotes (Kapp and Lorsch 2004). 
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Figure 1.4 The 80S ribosome. This cartoon depicts the three main sites within the 80S ribosome: 
The acceptor (A) site, which accepts incoming aminoacylated tRNA bound by eEF1A; the peptidyl 
(P) site which catalyses the formation of the peptide bond between the incoming amino acid and 
the polypeptide chain; and the exit (E) site, where deacylated tRNA is able to leave the ribosome. 
 
Protein synthesis inhibitors that target translation elongation are by far the most 
enumerated and can be divided into those that target the ribosome directly, and those that 
directly target elongation factors. Those inhibitors that target the ribosome do so by 
selectively binding to one of a number of different positions (Pestka 1971). Cycloheximide 
for instance has been shown to directly interact with the ribosome (Stocklein and 
Piepersberg 1980), preventing translocation and stabilizing translating ribosomes on 
mRNA (Obrig, Culp et al. 1971). It has been proposed that this occurs via an interaction 
with the ribosomal E-site and the deacylated tRNA positioned there (Pestova and Hellen 
2003; Schneider-Poetsch, Ju et al. 2010). In contrast anisomycin inhibits the peptidyl 
transferase reaction (Grollman 1967) by interacting with the A-site (Carrasco, Barbacid et 
al. 1973), and emetine which binds to the small subunit, also stabilizing the 
ribosome-mRNA interaction (Carrasco, Jimenez et al. 1976). Other inhibitors found to 
target the ribosome include streptovitacin (Bennett, Ward et al. 1965), verrucarin (Cannon, 
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Jimenez et al. 1976) and hygromycin B (Gonzalez, Jimenez et al. 1978) all of which inhibit 
polypeptide elongation. Didemnin B and sordarin on the other hand have been shown to 
inhibit elongation by targeting eEF1A (Crews, Collins et al. 1994) and eEF2 (Capa, 
Mendoza et al. 1998), respectively. 
 
The termination phase of translation results in the release of the polypeptide from the 
ribosome, this is facilitated by the eukaryotic release factor 1 (eRF1) which promotes the 
hydrolysis of the peptidyl-tRNA peptide bond when one of the three stop codons is present 
at the A-site (Traut and Monro 1964). To date there are no known inhibitors of the 
termination phase of translation, however, puromycin has been shown to cause premature 
polypeptide chain termination by mimicking the incoming aminoacylated-tRNA and being 
incorporated into the nascent polypeptide (Rosenbloom, Endo et al. 1976). 
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1.5 Aims and objectives  
The aim of this study is to identify the cellular targets of pateamine and to investigate the 
breadth of their functional specificity with respect to the phenotypes that this compound 
has been previously shown to induce. To this end, various complementary approaches are 
to be employed: 
 Initially, potential targets in mammalian cells will be identified using affinity 
chromatography with a pateamine derivatized affinity matrix.  
 The model organism Saccharomyces cerevisiae will be employed to isolate and 
characterize a pateamine-resistant mutant.  
 The recently developed method of chemogenomic profiling using the 
Saccharomyces cerevisiae gene deletion libraries will be employed to investigate 
the breadth of target specificity of pateamine. 
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2 Affinity isolation of the cellular target of pateamine 
 
2.1 Introduction 
Affinity chromatography is one of the oldest and simplest methods of determining 
potential target prfoteins for a biologically active compound. This generally involves 
coupling the compound to a solid phase support, passing a cell lysate or tissue homogenate 
by the resin and identifying any proteins selectively retained (Leslie and Hergenrother 
2008). Early application of this approach was centered on the use of metabolite analogues 
for the efficient enzyme purification (Lerman 1953; Arsenis and McCormick 1964; 
McCormick 1965; Arsenis and McCormick 1966), the first use of affinity chromatography 
to determine a drug target was when the cis-trans peptidyl-prolyl isomerase FK506-
binding-protein was established as the target of the immunosuppressant FK506 (Harding, 
Galat et al. 1989). Prior to the advent of mass spectrometry-based protein identification 
and genome sequencing technology, direct identification of a protein by its sequence was 
generally limited to N-terminal degradation methods (Henzel, Watanabe et al. 2003), the 
success of the chemical proteomic approach to identifying drug targets is partially due to 
advances in this area. In the case of so-called promiscuous compounds, that is those which 
target a large structurally related protein family, such as protein kinases, or exhibit broad 
target selectivity, such as staurosporine, the combination of affinity chromatography and 
mass spectrometry has enabled an appreciation of the breadth of potential drug-target 
interactions (Knockaert and Meijer 2002; Godl, Wissing et al. 2003). The case of protein 
kinase inhibitors illustrates the point that many of secondary target interactions will be due 
to binding site conservation rather than the interaction with a entirely different site 
(Bantscheff, Scholten et al. 2009).  
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Compound immobilization occurs via the coupling of a reactive group, such as an amine or 
hydroxyl, on the compound with a functionalized affinity resin. Often the affinity resin is a 
carbohydrate, agarose or sepharose for instance, that has been somehow functionalized, a 
hydrophilic aliphatic linker is often added which terminates in a reactive functionality, 
such as an epoxide or N-succinamidyl ester (Leslie and Hergenrother 2008); functionalized 
latex beads have also been used (Shimizu, Sugimoto et al. 2000). Natural products are 
structurally diverse; often possessing numerous functional groups capable of coupling to 
the resin (Feher and Schmidt 2003), however, unless a group of congeners with differential 
biological activity is found, often limited structure-activity-relationship data is available 
with which to make an informed decision as to the most or least desirable site to couple to. 
If conjugation to a functional group abrogates binding to the target, affinity purification is 
impossible or misleading. In cases where coupling does not abrogate binding it is still 
important to distinguish between specific and non-specific protein binding. 
  
Non-specific binding that occurs due to interactions between proteins and the solid phase 
support, the hydrophilic linker or the reagent used to block any un-reacted functional 
groups on the resin can be controlled for by comparison of the proteins retained by a 
blocked resin with no drug coupled. However, non-specific binding may also be due to 
high abundance protein interacting with the compound with relatively low affinity, or even 
a protein interacting specifically or non-specifically with a protein interacting with the 
compound, such binding events are somewhat more difficult to control for. Where 
possible, the use of an inactive analogue derivatized resin is the most desirable control 
(Kaida, Motoyoshi et al. 2007), unfortunately this is often not possible for natural 
products. Due to the fact that the degree of retention of protein(s) by a compound derived 
affinity resin is a function of both, the abundance of the protein(s) and their affinity for the 
compound, relative protein abundance in the eluate is poor indicator of the strength of 
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interaction. While specific elution of proteins retained by the resin using free ligand 
provides an indication of the specificity of interaction it is not always possible owing to the 
high concentration often required and the low availability and aqueous solubility of a lot of 
bioactive natural products. For this reason, denaturing methods that presumably remove all 
protein non-covalently bound to the resin are used, this heightens the need for specificity 
controls. The strength of the interaction may be qualitatively assessed by observing protein 
retention subsequent to high or low salt washes. Alternatively a change in pH may aid in 
assessing specificity of an interaction but pH and salt concentration are by no means 
definitive. The recent use of stable isotope labeling of cellular proteins prior to affinity 
chromatography has aided in determining non-specific binding (Ong, Schenone et al. 
2009).  
 
The in vitro nature of affinity chromatography means the likelihood of purifying the 
cellular target of a compound using affinity chromatography is dependent upon the nature 
of the target itself and the nature of its interaction with the compound. It is desirable to 
mimic the cellular environment that the target exists in as closely as possible when 
generating the lysate or homogenate to be used, this is impossible for every potential target 
protein. For instance proteins localized to the lysosome experience a different pH to those 
in the cytosol, also in order to solubilize membrane proteins strong detergents are used that 
may disrupt the interaction between the compound and the target. Generally as a 
compromise the conditions, (pH, tonicity, etc) in the cytosol are mimicked in the 
homogenate which often means the exclusion of membrane bound proteins and those with 
pI ~ 7.4, regardless there are some examples of membrane proteins being retained by an 
affinity resin (Bantscheff, Eberhard et al. 2007; Rix, Hantschel et al. 2007). 
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Given these difficulties in establishing absolute target specificity, it is important to treat 
affinity chromatography only as a screen for potential target proteins which must be 
verified. Verification of a specific interaction can occur at the level of the physical 
interaction, for instance with the use of isothermal calorimetry, surface plasmon resonance 
(Oda, Owa et al. 2003), NMR, or more simply by more traditional receptor binding 
analysis (Crews, Collins et al. 1994). Evidence of a physical interaction and even an 
assessment of its strength directly, however, does not necessarily mean it is the target, 
there must be a functional consequence to the target of drug binding. This is most readily 
assessed using cell based assays of protein function, or purified target function in an in 
vitro assay, where available (Brehmer, Godl et al. 2004; Bach, Knockaert et al. 2005; 
Kaida, Motoyoshi et al. 2007). With the advent of siRNA technology it is possible to 
assess the role of the putative target of a compound in the phenotype the compound 
induces in a direct “genetic” fashion (Kotake, Sagane et al. 2007). For instance, if the 
compound of interest induces apoptosis, the siRNA mediated knockdown of its target is 
likely to do so also. This approach relies on efficient knockdown of the target protein by 
the siRNA (below the threshold required for an effect to be seen), but also relies on the 
protein being inhibited by the compound and that the presence of a drug-bound non-
functional target is analogous to decreasing target function lowering its abundance. Where 
this is not the case it may be possible to assess a change in drug sensitivity during 
knockdown as a form of target verification (Dong, Low et al. 2008). It must not be 
disregarded that the phenotypic effects of a drug may be due to the combinatorial 
perturbation of a number of functionally diverse targets, a scenario difficult to assess. 
 
An advantage of affinity chromatography over previous methods, which generally 
involved tracking a radio-labeled analogue of the compound of interest during a traditional 
biochemical fractionation, is that the target is physically isolated. Schreiber and co-workers 
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in the 1990’s used immobilized natural products to purify the cellular receptors for the 
aforementioned FK506; didemnin B, which inhibits elongation factor 1α (Crews, Collins et 
al. 1994) and palmitoyl protein thioesterase (Meng, Sin et al. 1998); trapoxin a potent 
DNA acetylase inhibitor (Taunton, Hassig et al. 1996); the irreversible proteasomal 
inhibitor lactacystin (Fenteany, Standaert et al. 1995); and myriocin a serine 
palmitoyltranferase inhibitor (Chen, Lane et al. 1999). Since then the same approach has 
facilitated the identification of cellular targets for numerous diverse natural products from 
a variety of sources (Piggott and Karuso 2004; Rix and Superti-Furga 2009; Cheng, Wong 
et al. 2010). Herein this approach coupled with MALDI-MS peptide mass fingerprinting is 
applied in order to identify putative cellular targets of pateamine in cultured human cell 
lines. 
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2.2 Aims and objectives 
The overall aim of this study is to identify the cellular protein targets of pateamine in 
human cells. To this end, a pateamine affinity resin has been developed to isolate candidate 
protein targets and mass spectrometry used to identify them. For putative target proteins it 
has been established whether pateamine has a functional effect on these potential targets 
in vitro and in cultured human cell lines. 
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2.3 Material and methods 
2.3.1 Materials 
Samples of pateamine were obtained from the natural product chemistry group of Peter 
Northcote in the School of Physical and Chemical Sciences, Victoria University of 
Wellington, and were reported to be of 95-98% purity as determined by NMR 
spectroscopy. Pateamine samples were tracked via individual batch number in order to 
account for anomalous results. Where possible, each study was completed with a single 
batch. Dry samples were stored at -20 °C until use whereby they were dissolved in 
methanol, ethanol or DMSO (dimethyl sulfoxide). All pateamine solutions were stored at 
-80 °C. 
 
2.3.2 Tissue culture 
HL-60, HeLa and SH-SY5Y cell lines were cultured according to standard tissue culture 
techniques (Freshney 2005). Briefly, all cell lines were grown in RPMI 1640 (GIBCO) 
medium supplemented with 10% foetal calf serum (FCS) and 1% Penicillin-Streptomycin 
(PenStrep) in a humidified incubator at 37 ºC and 5% CO2. HL-60 cells were passaged by 
ten-fold dilution in fresh medium when the cell density reached 2 x 10
5
 cells/ml. HeLa and 
SH-SY5Y cells were passaged after removal by trypsin treatment (2.5 mg/ml porcine 
trypsin in HBSS) after reaching 70% confluence, and were diluted ten-fold on re-seeding. 
 
2.3.3 MTT assay 
In all MTT assays (Mosmann 1983), pateamine was serially diluted two-fold in triplicate in 
RPMI 1640 medium, supplemented with 10% FCS and 1% PenStrep, in a tissue culture 
grade 96-well plate (Greiner Bio-One, Frickenhausen, Germany) to give a final range of 3 
30 
 
pM to 100 nM. For the non-adherent HL-60 cell line pateamine was prepared in 50 µl of 
medium at double the final concentration, then 5 x 10
3
 cells per well were added in 50 µl to 
each well and the plate was incubated for 48 h in a humidified incubator at 37 ºC and 5% 
CO2. For adherent HeLa and SH-SY5Y cell lines, 2 x 10
3 
or 5 x 10
3
 cells respectively were 
seeded in 100 µl of medium per well and were allowed to attach for 18 h, after which the 
medium was aspirated and replaced with 100 µl of fresh media into which pateamine was 
then serially diluted. The carrier control was 0.1% ethanol in RPMI 1640 supplemented 
with 10% FCS and 1% PenStrep. After 48 h incubation, 20 l of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/ml in PBS 
(10 mM sodium phosphate, 138 mM sodium chloride, 27 mM potassium chloride, pH 7.4)) 
was added and the plate returned to the incubator for 2 h, after which 100 µl solubilizer 
(10% SDS (sodium dodecyl sulfate), 45% THF (tetrahydrofuran)) was added and 
incubated overnight before measuring the absorbance at 570 nm using an automated plate 
reader (VersaMax, Molecular Devices, Sunnyvale, CA, USA). The IC50 value was 
determined using SigmaPlot Ver 10.0 (Systat Software Inc., Richmond, CA, USA) for 
each individual assay. The results from three independent assays were then averaged and 
standard errors propagated through standard methods. This procedure was performed with 
each new batch of pateamine received to assist with batch-to-batch comparison. 
Assessment of viability in the presence of the pan-caspase inhibitor z-VAD-FMK 
(Promega Corp., Madison, WI, USA) was performed as with the same concentration range 
of pateamine with 5, 10 or 50 µM z-VAD-FMK added, in this case maximum and 
minimum growth as well as IC50 value were calculated using SigmaPlot Ver 10.0 (Systat 
Software Inc.). 
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The ability of HeLa cells to recover after pateamine treatment and withdrawal was 
assessed with the MTT assay. Cells were exposed to 10, 50 or 100 nM pateamine in RPMI 
media with 2% FCS and 1% PenStrep for 0.25, 0.5, 1 and 2 h, after removal by aspiration 
the cells were washed with warm RPMI media with 10% FCS and 1% PenStrep and 
allowed to recover in the same fresh media. In a non-withdrawal control, the fresh media 
contained the same concentration as the initial exposure. Cells were allowed to recover for 
11 h in a humidified incubator at 37 ºC and 5% CO2, after which viability was assessed 
with the MTT reagent as above. 
 
2.3.4 Pateamine affinity resin generation 
A pateamine-substituted affinity resin was generated from epoxy-activated Sepharose 6B 
(GE Health Sciences, Little Chalfont, UK), which was prepared according to the 
manufacturer’s instructions. Briefly, 150 mg of resin was washed with 200 ml 
double-distilled water followed by 5 ml of methanol. The washed resin was re-suspended 
in 0.3 ml of methanol containing 13 mg pateamine and 2.5 µl (1.1 eq) triethylamine and 
incubated at 45 °C with shaking overnight. The resulting yellow resin was washed with 
three 1 ml aliquots of methanol, then three 1ml aliquots of double distilled water. To block 
any un-reacted epoxy groups, the resin was re-suspended in 1 ml of 1 M diethanolamine 
pH 8.0, and incubated at 45 °C with shaking for 4 hours, the resin was washed sequentially 
with three 1 ml aliquots of 0.5 M NaCl, 0.1 M sodium acetate pH 4.0 and 0.5 M NaCl, 
0.1 M Tris-HCl pH 8.0, followed by three 1 ml aliquots of double distilled water. Beads 
were stored at -20 °C after lyophilisation. 
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To control for non-specific binding of proteins in the cell lysate, a blank control resin was 
generated by preparing the beads as described above, but re-suspending them in 1 ml of 
1 M diethanolamine immediately. The diethanolamine control resin was washed in the 
same manner as the pateamine resin. 
 
2.3.5 Cell lysate preparation 
HL-60 cells were grown to 5 x 10
5
 cells/ml; SH-SY5Y and HeLa cells were grown to 
approximately 70% confluence according to method 2.3.2. Cells were harvested by 
centrifugation or cell scraping, collecting about 1 x 10
7
 cells, washed three times with 
20 ml of ice cold PBS (10 mM sodium phosphate, 138 mM sodium chloride, 27 mM 
potassium chloride, pH 7.4) and re-suspended in 5 ml cold PBS with Complete Mini 
Protease Inhibitor tablets (Roche Diagnostics, Mannheim,
 
Germany). Cells were disrupted 
with 7 - 10 strokes of a tight fitting Dounce homogenizer, Triton X-100 was added to 0.1% 
and the homogenate rotated at 4 C for 30 min. The homogenate was centrifuged at 100k 
rpm for 30 min (SS-34 rotor, Evolution RC, Sorvall, Thermo Fisher Scientific, Waltham,  
MA, USA) and protein in the supernatant was quantified with the BCA Protein Assay Kit 
(Thermo Scientific Pierce, Rockford, IL, USA).  
 
2.3.6 Protein electrophoresis 
All protein electrophoresis, unless otherwise stated, was carried out with the NuPAGE 
LDS-PAGE system (Invitrogen, Carlsbad, CA, USA) on 4 - 12% gradient gels under 
reducing condition in MOPS buffer according to the manufacturer’s instructions. After 45 
min at 150V the gels were washed with water, fixed (50% ethanol (v/v), 2% 
orthophosphoric acid (v/v)) and visualized by staining with colloidal Coomassie stain 
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(0.05% Coomassie G-250, 17% ammonium sulfate (w/v), 2% orthophosphoric acid (v/v), 
34% methanol (v/v)), followed by de-staining with double-distilled water. 
 
2.3.7 Isolation of pateamine binding proteins  
To isolate putative pateamine targets, 30 µl of pateamine and control resin were 
equilibrated in 0.5 ml of 0.1% Triton X-100 in PBS (10 mM sodium phosphate, 138 mM 
sodium chloride, 27 mM potassium chloride, pH 7.4) for 30 min at 4ºC, and washed with 
another 0.5 ml of 0.1% Triton X-100 in PBS. The resins were incubated in 1 ml of 1 mg/ml 
cell lysate (prepared according to method 2.3.5), with agitation for 30 min at 4 ºC. Beads 
were recovered by centrifugation and washed three times with 0.1% Triton X-100 in PBS. 
Bounds proteins were eluted either by the addition of 30 µl of 2x LDS-PAGE sample 
loading buffer (Invitrogen) and incubation at 70 ºC for 10 min, or with 500 µM pateamine 
in 1% DMSO, 0.1% Triton X-100 in PBS. A high salt wash was performed with 
1 M sodium chloride, 0.1% Triton X-100 in PBS, and the remaining proteins were eluted 
with LDS-PAGE loading buffer. A competition assay was performed by adding pateamine 
(500 µM final concentration) to the cell lysate prior to incubation with the affinity resins. 
Isolated proteins were separated and visualized on LDS-PAGE gels as described in method 
2.2.6. 
  
2.3.8 Peptide mass fingerprinting 
Samples of the protein of interest were excised from a LDS-PAGE gel with a glass Pasteur 
pipette, washed twice with MilliQ water, then twice with 100 mM aqueous ammonium 
bicarbonate with the final wash lasting 10 min. Samples were reduced with 3 mM DTT 
(dithiothreitol) in 100 mM aqueous ammonium bicarbonate for 20 min at 60 ºC, cooled to 
room temperature and alkylated with the addition of iodoacetamide to a final concentration 
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of at least 6 mM, and incubated in the dark for 20 min. Samples were washed with 50% 
acetonitrile in 100 mM aqueous ammonium bicarbonate for 20 min, dehydrated with 100% 
acetonitrile for 10 min and lyophilized at room temperature in the speed-vac. 
 
The lyophilized gel pieces were rehydrated with 2 µl of 50 mM aqueous ammonium 
bicarbonate containing 0.1 - 0.25 µg of trypsin for 10 min. Gel pieces were overlaid with 
10 µl of 50 mM ammonium bicarbonate and incubated at 37 ºC for 3 h. After trypsin 
digestion, 5 µl of 0.2% trifluoroacetic acid (TFA) in MilliQ water was added and the digest 
solution removed to a fresh tube, 10 µl of a 1:1 mixture of acetonitrile and 0.4% aqueous 
TFA was added to the gel pieces and incubated for 30 min; the resulting solution was 
added to the previously recovered digest solution and replaced with 10 µl acetonitrile for 
30min, after which this was removed and added to the digest solution which was 
lyophilized at room temperature in the speed-vac. The lyophilized peptides were dissolved 
in 10 µl 0.2% TFA in MilliQ water and purified with ZipTips-C18 (Millipore, Bedford, 
MA, USA) according to the manufacturer’s instructions. The resulting purified peptides 
were eluted from the ZipTip-C18 with 2 µl 50% acetonitrile, 0.2% TFA and mixed 1:1 
with a saturated solution of α-cyano-4-hydroxy-cinnamic acid in 50% acetonitrile, 
0.2% TFA, and 1 µl was spotted on a MALDI sample plate at room temperature.  
 
Mass spectra were acquired using an Applied Biosystems DEPro MALDI-TOF mass 
spectrometer (Framingham, MA, USA) in positive ion reflector mode with accelerating 
voltage 20,000V, grid voltage 75% and 180 ns delay time. Peptide masses were calibrated 
internally using trypsin autolysis peaks. The resulting mass peak list was used to search all 
eukaryotic species in the NCBI protein database via the ProFound search engine 
(http://prowl.rockefeller.edu/prowl-cgi/profound.exe) (Zhang and Chait 2000), allowing 
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for methionine oxidation and acetamide adducts. A positive identification was achieved 
when more than five peptide masses were matched covering more than 20% of the peptide 
sequence, with a mass error tolerance of 25 ppm, and an expectation below 0.01. This 
indicates that a similar match would be found approximately once in every 100 similar 
sized databases that did not contain the sequence that matches the mass spectrometry data 
supplied. 
 
Theoretical protein digests were performed using the PeptideMass web tool (Wilkins, 
Lindskog et al. 1997) hosted by the ExPASy proteomics server (Gasteiger, Gattiker et al. 
2003) with amino acid sequences obtained from the SWISS-PROT knowledgebase 
(O'Donovan, Martin et al. 2002). All theoretical digests were achieved by selecting trypsin 
as the protease, and allowing for partial methionine oxidation and complete acetamide 
adduct presence. 
  
2.3.9 Purification of bovine microtubules 
Bovine microtubules were purified from the brain of an adult cow according to the method 
of Hamel et al. (Hamel and Lin 1981). The fresh brain was weighed after meninges were 
removed with Kim Wipes and tweezers. The brain tissue was homogenized with a polytron 
(Kinematica AG, Switzerland) in 1ml of 0.1 mM GTP (guanosine triphosphate), 
1 M monosodium glutamate (MSG) per gram of brain matter. The homogenate was first 
centrifuged at 21k rpm, 2 ºC for 30 min (SS-34 rotor, Evolution RC, Sorvall) the 
supernatant was retained and further centrifuged at 36k rpm at 2 °C for 1 h (Ti45 rotor, 
XL-80 Ultracentrifuge, Beckman Instruments Inc, Palo Alto, CA, USA). The supernatant 
was retained, GTP added to concentration of 0.1 mM and incubated at for 1 h at 4 °C with 
1 ml of DEAE-Sephacel (Amersham) pre-equilibrated with 0.8 M MSG per 5 ml 
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supernatant. The ion exchange resin was washed with five 100 ml aliquots of 1 M MSG 
with 0.1 mM GTP. Tubulin was eluted with five 40 ml aliquots of 0.1 mM GTP, 
1 M NaCl, 1 M MSG with each fraction collected separately. Fractions with an absorbance 
above 0.5 AU at 280 nm were pooled and GTP was added to 1 mM followed by 1 h 
incubation at 37 °C to polymerize the microtubules, which were recovered by 
centrifugation at 36k rpm (Ti45 rotor, XL-80 Ultracentrifuge, Beckman Instruments Inc) at 
37 °C for 1 h. The resulting supernatant was discarded and the pellet was re-solubilized in 
1 M MSG with 0.1 mM GTP using a Teflon homogenizer. Insoluble matter was removed 
by centrifugation at 36k rpm (Ti45 rotor, XL-80 Ultracentrifuge, Beckman Instruments 
Inc) at 2 °C for 30 min. GTP was added to 1 mM followed by incubation at 37 °C to 
polymerize the microtubules. The cycle of polymerization-de-polymerization was repeated 
four times, after which the final pellet was re-solubilized with a Teflon homogenizer, the 
insoluble matter removed by centrifugation. The protein content of the supernatant was 
assessed using the BCA protein quantification assay (Pierce) and 10 g of protein was run 
on a LDS-PAGE gel (Invitrogen) and stained with colloidal Coomassie stain to assess 
purity. Solubilized microtubules were stored in 0.1 mM GTP, 1 M MSG, 20% glycerol at 
-80 °C until use. 
 
2.3.10 Tubulin polymerization assay 
Purified tubulin was buffer exchanged using G25 Sephadex into polymerization buffer 
(2 mM ethylene glycol tetraacetic acid (EGTA), 1 mM DTT, 0.1 mM GTP 0.1 M PIPES, 
pH 6.9), protein content determined by the BCA method (Pierce) and concentrated 
centrifugally to 2 mg/ml. The so-formed tubulin solution (95 l) was added to the plate 
with pateamine in 5 µl of 40% ethanol for final concentrations of 20, 100 and 200 µM and 
absorbance at 350 nm was recorded every 5 min for 2 h in a microtitre plate reader 
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(VersaMax, Molecular Devices) in kinetics mode, at 37 C. Ethanol (2%) was included as 
a carrier control, colchicine (20 µM) and taxol (20 µM) were included as controls for 
microtubule destabilization and microtubule stabilization respectively. 
 
2.3.11 Pyrene-actin microfilament polymerization assay 
In vitro actin polymerization was assessed using pyrene labeled actin (Kouyama and 
Mihashi 1981). The Actin Polymerization Biochem Kit (Cytoskeleton Inc, Denver, CO, 
USA) was used according to the manufacturer’s instructions. Briefly, pyrene-actin was 
reconstituted on ice for 1 h in A-buffer (0.5 mM DTT, 0.2 mM CaCl2, 0.2 mM ATP 
(adenosine triphosphate), 5 mM Tris-HCl, pH 8.0) at a concentration of 4.3 µg/ml, 85 l of 
this solution was added to each well of a black 96-well plate, pateamine was added in 5 µl 
of DMSO for a final concentration range of 25 - 200 µM, 5 µl of DMSO was included as a 
carrier control. Polymerization was induced by the addition of 10 µl of 10 x polymerization 
inducing buffer (500 mM KCl, 20 mM MgCl2, 10 mM ATP). Polymerization was 
monitored on a fluorescent micro-titre plate reader (SpectraMax, Gemini, Molecular 
Devices) with excitation at 365 nm, monitoring emission at 407 nm every 5 min for 1 h. 
Polymerization conditions were modified in the following manner: addition of 0.5x 
(1.8 µg/ml) pyrene-actin; addition of 0.25x polymerization inducing buffer (final 
concentrations: 12.5 mM KCl, 0.5 mM MgCl2, 0.25 mM ATP); addition of 
0.25x polymerization inducing buffer supplemented with 1 mM ATP, or 2 mM MgCl2; 
addition of 2 mM EGTA. 
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2.3.12 Cell cycle analysis 
A 24-well plate was seeded with 2 x 10
5
 HeLa cells and left overnight to attach in a 
humidified incubator at 37 ºC with 5% CO2. Cells were treated with 10 nM pateamine in 
0.1% ethanol, RPMI 1640 media supplemented with 10% FCS and 1% PenStrep, for 18 h 
in a humidified incubator at 37 ºC and 5% CO2, after which they were harvested with 
trypsin (according to method 2.3.2), washed twice with 1 ml of PBS (10 mM sodium 
phosphate, 138 mM sodium chloride, 27 mM potassium chloride, pH 7.4) and re-
suspended in PI buffer (0.05 mg/ml propidium iodide, 0.1% Sodium citrate, 0.1% TX-100) 
and incubated for 30 min on ice. DNA content was analyzed on the FL2 channel of a 
FACScan flow cytometer (BD Biosciences), 10,000 cell events were collected and the data 
were analyzed by CellQuest Pro software (BD Biosciences). 
 
2.3.13 Annexin V binding assay 
Into each well of a 24-well tissue culture grade plate (Greiner), 5 x 10
4
 HeLa cells 
(maintained as according to method 2.3.2) were seeded and allowed to attach overnight. 
Pateamine (10 nM in 0.1% ethanol, RPMI 1640 media supplemented with 10% FCS and 
1% PenStrep) or 0.1% ethanol RPMI 1640 media, supplemented with 10% FCS and 1% 
PenStrep, as control was added and the plate incubated in a humidified incubator at 37 ºC 
and 5% CO2 for 3, 6, 12, 18 or 24 h, after which loose cells were washed off the well 
surface with media and retained. The remaining attached cells were removed with trypsin, 
according to method 2.2.2, and added to the previously recovered cells. Cells were washed 
with three 1 ml aliquots of Annexin V buffer (150 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 
1 mM MgCl2, 10 mM HEPES, pH 7.4), re-suspended in 100 µl of the same buffer and 
stained with Annexin-V-Fluos (Roche Diagnostics) according to the manufacturer’s 
recommendations. Cells were then washed with 1 ml of Annexin V buffer and 
re-suspended in 100 µl of the same buffer. Cell membrane permeability was assessed with 
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the addition of 10 µg/ml propidium iodide. Cellular fluorescence was measured using a 
FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), 10,000 cell events 
were collected, and percentage cell populations were established using CellQuest Pro 
software (BD Biosciences). An unpaired t-test was performed using SigmaPlot Ver 10.0 
(Systat Software Inc.). 
 
2.3.14 Caspase 3/7 activation assay 
The FAM-DEVD-FMK reagent (FLICA Caspases 3 and 7 Kit, Immunochemistry 
Technologies
 LLC, Bloomington, MN, USA) was used according to manufacturer’s 
instructions with minor modifications. Briefly, a 24-well plate was seeded with HeLa cells 
at 5 x 10
4
 cells per well (maintained as according to method 2.2.2) in 1 ml of RPMI 1640 
media, supplemented with 10% FCS and 1% PenStrep, and allowed to attach overnight. To 
asses chronic exposure to pateamine it was added to a final concentration of 10 nM in 
0.1% ethanol in RPMI 1640 media, supplemented with 10% FCS and 1% PenStrep, and 
the plate incubated in a humidified incubator at 37 ºC and 5% CO2 for 18 h, to asses early 
caspase 3/7 activation kinetics in the presence of high concentrations of pateamine, it was 
added to 1 µM and cell were harvested after 1, 2 and 4 h, after which loose cells were 
washed off the well surface with media and retained. The remaining attached cells were 
removed with trypsin and added to the previously recovered cells. Cells were washed with 
three 1ml aliquots of fresh media, re-suspended in 30 µl of fresh media containing 
0.25x FAM-DEVD-fmk and incubated in a humidified incubator at 37 ºC and 5% CO2 for 
1 h. Cells were recovered by centrifugation and washed with 1 ml of apoptosis wash buffer 
(Immunochemistry Technologies
 
LLC) and re-suspended in 300 µl of the same buffer 
containing 10 µg/ml propidium iodide. Cellular fluorescence was measured using the 
FACScan flow cytometer (BD Biosciences) 10,000 cell events were collected, and 
percentage cell populations were established using CellQuest Pro software 
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(BD Biosciences). An unpaired t-test was performed using SigmaPlot Ver 10.0 (Systat 
Software Inc.). 
 
2.3.15 Protein alignment 
All protein alignments were performed using Matlab Ver 7.8.0.347 (R2009a) (MathWorks, 
Inc. Natick, MA, USA) with amino acid sequences from the SWISS-PROT knowledgebase 
(O'Donovan, Martin et al. 2002). Global multiple alignments were peformed with the 
multalign function, and local pairwise alignments with the swalign function (Smith and 
Waterman 1981), both part of the bioinformatics toolbox. 
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2.4 Results 
2.4.1 Pateamine is cytotoxic to cultured cells 
To ensure that the batches of pateamine supplied for this study were of comparable 
biological activity to samples tested in previous studies, and to account for batch-to-batch 
variations in purity, the MTT assay was performed with three transformed human cell 
lines, leukemic HL-60 cells (Gallagher, Collins et al. 1979), cervical epithelial HeLa cells 
(Scherer and Hoogasian 1954) and the neuroblastoma cell line SH-SY5Y (Biedler, Roffler-
Tarlov et al. 1978). Figure 2.1 contains representative dose-response curves for the three 
cell lines tested, Table 2.1 contains the mean IC50 values from three independent 
experiments and shows that pateamine displays similar cytotoxicity in the three cell lines 
tested here, with IC50 values comparable to previously published literature (Hood, West et 
al. 2001), additionally the potency of each batch of pateamine was within two standard 
deviations of these values. These three cell lines were used for subsequent binding protein 
studies.  
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Figure 2.1 Pateamine cytotoxicity dose-response curves. Representative pateamine MTT 
assay dose-response curves, each cell line was tested in triplicate three times, shown above is a 
best fit sigmoidal curve for a single assay in triplicate for each cell line.  
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Cell Line  Mean IC50 
HL-60 1.43 ± 0.06 nM 
HeLa 1.5 ± 0.04 nM 
SH-SY5Y 1.98 ± 0.08nM 
Table 2.1 Summary of cytotoxicity assay results for pateamine sensitive cell lines. The 
average ± standard error of three independent MTT dose-response assays performed in triplicate 
is shown. 
 
2.4.2 Pateamine affinity resin generation 
The exact mechanism by which the coupling reaction proceeded was not established 
although it is assumed that it is achieved through the primary amine of pateamine 
performing a nucleophilic attack on the terminal epoxy-carbon of the affinity resin (Figure 
2.2). Direct quantification of the level of substitution was not performed, however after the 
coupling reaction the resin appeared to be yellow in color and 9 mg of pateamine was 
recovered from the subsequent methanol washes, indicating approximately 4 mg of 
pateamine reacted with 120 mg of epoxy-activated Sepharose 6B, which corresponds to 
approximately 20 µmol pateamine per ml of swollen resin. 
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Figure 2.2 Pateamine affinity resin. Immobilization of pateamine onto the epoxy activated 
Sepharose solid phase is presumed to occur through the C3 primary amine as shown. 
 
2.4.3 Pateamine binding protein isolation and elution 
Equal amounts of swollen pateamine resin and diethanolamine control resin were used to 
isolate pateamine binding proteins from HL-60, HeLa and SH-SY5Y cell lysates, the 
control resin was used to establish non-specific protein-binding to the solid phase and 
linker regions of the resin. To ensure recovery of all proteins bound by both resins, 
LDS-PAGE loading buffer was initially used to elute bound protein from the resins. As can 
be seen in Figure 2.3, three proteins (1 - 3) were consistently eluted from the pateamine 
resin that did not appear in the control resin eluates for the three cell lines tested, while 
other bands specific to each cell line appear, these were not investigated due to their low 
amount and lack of representation in all three cell lines. In order to establish the specificity 
of these proteins for the pateamine resin an attempt to elute these proteins with 500 µM 
pateamine in PBS was made (Figure 2.3a). However, elution with pateamine resulted in a 
large smear rather than separated and resolved bands on the LDS-PAGE gel. An alternative 
method to validate the pateamine-specificity of these binding proteins was undertaken by 
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adding pateamine (500 µM) to the lysate prior to incubation with each of the resins to 
demonstrate the ability of soluble pateamine to compete with the resin for these binding 
proteins. Figure 2.3b shows the pre-incubation of the HL-60 cell lysate with pateamine 
prevents the binding of any of the three previously recovered proteins to the pateamine 
resin. In order to estimate the relative strengths of the binding interactions of these three 
proteins the resin was washed with 1 M sodium chloride prior to LDS-PAGE loading 
buffer elution. Figure 2.3c shows that the high salt wash significantly decreased the 
amount of bands 1 and 3, but band 2 stained with a similar intensity to that previously 
observed, a similar pattern of elution was observed when a non-reducing elution with a 
solution of 7 M urea, 2 M thiourea and 4% CHAPS (data not shown). 
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Figure 2.3 Isolation and separation of cellular pateamine targets by affinity chromatography. 
Lanes marked M contain molecular weight markers, Pateamine labeled lanes show proteins 
isolated with pateamine resin and lanes labeled Cont. indicates protein isolated with the control 
resin. Proteins were isolated from whole cell lysates from three cell lines: A. SH-SY5Y cells; B. 
HeLa cells; C. HL-60 cells. Bound proteins were eluted from both resins with LDS-PAGE loading 
buffer (Invitrogen), separated on NuPAGE 4-12% gradient Bis-Tris gels and run at 200V in MOPS 
buffer, followed by fixation and staining with colloidal Coomassie. Each gel is a representative of at 
least two independent isolations, the three bands consistently isolated from all three cell lines are 
labeled 1-3. 
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Figure 2.4 Pateamine affinity chromatography specificity of interaction. Lanes marked M 
contain molecular weight markers, Pateamine labeled lanes show proteins isolated with resin 
derivatized with pateamine and lanes labeled Cont. indicates protein isolated with the control resin 
derivatized with diethanolamine. Proteins were isolated from HL-60 cell whole cell lysates and: 
A. Attempted specific elution with PBS containing 0.1% Triton X-100 and 500 µM pateamine; 
B. Binding competition with 500 µM pateamine followed by elution with LDS-PAGE loading buffer; 
C. Protein retention by the pateamine affinity resin subsequent to an additional wash step with 
1 M sodium chloride, 0.1% Triton X-100, 10 mM sodium phosphate (pH 7.4), proteins remaining 
were recovered by elution with LDS-PAGE loading buffer.  
  
2.4.4 Identification of putative pateamine binding proteins by peptide 
mass fingerprinting 
The three putative pateamine binding proteins (1 - 3) isolated from each cell line using the 
pateamine affinity resin were identified by peptide mass fingerprinting after trypsin 
digestion. Table 2.2 shows a summary of typical results attained for the putative pateamine 
binding proteins isolated from each cell line after searching the NCBI database with the 
ProFound search engine, only the first positive hit to a human protein for each search is 
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listed for brevity, Sheets 2 - 4, Supplementary File 1 contains full search results for each 
gel band and cell line. Each positive identification was achieved with at least 7 
independent peptides covering at least 27% of each protein with expectation scores less 
than 0.0096. 
 
 In all cell lines except SH-SY5Y, binding protein 1 was identified as being a member of 
the β-tubulin family with no less than 7 independent peptides covering at least 27% of the 
amino acid sequence (Figure 6.6, Appendix A; Sheet2 - 4, Supplementary File 1), it has 
been reported that there exist at least nine β-tubulin isotypes in the Homo sapiens, all 
sharing a very high degree of amino acid sequence similarity (Luduena 1998). A 
significant portion of this family is present with equal expectancy in the list of hit from the 
ProFound search, inspection of the spectra used to search the database shows the presence 
of peptides from at least 5 β-tubulin isotypes (Figure 6.2, Appendix A). Whilst the band 1 
from SH-SY5Y was of the same apparent molecular weight as that from the other cell 
lines, no significant hits were obtained from the mass fingerprinting. 
 
Binding protein 2 isolated from each cell line was identified as eukaryotic initiation factor 
4A (eIF4A) with 14 independent peptides covering at least 27% of amino acid sequence 
(Tabl2 2.2; Sheets 2 - 4, Supplementary File 1). There exist three isoforms of this protein 
in the Homo sapiens. Isoforms I and II are approximately 98% similar, whereas eIF4AIII is 
approximately 70% similar to eIF4AI (Linder 2006).  
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Figure 2.5 shows a typical spectrum obtained for gel band 2 isolated from the HeLa cell 
line, and while eIF4AIII does not appear in the list of hits attained using the ProFound 
search engine (Sheets 2 – 4, Supplementary File 1), a closer inspection of this spectrum 
(Figure 2.6; Figure 6.3, Appendix A) reveals the presence of peptides that are unique to 
eIF4AIII (see Sheet 5, Supplemenatry File 1) for theoretical tryptic digest results). While 
MALDI-ToF MS is only semi-quantitative (Dreisewerd 2003), the lower signal intensity of 
the eIF4AIII specific peptides in the spectrum probably reflective of this protein’s lower 
abundance compared to isoforms I and II (Linder 2003). The presence of eIF4AI, II and III 
in the pateamine resin eluate obtained from the HL-60 cell line was confirmed by western 
blot with isoform specific antibodies (Bordeleau, Matthews et al. 2005).  
 
Gel band three was identified as β/γ-actin from each of the three cell lines with at least 9 
independent peptides covering at least 30% of the amino acid sequence and an expectation 
score no greater than 0.0093. Due to a lack of unique peptides for either β or γ actin it is 
not clear whether one or both isoforms are present in the eluates (Figure 6.4, Appendix A; 
Sheets 2-4, Supplementary File 1). 
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Figure 2.5 MALDI mass spectrum acquired from gel band two from the HeLa cell lysate after 
digestion with trypsin. Three isoforms of eIF4A are retained by the pateamine affinity resin, 
database searching identified this band as eIF4A isoform I and II, peaks with masses 
corresponding to those from each isoforms including eIF4AIII are labeled.  
 
 
Figure 2.6 eIF4AIII isolated by pateamine affinity chromatography. Close up of mass spectrum 
acquired from gel band two isolated from the HeLa cell lysate shows masses corresponding to 
peptides found only from the tryptic digest of eIF4AIII. Peaks are labeled as described in figure 2.5 
. 
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Cell 
Line 
Band Identity Expectation Matched 
Peptides 
Sequence 
Coverage 
Predicted 
MW 
Observed 
MW 
HeLa 1 gi|29788785| 3.6 × 10
-3
 7 27% 50.11 50 kDa 
tubulin, beta [Homo sapiens] 
  2 gi|4503529 4.6 × 10
-5
 14 31% 46.36 46 kDa 
|eukaryotic translation initiation factor 4A isoform 1 [Homo 
sapiens] 
  3 gi|15277503| 9.3 × 10
-3
 10 34% 40.54 40 kDa 
ACTB protein [Homo sapiens]  
HL-60 1 gi|2119276|  9.6 × 10
-3
 9 27% 49.38 50 kDa 
beta-tubulin - human (fragment) 
  2 gi|4503529| 1.2 × 10
-6
 14 33% 46.36 46 kDa 
eukaryotic translation initiation factor 4A isoform 1 [Homo sapiens] 
  3 gi|15277503|  6.8 × 10
-3
 11 34% 40.54 40 kDa 
ACTB protein [Homo sapiens]  
SH-
SY5Y 
1 No significant hits NA   NA NA 50 kDa 
  2 gi|4503529| 6.7 × 10
-5
 14 33% 46.36 46 kDa 
eukaryotic translation initiation factor 4A isoform 1 [Homo sapiens] 
  3 gi|15277503|  3.7×10
-3
 9 30% 40.54 40 kDa 
ACTB protein [Homo sapiens]  
Table 2.2 Summary of ProFound search results for putative pateamine binding proteins. Each assignment was achieved at least twice for each cell 
line and protein, reported is representative results for each protein band, for brevity the first database entry for each search is reported. See method 2.3.8 
for an explanation of the expectation score. 
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2.4.5 Pateamine displays duel effects on in vitro microtubule 
polymerization  
An in vitro microtubule polymerization assay was performed to assess whether pateamine 
could affect the polymerization of tubulin. To this, end tubulin was isolated and purified to 
approximately 95-99% purity (Figure 6.5, Appendix A) from bovine brain grey matter, and 
the effect of pateamine on its ability to polymerize was assessed by measuring the increase 
in turbidity (indicating polymerization) and compared to taxol and colchicine which are 
known to enhance (Lopes, Miller et al. 1997) and inhibit (Borisy and Taylor 1967) 
microtubule formation respectively. Figure 2.7 shows that high concentrations 
(100 - 200 µM) of pateamine seem to significantly enhance tubulin polymerization, 
although even at 200 µM, the rate of microtubule formation is lower than that achieved 
with 20 µM taxol. In contrast, a lower concentration (20 µM) seems to prevent 
polymerization to a similar level to that achieved by the same concentration of colchicine 
(See Sheet 6, Supplementary File 1 for raw data). 
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Figure 2.7 In vitro microtubule polymerization assay. Purified bovine tubulin polymerization was 
monitored in a microtitre plate at 37 ⁰C by measuring absorbance at 350 nm in the presence of the 
indicated drugs, or 2% ethanol as a carrier control. Pictured is a representative of at least three 
independent assays.  
 
2.4.6 High concentrations of pateamine disrupt polymerization of rabbit 
α-actin in vitro 
Fluorescently labeled rabbit α-actin was used to assess the in vitro effect of pateamine on 
microfilament formation due to the commercial availability of the reagent and the 
similarity between rabbit α-actin and human β and γ-actin (Figure 6.6, Appendix A). 
Figure 2.8a shows that pateamine causes dose dependant suppression of both the initial rate 
of actin polymerization and the maximum fluorescence intensity attained at concentrations 
comparable to those that seem to stabilize microtubule polymerization; this was only seen 
after the addition of ATP (data no shown). In contrast to microtubule polymerization, 
where it appears pateamine has a duel effect, stabilizing or destabilizing depending on the 
concentration, microfilament polymerization is suppressed at all concentration of 
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pateamine tested. When the concentration of actin in the assay is halved (Figure 2.8b) 
pateamine inhibits both the initial rate and maximum fluorescence proportionally, whereas 
decreasing the concentration of the polymerization buffer fourfold (Figure 2.8c) causes an 
increase in the level of suppression of these parameters. Supplementation of the depleted 
polymerization buffer with 1 mM ATP (Figure 2.8d) has no effect on the suppression of 
the initial rate of polymerization and maximum fluorescence by pateamine, whereas when 
the depleted polymerization buffer is supplemented with 2 mM Mg
2+
 (Figure 2.8e) a higher 
level of suppression of these parameters occurs. When the assay is performed in the 
presence of 2 mM EGTA (Figure 2.8f) abrogation of inhibitory effects of pateamine on the 
both the initial rate of polymerization and the total fluorescence are observed (see sheet 7, 
Supplementary File 1). 
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Figure 2.8 In vitro microfilament polymerization assay. Pyrene labeled rabbit α-actin 
polymerization in the stated conditions was monitored by fluorescence, 2% ethanol was used as a 
carrier control. A. Standard assay conditions. B. 0.5x actin assay. C. 0.25x polymerization buffer 
assay. D. ATP re-supplementation assay. E. Mg
2+
 re-supplementation assay. F. EGTA addition 
assay 
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2.4.7 Pateamine does not specifically disrupt cell cycle progression 
Given the well established roles of both the actin microfilaments and tubulin microtubules 
in mitosis (Lodish 2003), and the observation that drugs that target these proteins tend to 
cause a change in the distribution of cells across the cell cycle (Lopes, Miller et al. 1997; 
Usui, Kazami et al. 2004; Lee and Keng 2005), the effects of pateamine on cell cycle 
progression was carried out using flow cytometry. As Figure 2.9 shows, rather than an 
increase in the number of cells with 4n DNA (corresponding to those cells at the G2/M 
phase transition), as would be expected with a compound that affects tubulin function 
(Hood, West et al. 2002), or an increase in the number of cell with 8n or 16n DNA 
(corresponding to cells unable to complete cytokinesis) as would be expected with a 
compound that inhibits actin function (Usui, Kazami et al. 2004), pateamine caused a 
statistically significant increase in the amount of small debris in the sub-G1 region 
(unpaired t-test, P < 0.0003), possibly corresponding to an increase in apoptotic bodies. 
Consistent with this result and previous literature (Hood, West et al. 2001), Figure 2.8 
shows that 10 nM pateamine is able to induce statistically significant caspase 3/7 activation 
(unpaired t-test, P < 0.0015) and causes a statistically significant loss of phophatidyl serine 
asymmetry (unpaired t-test, P < 0.003) after 18 h exposure confirming that the increase in 
sub-G1 sized debris is due to the induction of apoptosis. Consistent with the role of caspase 
activation in the cytotoxicity of pateamine, co-treatment with the pan-caspase inhibitor 
z-VAD-FMK, alters the response of HeLa cells to pateamine treatment (Figure 2.11). 
Table  2.4 illustrates that simple IC50 values can be misleading. Whilst high concentrations 
of the pan-caspase inhibitor modestly lowers the IC50 value for pateamine, as might be 
expected, it is noticeable that this treatment with z-VAD-FMK results in a significant 
increase in the level of survival relative to control at high pateamine concentrations, 
denoted by the minimum value in Table 2.3. Thus unexpectedly, it can be seen that the 
pan-caspase inhibitor actually provides significant protection against pateamine. The 
inhibitory effect on the maximum response in the presence of the 50 µM z-VAD-FMK 
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suggests decreased viability or MTT response (i.e. respiration) at this concentration of the 
pan-caspase inhibitor in the absence of pateamine.  
 
 
Figure 2.9 Cell cycle distribution in the presence of pateamine. HL-60 cells were treated for 18 
h with 10 nM pateamine in RPMI media supplemented with 10% FCS. Cells were washed, 
membranes permeabilized and DNA stained with propidium iodide. DNA content was measured by 
flow cytometry and the control cell samples were used to identify cell cycle stages. The increase in 
sub G1 population is statistically significant (p < 0.0003, unpaired t-test) whilst the decrease in the 
G1 or S phase was not significant (Sheet 8, Supplementary File 1).  
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Figure 2.10 Chronic exposure to pateamine activates caspase 3/7 and causes a loss of 
phophatidyl serine asymmetry. HL-60 cells were treated for 18 h with 10 nM pateamine in RPMI 
media supplemented with 10% FCS then stained with propidium iodide (PI positive) and either: A. 
Caspase 3/7 specific FLICA probe (Caspase 3/7 positive); or B. FITC-Annexin V conjugate 
(Annexin V positive). Flow cytometry was used to measure cellular fluorescence, 0.1% ethanol in 
RPMI media supplemented with 10% FCS was used as a carrier control. Each of the three cell 
population labeled above was significantly enriched in the pateamine treated samples (P < 0.003, 
unpaired t-test). Cells indicated as only PI permeable were negative for caspase 3 or annexin V. 
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Figure 2.11 Pateamine dose-response in the presence of the pan-caspase inhibitor 
v-ZAD-FMK. HeLa cells, Red: 0.5% DMSO as carrier control, Green: 5 µM v-ZAD-fmk, 
Blue: 10 µM z-VAD-FMK, Black: 50 µM z-VAD-FMK. 
 
z-VAD-FMK (µM) 0 5 10 50 
Minimum value 13.00 ± 
1.65 
9.74 ± 
3.11 
6.16 ± 
7.20 
33.36 ± 
1.54 
Maximum value 97.12 ± 
3.02 
99.90 ± 
5.95 
96.22 ± 
18.83 
74.44 
±3.50 
IC50 Value 1.77 ± 
0.10 
2.54 ± 
0.33 
1.93 ± 
0.88 
1.13 ± 
0.16 
Table 2.3 Summary of curve parameters for z-VAD-FMK inhibited MTT assays. 
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Pateamine (nM)  P-value 
50 5.53 x 10
-5
 
25 1.58 x 10
-6
 
12.5 5.66 x 10
-7
 
Table 2.4 P-values for selected points in the pan caspase inhibited MTT assay (Figure 2.). An 
unpaired t-test was performed with each data point at each pateamine concentration in the 50 µM 
z-VAD-FMK treated curves, relative to the untreated pateamine data point. 
 
2.4.8 Pateamine cytotoxicity is irreversible  
Following observations that the inhibitory effect of pateamine on protein synthesis was 
irreversible (Bordeleau, Matthews et al. 2005), as is the formation of stress granules (Dang, 
Kedersha et al. 2006), the reversibility of pateamine induced cytotoxicity was investigated. 
As seen in Figure 2.12, a short exposure of 15 min to 100 nM pateamine is enough to cause 
more than 60% cytotoxicity after 11 h recovery, when this exposure time is increased to 
30 min the MTT response is indistinguishable from constant exposure for 11.5 h, as is 
exposure to 50 nM pateamine for 2 h. This suggests pateamine induced cytotoxicity is 
irreversible at concentrations comparable to those that irreversibly inhibit protein synthesis 
and induce stress granule formation. To establish whether this irreversibility is due to the 
rapid activation of caspase 3/7 its activation kinetics to 1 µM pateamine were established 
(Method 2.3.14). Figure 2.13 and Table 2.5 show that statically significant proportions of 
the 1 µM pateamine treated population has active caspase 3/7 after 2 h of exposure. 
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Figure 2.12 Pateamine withdrawal MTT assay. HeLa cells were exposed to pateamine for the 
indicated times and then removed, washed with warm media and allowed to recover for 10 h in 
fresh media (red lines) for or media containing the same concentration of pateamine as initially 
exposed to (black lines). MTT reagent was used to assess viability which is expressed relative to 
untreated control cell response. The assay was performed in triplicate three times, average data is 
presented and error bars correspond to compounded standard deviation across three independent 
experiments. 
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Figure 2.13 Activation kinetics of caspase 3/7 by pateamine by flow cytometry. Performed in 
HeLa cells over four hours after treatment with 1 µM pateamine, expressed as the percentage of 
the total treated population, cells with activated caspase 3/7 were detected with the use of a 
fluorescent alkylating probe for caspase 3/7. The assay was performed in triplicate three times, 
average data is presented and error bars correspond to compounded standard deviation across 
three independent experiments, see Table  for summary statistics. 
 
Time (h) 0 1 2 4 
Mean (%) 8.90 11.58 22.48 61.67 
Standard Deviation 0.36 4.21 9.69 3.59 
P-value  0.07491 0.0007 <0. 00001 
Table 2.5 Summary of caspase 3/7 activation kinetics in HeLa cells. Measurements were taken 
over four hours after treatment with 1 µM pateamine. Assay was performed by flow cytometry and 
a fluorescent alkylating probe for caspase 3/7. The experiments were performed three times in 
triplicate, mean cell percentages with active caspase 3/7 and standard deviations are shown, 
P-values were assessed by means unpaired t-test with comparison to time 0 h. 
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2.5 Discussion 
2.5.1 Putative target proteins isolated from human cell lines 
Upon commencement of these experiments the nature of the cellular target of pateamine 
was unknown, given that the majority of drug targets are proteins it was reasoned that the 
target of pateamine would be also In order to isolate putative pateamine protein targets 
from whole cell lysates of HL-60, HeLa and SH-SY5Y cells, a pateamine derivatized 
affinity resin was generated using epoxy-activated Sepharose. The primary amine at C3 is 
the most reactive functional group on the molecule and several analogues derivatized at 
this position retain significant biological activity (Romo, Rzasa et al. 1998). This group 
and the methyl group at C5 are dispensable for activity (Romo, Choi et al. 2004), hence it 
was presumed that coupling to the affinity resin through the C3 amine group would not 
abrogate binding to potential targets. Proteins retained by the affinity resin were separated 
using LDS-PAGE and visualized after staining the gels with colloidal Coomassie. For 
reasons undetermined it was not possible to specifically elute bound proteins from the 
affinity resin with aqueous pateamine (Figure 2.4a), although non-selective binding of 
pateamine to protein surfaces at the high concentration tested could result in disrupted and 
variable association with dodecyl sulphate, leading to the lack of resolution observed. Thus 
the elution of both specific and non-specific binding proteins was achieved with 
LDS-PAGE loading buffer. A control resin consisting of the epoxy-activated Sepharose 
coupled with diethanolamine was used to determine non-specific protein retention by the 
solid phase. The HL-60, HeLa and SH-SY5Y cell lines were used in an attempt to control 
for non-specific binding to the solid phase that is specific to each cell line; these were used 
as they are all comparably sensitive to pateamine (Figure 2.1).  
 
Consistent isolation of three proteins (Figure 2.3) not retained by the control resin from 
each of the three cell lines was achieved. While other, different bands are also visible in the 
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pateamine resin lanes from each cell line they were generally at lower abundance, varied 
between experiments and often related to proteins found in the control lane. For example, 
the band prominent at approximately 55 and 60 kD in panes A and C of Figure 2.3 are 
cytokeratin and a fragment of cytokeratin respectively. In each case, cytokeratin or a 
fragment of it was represented in the control resin. For this reason, only those that were 
retained from all three whole cell lysates were considered potential targets. Although 
elution with aqueous pateamine was not possible (Figure 2.4a), the binding of all three 
proteins to the pateamine affinity resin was prevented by the addition of pateamine to cell 
lysate prior to the affinity purification (Figure 2.4b) suggesting specific retention of all 
three. Proteins 1 and 3 were significantly reduced in abundance subsequent to the resin 
being subjected to a high salt wash (Figure 2.4c) which may suggest a lower affinity 
interaction than with protein 2, or at least an interaction mediated predominantly by ionic 
interactions. 
 
Peptide mass fingerprinting was used to identify proteins 1 - 3. Each protein was digested 
with trypsin and the masses of the resulting peptide fragments determined using 
MALDI-MS, these masses were used to search the NCBI database for potential hits. 
Except for protein 1 isolated from the SH-SY5Y whole cell lysate, significant hits for all 
three proteins from each cell lines were attained (Table 2.2). Protein 1 isolated from the 
HL-60 and HeLa whole cell lysates was identified as β-tubulin, protein 2 from all three cell 
lines was identified as eIF4A, and protein 3 from all three cell lines was identified as β-
actin. Each of these proteins is highly expressed in the majority of cell types (Duncan and 
Hershey 1983; Nielsen and Trachsel 1988; Williams-Hill, Duncan et al. 1997; Luduena 
1998; Lodish 2003), however there seems to be little sequence similarity between them 
though they all bind and hydrolyse ATP or GTP. 
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2.5.2 Protein 1 – β-tubulin 
Microtubules are a major cytoskeletal component present in all eukaryotic cells and are 
essential for chromosome separation during mitosis and vesicular trafficking during 
interphase. They consist predominantly of heterodimers comprised of tightly associated 
α and β-tubulin subunits arranged in a head-tail fashion into proto-filaments, a polymerized 
microtubule consists of 13 - 15 proto-filaments forming a tubular structure. The free 
α/β-tubulin heterodimer bind two molecules of GTP one of which is hydrolyzed after 
incorporation into a microtubule (Nogales 2001). Microtubules are a common target for a 
number of cytotoxic compounds; the tubulin subunits were in part characterized due the 
ability to bind to radioactively labeled colchicine, a potent anti-inflammatory isolated from 
Colchicum autumnale, that destabilizes microtubules, and is cytotoxic to cultured cells 
(Borisy and Taylor 1967). More specifically the β-tubulin subunit is directly targeted by 
the vinca alkaloids, taxane and epothilone classes of compounds. These compounds, which 
include a number of well established clinical anti-neoplastic agents, alter the 
polymerization dynamics of microtubules, stabilizing or destabilizing the polymerized 
form (Jordan and Wilson 2004; Singh, Rathinasamy et al. 2008). A number of marine 
natural products have been found to alter microtubule polymerization. These include 
peloruside A, also isolated from the sponge Mycale hentscheli which is cytotoxic, 
stabilizes the polymerized form of microtubules both in vivo and in vitro and causes cell 
cycle arrest the at G2/M phase checkpoint (Hood, West et al. 2002). 
 
Of the 14 β-tubulin isoforms encoded by the human genome peptides from at least five we 
present in the mass spectra obtained from protein 1 from HeLa whole cell lysate (Appendix 
A). Pateamine appears to be able to promote bovine microtubule polymerization in vitro, 
albeit at a concentration approximately 100,000 fold higher than those required for 
cytotoxicity and with differing kinetics to that of taxol (Figure 2.5). Generally, microtubule 
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stabilizing drugs that are cytotoxic at low nanomolar concentrations are effective in an in 
vitro assay tubulin polymerization assay at low micromolar concentrations (Jordan, Toso et 
al. 1993; Bollag, McQueney et al. 1995; Ter Haar, Kowalski et al. 1996; Hood, West et al. 
2002; Pryor, O'Brate et al. 2002). Conversely a concentration of pateamine ten-fold lower 
than those observed to enhance microtubule polymerization seems to prevent 
polymerization in an analogous manner to colchicine (Figure 2.5). Dynamic microtubule 
function is required during mitosis; microtubules grow from the centriole to attach to the 
centromere of each chromosome facilitating equatorial alignment of each chromosome and 
the subsequent separation after the loss of sister chromatid cohesion. Subsequent to 
chromosome separation the microtubules must be depolymerized to allow the new nuclear 
envelope to form. Taxol and colchicines for instance, prevent progression through the 
G2/M phase checkpoint of the cell cycle to G1 phase and hence causing an increase in the 
number of cells containing 4n DNA, a hallmark of microtubule perturbing agents (Honore, 
Pasquier et al. 2005). Pateamine did not cause an increase in the number of HeLa cells with 
4n DNA (Figure 2.9), instead an increase in the sub-G1 population was observed. Which, 
given the increase in the number of cells that stain positive with Annexin V and have 
active caspase 3/7 (Figure 2.10), both indicators of apoptosis (Strasser, O'Connor et al. 
2000), can be presumed to be cellular debris or apoptotic bodies resulting from the 
induction of apoptosis rather than a specific cell cycle effect. 
 
This absence of a subset of cells blocked at the G2/M checkpoint indicates that, whilst 
alteration of microtubule dynamics is a potential mode of action of pateamine and occurs at 
a concentration equivalent to that of colchicine, it is unlikely to be pateamine’s primary 
mode of action. The observed apoptosis in the absence of significant changes in the ratios 
of G1, S and G2/M cell populations indicates an alternative primary mode of action.  
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2.5.3 Protein 2 – eIF4A 
Members of the eIF4A (eukaryotic initiation factor 4A) family are ATP-dependent, RNA 
helicases (Grifo, Tahara et al. 1983) and are the archetypal DEAD-box helicase. These, 
and the related DEXD/H box family members are characterized by seven highly conserved 
amino acid motifs that have been implicated in their RNA remodeling role (Linder 2006). 
There are three members of the eIF4A family in humans: eIF4AI and eIF4AII show 
90 - 95% amino acid similarity and are both cytoplasmically localized and are involved in 
translation initiation as a part of the eIF4F complex (Grifo, Tahara et al. 1983; Yoder-Hill, 
Pause et al. 1993); eIF4AIII is approximately 70% similar to eIF4AI, is a 
nucleocytoplasmic shuttling protein and does not compensate for the loss of eIF4AI in an 
in vitro translation system but is required for non-sense mediated mRNA decay (NMD) as 
a part of the exon-junction complex (EJC) (Li, Imataka et al. 1999; Chan, Dostie et al. 
2004; Ferraiuolo, Lee et al. 2004; Palacios, Gatfield et al. 2004; Shibuya, Tange et al. 
2004).  
 
The recruitment of the ribosome to the newly exported mRNA transcript is the rate limiting 
step in protein synthesis and represents a major point of post-transcriptional regulation. In 
eukaryotes there are two major pathways of translation initiation: Cap-dependent and 
internal ribosome entry site-mediated initiation. In cap-dependent initiation, in which the 
5` 7-methyl guanine cap structure of the mRNA transcript is first bound by the eIF4F 
complex. eIF4F is comprised of: eIF4E, which bind directly to the cap structure; eIF4G 
which acts a scaffolding proteins binding eIF4E, the mRNA transcript and eIF3 
(Sonenberg, B. et al. 2000). The eIF4G protein also recruits eIF4AI/II (hereon referred to 
as eIF4AI). With the help of eIF4B and eIF4H, eIF4AI prepares the transcript for ribosome 
scanning by removing secondary structure in the 5`-UTR immediately proximal to the cap. 
Both free eIF4A and eIF4F are required for cap-dependent translation initiation, and it is 
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thought that eIF4A cycles through the eIF4F complex as RNA unwinding occurs (Ray, 
Lawson et al. 1985; Pause, Methot et al. 1994; Svitkin, Pause et al. 2001). In contrast, 
internal ribosome entry site (IRES) mediated translation initiation occurs in a fashion that 
is independent of the 5` cap structure (Sonenberg, B. et al. 2000). Different IRES elements 
have differing requirements for the aforementioned initiation factors, for instance initiation 
at the hepatitis C virus (HCV) IRES is not dependant on eIF4AI activity, whereas at the 
encephalomyocarditis virus IRES it is dependent on both eIF4G and eIF4AI (Pestova, 
Shatsky et al. 1998). 
 
The mass spectrum acquired for protein band 2 identified as eIF4AI showed the presence 
of peptides that were unique to all three eIF4A isoforms (Figures 2.5 and 2.6), the retention 
of eIF4AI and eIF4III by the pateamine affinity resin was confirmed by Western blot 
(Bordeleau, Matthews et al. 2005). Protein band 2 was less affected by the high salt 
washing during the affinity isolation suggesting a more stable interaction with the resin 
than protein bands 1 and 3 (Figure 2.4). Consistent with the notion of eIF4AI as a cellular 
target of pateamine was its identification in a high throughput screen for translation 
(Novac, Guenier et al. 2004). A bicistronic mRNA transcript was prepared in vitro bearing 
firefly and renilla luciferase whose translation is dependent on the 5` 7-methyl guanine cap 
or the HCV IRES respectively. This was used in an in vitro translation extract as a 
multiplexed assay used to screen for compounds that act as initiation specific and general 
translation inhibitors.  
 
Further work showed pateamine as able to rapidly inhibit protein synthesis in HeLa cells 
with an IC50 of 5 nM and prevented the formation of the 48S pre-initiation complex and 
subsequent polysomes, suggesting cellular targeting of eIF4AI. In vitro, pateamine was 
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shown to stimulate the ATP binding and ATP hydrolytic activity of purified murine 
eIF4AI in an RNA dependent manner, and RNA binding was stimulated even in the 
absence of ATP. Furthermore, the RNA and ATP binding abilities of the eIF4F complex 
were not perturbed by pateamine. The helicase activity of eIF4AI in the presence of 
pateamine was also stimulated in a manner dependant on ATP. It seems this effect is 
specific to the eIF4A family of proteins as the closely related DEAD-box helicase Ded1p 
from S. cerevisiae (Struhl 1985) is not stimulated by pateamine.  
 
Additionally, pateamine has no effect in an in vitro splicing assay, further evidence of 
eIF4A specificity as splicing involves between 7 and 13 DEXD/H box helicases 
(Bordeleau, Matthews et al. 2005; Linder 2006). Using a biotinylated pateamine derivative 
and streptavidin beads Low et al. confirmed the ability for pateamine to purify eIF4AI 
from HeLa whole cell lysate, as well as confirming the inhibitory effect on protein 
synthesis and polysome formation, and the stimulatory effects on the purified protein 
previously noted. They also noted that over-expression of eIF4AI in HeLa cells led to a 
modest but significant increase in resistance to pateamine in a cellular proliferation assay, 
and that pateamine treatment caused the aggregation of eIF4AI into stress granules, both 
suggestive of cellular targeting of at least eIF4AI by pateamine (Low, Dang et al. 2005). 
 
Additional to the western blot analysis of the eluate of from the pateamine resin that 
showed the presence of eIF4AIII (Bordeleau, Matthews et al. 2005), biotinylated 
pateamine was also shown to interact with eIF4AIII (Dang, Low et al. 2009) and its 
ATPase activity is also stimulated the desamino- desmethyl- analogue of pateamine (Low, 
Dang et al. 2007). In vivo 0.5-1 µM pateamine is able inhibit NMD through stabilization of 
the interaction between the EJC and mRNA, which inhibits the degradation of a premature 
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termination codon (PTC) containing transcript. The inhibitory effect on NMD is 
independent of the effect of pateamine on translation initiation (Dang, Low et al. 2009). 
The NMD pathway functions to degrade mRNA transcripts that contain a PTC more than 
50-55 nucleotides upstream of the final exon-exon junction. Translation of these transcripts 
may lead to the production of a truncated, partially or completely non-functional, protein 
product. A PTC can be present in a transcript due to non-sense or frame-shift mutations, or 
because of errors during transcription or splicing (Sonenberg, B. et al. 2000).  
 
After an intron is removed from a transcript the EJC is deposited on the resulting 
exon-exon junction. This complex is dynamic in nature, its core components in mammals 
are eIF4AIII, Y14, Magoh and MLN51 (Le Hir, Izaurralde et al. 2000; Le Hir, Gatfield et 
al. 2001). The role of eIF4AIII in the EJC is to mediate the interaction between the 
transcript and the rest of the EJC components, the interaction with MLN51 inhibits its 
ATPase activity fixing it to the exon-exon junction (Bono, Ebert et al. 2006). In this way, 
eIF4AIII functions in a distinctly different manner to eIF4AI, which hydrolyses ATP in 
order to unwind RNA. The exact mechanism by which a PTC containing transcript is 
detected and marked for degradation has not been fully elucidated but it involves the 
recruitment of the proteins Upf1-3 (Tange, Nott et al. 2004) to the EJC and functioning 
ribosomes (Carter, Doskow et al. 1995), suggesting that detection occurs during the 
pioneer round of translation. Knockdown of eIF4AIII by siRNA inhibits the degradation of 
a PTC containing transcript by preventing the deposition of the EJC on the exon-exon 
junction (Ferraiuolo, Lee et al. 2004). Pateamine most likely inhibits NMD by preventing 
the removal or dissolution of the EJC complex during the pioneer round of translation 
(Dang, Low et al. 2009). 
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Although it seems pateamine is the first compound characterized to specifically inhibit 
NMD, hippuristanol, a polyhydroxysteroid isolated from the coral Isis hippuri, and 
resveratrol have also been shown to target eIF4AI and cap-dependent protein synthesis 
(Bordeleau, Mori et al. 2006; Lomenick, Hao et al. 2009). Although it is not clear whether 
eIF4AIII and NMD are also affected, these compounds are also, albeit weakly, cytotoxic. 
A considerable number of other inhibitors of protein synthesis have been discovered, as 
discussed in section 1.3.  
 
These compounds are typically toxic to cultured cell lines, for instance: cycloheximide 
binds to the translocating ribosome during polypeptide elongation causing it to stall 
(Alessenko, Boikov et al. 1997; Lemaire, Andreau et al. 1999; Tang, Lahti et al. 1999; 
Kageyama, Kusano et al. 2002); puromycin which binds to the A-site on the 80S ribosome 
and causes premature polypeptide termination (Carter, Doskow et al. 1995); anisomycin 
inhibits the peptidyl transferase activity of the 80S ribosome (Grollman 1967; Kageyama, 
Kusano et al. 2002). Didemnin B on the other hand has been shown to inhibit polypeptide 
elongation by inhibiting elongation factor 1α (EF1α) (Sir Deshpande and Toogood 1995; 
Baker, Grubb et al. 2002), and reveromycin A targets isoleucyl tRNA synthetase inducing 
apoptosis in osteoclasts (Woo, Kato et al. 1999). Despite the fact protein synthesis 
inhibition is a verified mode of inducing apoptosis, the simultaneous siRNA mediated 
knockdown of eIF4AI and eIF4AII does not appear to have a significant effect on viability 
HeLa cells over 48 h, perhaps due to the existence of IRES controlled anti-apoptotic 
proteins (Holcik and Korneluk 2000; Miyamoto, Machida et al. 2002; Van Eden, Byrd et 
al. 2004), whereas an 85% reduction in eIF4AIII by siRNA appears to reduce cell number 
over (Ferraiuolo, Lee et al. 2004). 
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2.5.4 Protein 3 – β-actin 
A ubiquitous cytoskeletal protein, β-actin, is one of 6 isoforms of actin found in humans, it 
polymerizes to form filamentous structures known as microfilaments, which provides the 
plasma membrane with structural integrity, facilitate cytoplasmic membrane bound 
vesicular transport and fulfills an essential role in cytokinesis and cell migration and 
motility (Fenteany and Zhu 2003; Rao and Li 2004). Microfilaments are targeted by a 
number of cytotoxic agents, for instance the latrunculins were originally isolated from the 
sea sponge Latrunculia rnagnifca and are potent destabilizers of microfilament 
polymerization and induce apoptosis (Spector, Shochet et al. 1983; Martin and Leder 
2001). Jasplakinolide, from the marine sponge Jaspis Johnston also, stabilizes 
microfilaments in vitro and is also cytotoxic (Bubb, Senderowicz et al. 1994; Odaka, 
Sanders et al. 2000).  
 
In vitro microfilaments undergo polarized growth, the addition of actin monomers onto the 
plus or barbed end is favored over addition to the minus or pointed end, concomitant with 
polymerization is the hydrolysis of ATP and the slow release of Pi and ADP. 
Polymerization can be induced in vitro with the addition of hypertonic buffer and ATP, 
however, the rate of polymerization is particularly sensitive to the presence of divalent 
cations, particularly Mg
2+
 and Ca
2+
 (Gordon, Boyer et al. 1977; Estes, Selden et al. 1992).  
 
Pateamine seems to decrease the initial rate of polymerization in a dose dependant manner 
that is dependent on the composition of the buffer in which the assay is performed (Figure 
2.8). Although reducing the concentration of the polymerization buffer seems to exacerbate 
the inhibitory effect of pateamine (Figure 2.8c) this can be most likely be attributed to the 
combined effect of reducing the tonicity of the buffer and the mild effect of pateamine, 
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rather than a synergistic interaction between the way in which the two affect 
polymerization. The apparent amelioration by EGTA may suggest Ca
2+
 bound actin is 
more sensitive to pateamine inhibition, but given Ca
2+
 is tightly regulated within the 
cytoplasm Mg
2+
 bound actin is likely to be the predominant species present. 
 
While the effect on microfilament polymerization of pateamine occurs at a concentration 
lower than the effects on microtubule polymerization this still occurs at a concentration 
that is 50,000 fold higher than those required for apoptosis induction. Generally actin 
targeting compounds are effective at sub-micromolar concentrations in in vitro 
polymerization assays and cytotoxic in the low nanomolar range (Spector, Shochet et al. 
1983; Coue, Brenner et al. 1987; Bubb, Senderowicz et al. 1994; Martin and Leder 2001).  
 
 
This discrepancy in effective concentration between in vitro and in vivo drug activities is 
not an uncommon phenomenon and can be rationalized by taking the following into 
account: 1. The difference in the nature of each of the assays: the actin polymerization 
assay directly measures an effect on microfilaments, that is the drug target itself, whereas a 
cellular viability assay measures the cells response, in viability terms, on exposure to a 
drug, this is a biological phenomenon that involves multiple pathways or processes and 
hence takes longer to manifest but is also subject to amplification. 2. Intracellular 
accumulation of the drug: Due to an overall negative plasma membrane potential (Okada, 
Ogawa et al. 1973) most cells accumulate cationic drug, such as pateamine, this has been 
shown to influence the intracellular concentrations of charged dyes (Farkas, Wei et al. 
1989), doxorubicin (Robinson and Roepe 1996) and 2-N-methyl-ellipticinium (Charcosset, 
Jacquemin-Sablon et al. 1984).  
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However, it can be presumed that regardless of cellular potential drug will accumulate due 
to the sequestering effect of being bound by the their targets, this would be particularly true 
for compounds that form a covalent bond with their target. The net results is that the 
intracellular concentrations, and hence the concentration around the target, of most drugs 
will exceed that of the surrounding media. Although the concentration required for in vitro 
effects on microfilament polymerization are 50,000-fold higher than those required for 
cytotoxicity over 24 h, only 1,000 – 10,000-fold of this difference can be attributed to the 
expected difference between in vivo and in vitro activities. Therefore the effect on actin 
can be estimated to be occurring at a concentration of pateamine around 50- to 500-fold 
above that required for apoptosis, a proposition that could be assessed by visualization by 
fluorescence of the actin cytoskeletal following a treatment of a high concentration of 
pateamine, and the kinetics of any affect observed related to the kinetics of the induction of 
caspase activity and therefore the induction of apoptosis to ensure that the effect observed 
preceded this. 
 
2.5.5 Irreversibility of pateamine-induced cytotoxicity 
The irreversible nature of pateamine-induced protein synthesis inhibition (Bordeleau, 
Matthews et al. 2005) can be explained in two ways: 1. Pateamine binds covalently or with 
exceptionally high affinity to eIF4AI/II; 2. Pateamine rapidly induces apoptosis. This work 
has shown that a short time exposure to pateamine is also able to irreversibly induce 
cytotoxicity, presumably via the induction of apoptosis, it has also shown that pateamine 
treatment activated caspase 3 and that inhibition of caspase activation by the treatment 
with z-VAD-FMK somewhat prevents pateamine induced cell death. It has previously been 
shown that activated caspase 3 is able to cleave the translation initiation factors eIF4GII 
and eIF2α and this, at least in part contributes to the inhibition of translation initiation after 
the induction of apoptosis (Marissen and Lloyd 1998; Marissen, Gradi et al. 2000; 
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Marissen, Guo et al. 2000), therefore it is possible protein synthesis is irreversibly inhibited 
by pateamine through the induction of caspase 3, which then cleaves other initiation 
factors, preventing recovery of translation. However, only 15-30 min is required for the 
irreversible induction of cell death, and significant caspase 3 activity is only observed after 
1 h of exposure to pateamine which suggests it is not responsible for the observed effect on 
protein synthesis, although this does not exclude the possibility of a mechanism that 
precedes caspase 3 activation acting on translation initiation, which also causes a 
commitment to apoptosis.  
 
The alternative hypothesis regarding a high affinity or covalent interaction between 
pateamine and eIF4AI/II is supported by the observation that it was difficult to elute eIF4A 
from the affinity resin by means other than the application of completely denaturing and 
reducing conditions. The requirements for reducing conditions combined with the presence 
of a possible point of Michael addition in pateamine, and the presence of a conserved 
cysteine in pateamine-sensitive eIF4As that is not present in the pateamine-insensitive 
Ded1p, and is in close in proximity to an area of significant movement in eIF4AIII upon 
RNA binding and the fact that RNA is required for the binding of pateamine to eIF4A 
(Low, Dang et al. 2007) all circumstantially suggests that eIF4A may form a covalent 
complex with pateamine. While this is speculation, the characterization of the 
eIF4A-pateamine adduct should be easily amenable to identification by mass spectrometry. 
 
2.5.6 Mammalian pateamine targets 
Other than eIF4AIII, all of the putative protein targets identified by pateamine affinity 
chromatography are known targets of cytotoxic compound or involved in pathways 
targeted by toxic compound, however, the most likely relevant target for pateamine in 
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mammalian cells is the eIF4A family of proteins. Although it has been shown here that 
β-tubulin and β-actin are able to interact with the pateamine affinity resin, and seem to be 
affected in their ability to polymerize in the presence of soluble pateamine in vitro, it is 
unlikely they are targeted at concentrations comparable to the 24 h IC50 value for a number 
of reasons. First, the concentration required to affect microtubule or microfilament 
polymerization in vitro are 10,000-10,000 fold greater than those that are cytotoxic, a 
discrepancy not seen with compounds that have been verified to affect these structures 
such as taxol and latrunculin. Second, a cellular phenotype, such as cell cycle blockage, 
specific for targeting of either actin or tubulin was not observed in the presence of 
pateamine. Third, the interaction between eIF4AI/II/III and the pateamine affinity resin 
was less prone than that of β-tubulin and β-actin to disruption by a high concentration of 
salt, though it must be noted that if the interaction between eIF4A and pateamine is due to 
hydrophobic interactions the high salt wash would increase the observed stability of 
interaction.  
 
Even though eIF4A function has been perturbed in vitro at low micromolar concentrations 
of pateamine, approximately 1,000 fold greater than the cytotoxic concentration, total 
protein synthesis and the translation of a cap-dependent reporter gene are significantly 
inhibited at a concentration directly comparable to the 24 h IC50 value for cytotoxicity 
(Bordeleau, Matthews et al. 2005; Low, Dang et al. 2005), at this concentration (5 – 10 
nM) microfilament and microtubule function are unlikely to be affected appreciably. What 
is less clear is whether the inhibition of both cap-dependent protein synthesis and non-
sense mediated decay is required for the induction of apoptosis by pateamine, given the 
latter is only inhibited at higher concentrations. 
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2.6 Conclusions 
Putative cellular targets of pateamine belonging to the eIF4A family of proteins, and the 
cytoskeletal components β-tubulin and actin were isolated by affinity chromatography and 
identified with peptide mass-fingerprinting. The results of the in vitro microfilament and 
microtubule polymerization assays suggest these structures are not targeted at 
concentrations of pateamine that induce apoptosis over a two to four hour time period, 
though actin polymerization might be affected at concentrations much higher than this. In 
comparison the evidence, both in vitro and in vivo, regarding the specific action of 
pateamine on translation initiation through perturbation of eIF4A strongly implicates it as 
the primary target responsible for the induction of apoptosis. This proposition is further 
assessed in future chapters using the model organism Saccharomyces cerevisiae. 
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3 The generation and characterization of pateamine 
resistant yeast 
 
3.1 Introduction 
The generation and characterization of drug resistant mutants has been used in a number of 
cases to determine the target and mode-of-action of bioactive compounds in numerous 
organisms. The first drug resistant S. cerevisiae mutant reported in the literature was raised 
against the protein synthesis inhibitor cycloheximide, to which resistance was determined 
by a single dominant mutation (Middlekauff, Hino et al. 1957). Following this, a further 
five resistance conferring mutations were reported, where these ranged from completely 
recessive, semi-dominant and completely dominant mutations (Wilkie and Lee 1965). The 
motivation behind these studies was not to determine the target of the compound but rather 
the mode of resistance conferred by the mutations. Technology at the time allowed a 
relatively crude mapping procedure based on linkage disequilibrium with a small number 
of genetic markers. It was later found that the ribosomes isolated from the recessive 
cycloheximide resistant mutant were able to confer resistance to cycloheximide in an in 
vitro protein synthesis assay, whereas the extracts made from the semi-dominant mutants 
showed the same in vitro sensitivity to cycloheximide (Cooper, Banthorp et al. 1967).  
 
In the case of cycloheximide it was well established that the ribosome was the target for a 
number of years before the exact nature of the drug resistance conferring mutations within 
the ribosome was determined. As would be expected for a compound that targets a large 
multi-subunit protein complex, such as the ribosome, mutations in a number of these 
subunits conferred cycloheximide resistance that have been shown to be recessive or 
semi-dominant in nature (Sutton, Ares et al. 1978; Stocklein and Piepersberg 1980; 
Stocklein, Piepersberg et al. 1981; Fried and Warner 1982; Kaaufer, Fried et al. 1983).  
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Following studies with cycloheximide in S. cerevisiae the same approach was used to 
generate mutants resistant to a number of small molecule inhibitors including: caffeine and 
nicotine (Lindegren, Lindegren et al. 1959); nystatin (Ahmed and Woods 1967); 
oligomycin (Wakabaya.K and Gunge 1970); aminopyrazolo-(3,4-d)-pyrimidine (Pickerin 
and Woods 1973); cryptopteurine (Grant, Sanchez et al. 1974); anisomycin (Jimenez, 
Sanchez et al. 1975); trichodermin (Grant, Schindler et al. 1976); axenomycin (Sora, 
Ciferri et al. 1980); edeine (Herrera, Franceschi et al. 1986). In a number of cases these 
resistant mutants were integral in the determination of the targets of these compounds.  
 
While it is easy to generate a drug-resistant mutant, the challenge remained to identify the 
exact gene in which it occurred and the nature of the mutation, with respect to whether it 
occurs in the target encoding gene or a one that alters the response of the cell to the drug. 
In the case of cycloheximide, the first molecular identification of a protein potentially 
containing a resistance conferring mutation was achieved by comparison of ribosomes 
purified from a resistant mutant and from a wild-type strain by two-dimensional 
SDS-PAGE (Stocklein and Piepersberg 1980). The resulting amino acid substitution was 
identified by tryptic digest and peptide sequencing fragments differing from the wild-type 
protein (Stocklein, Piepersberg et al. 1981), the gene encoding this protein was 
subsequently cloned with the use of a cosmid clone bank (Fried and Warner 1982). 
 
With the advent of modern molecular biological techniques including gene cloning, DNA 
sequencing and PCR, the ability to map and characterize drug resistance conferring 
mutations has increased markedly. In the case of cycloheximide, the best part of 25 years 
was required to identify the genetic basis of mutations conferring resistance to it, in the last 
decade this has been reduced, in some cases, to a matter of months. A common procedure 
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used to identify the gene bearing the resistance mutation involves producing a 
plasmid-borne genomic library from the resistant mutant (Fried and Warner 1981). This is 
transformed into the parental strain the resistant mutant was derived from, and the selection 
of the fragment containing the resistance conferring mutation is carried out using a high 
concentration of the drug. This fragment can then be sequenced to determine the position 
of the mutation.  
 
In this way, it was shown trichodermin and curvularol inhibit protein synthesis by targeting 
the large ribosome subunit, Rpl3p specifically (Fried and Warner 1981; Kobayashi, 
Mizunuma et al. 2006), whereas reveromycin does so by inhibiting isoleucyl-tRNA 
transferase (Miyamoto, Machida et al. 2002), and GM193663 by targeting eukaryotic 
elongation factor 2 (Capa, Mendoza et al. 1998); also NKH-7 was shown to affect cell 
cycle progression by targeting α-tubulin (Chanklan, Mizunuma et al. 2008). However, in 
order to recover the mutation bearing vector from the genomic library the mutation must be 
dominant or at least semi-dominant. Ho et al. have developed a method to identify 
recessive drug-resistance conferring mutations using a molecular barcoded yeast ORF 
library and a microarray based growth assay. In this assay, a drug resistant mutant is 
transformed with a library of plasmids containing the native ORFs, each ORF bearing 
plasmid is marker with unique DNA barcodes. In the case of a recessive drug resistant 
mutant the transformant that has received the wild-type copy of the drug resistance genes 
will not grow in the presence of the drug, and once identified using the barcode and an 
oligo-nucleotide microarray, the mutant gene is cloned and sequenced (Ho, Magtanong et 
al. 2009). 
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While it is relatively easy these days to identify drug resistance conferring mutations, it is 
more challenging to identify a drug-target gene purely on this basis, in most cases there are 
many ways to become resistant to a bioactive compound. While it makes intuitive sense 
that a mutation that prevents the drug binding to its target will be dominant, this is not 
always the case. The dominant or recessive nature of the mutant allele is likely dependent 
on a number of factors, including the mechanism by which the compound affects its target 
function, the nature of the target function, and the consequence of the mutation with 
respect to drug binding and functional perturbation of the target.  
 
Drug resistant mutants can be categorized broadly into three groups, those that occur in: 
drug target genes; drug efflux pumps or the transcription factors that control them; or genes 
related to the response of the cell to the inhibition of the target. For instance cycloheximide 
resistance conferring mutations have been found in ribosomal genes mentioned above, 
genes that control drug efflux pump expression (Keeven, Ko et al. 2002) and numerous 
protease components (McCusker and Haber 1988; McCusker and Haber 1988; Gerlinger, 
Guckel et al. 1997). While the proteasome is not directly targeted by cycloheximide, the 
short half-life of ubiquitin means protein synthesis inhibition significantly decreases the 
pool of ubiquitin available for ligation (Hanna, Leggett et al. 2003). As such, the 
proteasome component mutations were resistant to the compound because they increased 
the ubiquitin pool by preventing its degradation by the proteasome. 
 
Another example is rapamycin, an immunosuppressant cyclic peptide which first binds to 
FK506 binding protein 12 (FKBP12), this complex then binds to and inhibits Tor1p and 
Tor2p as a part of the TOR1C complex. Rapamycin mimics amino acid deprivation, which 
also inhibits the TOR1C, and prevents exit from G1 phase of the cell cycle (Crespo and 
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Hall 2002). Resistance conferring mutations in the FPR1 gene, which encodes FKBP12, 
are often recessive, whereas numerous mutation have been found in TOR1 and TOR2 that 
are recessive, dominant or temperature-sensitive semi-dominant (Heitman, Movva et al. 
1991; Lorenz and Heitman 1995). On the other hand, only recessive resistant conferring 
mutations have been reported for the topoisomerase II inhibitor etoposide (Liu, Hsiung et 
al. 1994). This can be rationalized by the observation that etoposide requires the enzymatic 
activity of topoisomerase II to be toxic (Nitiss and Beck 1996), any wild-type protein 
present will be able to cause toxicity. In the cases of drug resistance conferring mutants in 
the literature there is no correlation between the dominance or recessiveness of the mutant 
and the nature of the gene with respect to being the drug target. The determination of the 
dominant-recessive nature of the drug resistant allele can provide vital information 
necessary for the mapping of the mutation, and as seen in the above examples, can often be 
rationalized when more details of the drug mechanism of action are known, unfortunately 
this knowledge alone does not allow the distinction between target and non-target 
conferring mutations when multiple loci are found to confer resistance.  
 
To avoid the generation of a resistant clone because of increased drug efflux, a number of 
the previously mentioned studies used yeast strains that have, at times multiple, genes 
deleted that result in hypersensitivity to most drugs. For example, the pleiotropic drug 
resistance (PDR) genes which include a number of transmembrane pumps that are 
responsible for the removal of xenobiotics from the cytosol (Balzi and Goffeau 1995; Cui, 
Hirata et al. 1996). Without taking such steps, mutations can be found that cause existing 
pumps to export the drug more efficiently (Tutulan-Cunita, Mikoshi et al. 2005), or in 
transcription factors that control the expression of the pumps, Pdr1p for instance 
(McCusker and Haber 1988; Wendler, Bergler et al. 1997). These mutations are the least 
informative with respect to the target of the drug or its mechanism. The deletion of genes 
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associated with ergosterol synthesis, which decreases the sterol content of the plasma 
membrane whilst increasing membrane fluidity and permeability, also sensitizes yeast to a 
number of bioactive compounds (Mukhopadhyay, Kohli et al. 2002; Abe and Hiraki 2009). 
 
In addition to inducing apoptosis in mammalian cell lines, pateamine has also been shown 
to affect the growth of the fungi Trichophyton mentagrophytes, Cladosporium resinae and 
the yeast Candida albicans (Northcote, Blunt et al. 1991). Yet there is no reported 
inhibitory effects on any prokaryotic organism and no effect observed in an in vitro 
translation extract derived from E. coli cells (Bordeleau, Matthews et al. 2005). 
S. cerevisiae has orthologues of all of the genes that encode all of the proteins identified as 
being putative pateamine target in mammalian cells: Actin (Ng and Abelson 1980), 
β-tubulin (Water and Kleinsmith 1976), and the eIF4A family proteins. Yeast eIF4A is 
encoded by two genes, TIF1 and TIF2, which, in contrast to human eIF4AI and II, differ 
only at six nucleotide positions but encode an identical polypeptide sequence (Linder and 
Slonimski 1988; Linder and Slonimski 1989). The closest yeast orthologue of eIF4AIII is 
Fal1p, an essential gene integral for 40S ribosomal subunit maturation (Kressler, de la 
Cruz et al. 1997). 
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3.2 Aims and objectives 
The aim of this study is to generate a pateamine resistant mutant and establish the genetic 
basis for this resistance. In order to generate a strongly resistant mutant, a sensitized 
starting strain from a collection of deletion mutants was chosen, mutagenized, and exposed 
to a high concentration of pateamine. As the most likely target for pateamine is eIF4A, the 
starting strain was one with a sensitizing deletion and the deletion of TIF2, this was done 
to simplify the isolation of the eIF4A sequence at the TIF1 locus. Resistant clones were 
genotyped at the TIF1 locus and this sequence was cloned and re-introduced into the 
starting strain on a 2µ plasmid to verify pateamine resistance.  
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3.3 Materials and methods 
3.3.1 Yeast strains 
All strains of S. cerevisiae used in this study were of the MATa mating type of the BY4741 
background and have a genotype of his3Δ1, leu2Δ0, met15Δ0 and ura3Δ0. For this study 
the strain his3Δ::KanR was used as a surrogate wild-type strain, replacement of the HIS3 
gene with the kanamycin resistance cassette is presumed to be inconsequential since 
BY4741 is a histidine auxotroph. All deletion strains were purchased from Thermo 
Scientific-Open Biosystems (Huntsville, AL, USA) as a part of the YKO MATa Strain 
Collection (Winzeler, Shoemaker et al. 1999). The tif2Δ::NatR pdr5Δ::KanR, tif2Δ::NatR 
erg2Δ::KanR, tif2Δ::NatR erg3Δ::KanR, tif2Δ::NatR erg5Δ::KanR and tif2Δ::NatR 
erg6Δ::KanR, tif2Δ::NatR his3Δ::KanR double deletion strains were kindly supplied by 
Veronica Venturi (Chemical-genetics Laboratory, School of Biological Sciences, Victoria 
University of Wellington) and were constructed via the synthetic genetic array mass 
mating method (Tong and Boone 2006) using a MATα query strain containing tif2Δ::NatR. 
 
3.3.2 Growth media 
All cultures were performed in the media below supplemented with G418 (Invitrogen, 
Carlsbad, CA) or G418 and clonNAT (Werner BioAgents, Jena, Germany). All yeast 
strains were cultured according to standard yeast methods (Amberg, Burke et al. 2005) in 
one of the following media: 
YPD (1% (w/v) yeast extract, 2% (w/v) bacto-peptone, 2% (w/v) glucose);  
YPGal (1% (w/v) yeast extract, 2% (w/v) bacto-peptone, 2% (w/v) galactose);  
SC (synthetic complete media: 0.17% (w/v) Bacto-yeast nitrogen base (without amino 
acids or ammonium sulphate), 0.1% (w/v) monosodium glutamate, 0.2% (w/v) “amino 
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acid mix” (3 g adenine, 2 g uracil, 2 g inositol, 0.2 g para-aminobenzoic acid, 2 g alanine, 
2 g arginine, 2 g asparagine, 2 g aspartic acid, 2 g cycteine, 2 g glutamic acid, 
2 g glutamine, 2 g glycine, 2 g histidine, 2 g isoleucine, 10 g leucine, 2 g lysine, 
2 g methionine, 2 g phenyalanine, 2 g proline, 2 g serine, 2 g threonine, 2 g tyrosine, 
2 g tryptophan, 2 g valine);  
SD –Ura (synthetic dropout minus uracil; as with SC but without uracil in the “amino acid 
mix”);  
SD –Leu (as with SC but without leucine in the “amino acid mix”).  
 
3.3.3 Plasmids used in this study 
The DH5α E. coli clone bearing a 2 micron plasmid containing the TIF1 open reading 
frame fused to a tandem affinity tag (Protein A and 6xHis domains) was purchased from 
Thermo Scientific-Open Biosystems. This plasmid was derived from pRSAB1234 by 
modification of the C-terminal fusion tag to create BG1805 (Gelperin, White et al. 2005), 
herein the plasmid containing the wild type TIF1 ORF are referred to as pBG1805-TIF1, 
while plasmids containing potential pateamine resistant alleles of TIF1 are referred to as 
pBG1805-PAR1 - 5. Gene expression is driven by the S. cerevisiae GAL1 promoter. This 
plasmid contains the URA3 gene for selection in S. cerevisiae and an ampicillin resistance 
gene for selection in E. coli. 
 
3.3.4 Liquid growth assay 
The sensitivity of haploid MATa, his3Δ::KanR, S .cerevisiae to pateamine was determined 
by measuring turbidity in 96-well plates. Briefly, pateamine was serially diluted 2-fold, in 
triplicate, in 50 µl of YPD containing 0.2% DMSO, to give a range final concentration of 
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40 – 0.625 µM, after which 50 µl of YPD containing 1 x 105 cells was added to each well. 
The carrier solvent control was YPD containing 0.1% DMSO. The plate was incubated for 
30 h at 30 °C, and the absorbance at 590 nm measured using the Wallac EnVision 2102 
plate-reader (Perkin-Elmer, Waltham, MA, USA). 
 
3.3.5 Pateamine recovery assay 
The ability of haploid MATa, his3Δ::KanR, S .cerevisiae to recover from pateamine 
induced growth inhibition was assessed. A single colony was inoculated into 2 ml of YPD 
and incubated overnight at 30 °C on a rotator. The overnight culture was diluted to an 
OD600 of 0.2 in 2 ml of YPD containing either 0.1% DMSO, 250 mM acetic acid, 1 µM 
cycloheximide, 10 µM or 50 µM pateamine, and returned to the incubator. After 24 h, cells 
were recovered by centrifugation, washed three times with ddH2O, and resuspended in 
10 ml of YPD media to an OD600 of 0.01. Cultures were incubated at 30 °C with agitation 
and the OD600 measured at 6, 12, 24, 30 and 48 h using the Genova spectrophotometer 
(Jenway Ltd., Dunmow, Essex, UK). 
 
3.3.6 Colony forming unit assay 
A single MATa, his3Δ::KanR, colony was inoculated into 2 ml of YPD and incubated 
overnight at 30 °C on a rotator. The overnight culture was diluted to an OD600 of 0.2 in 
2 ml of YPD containing either 250 mM acetic acid or 50 µM pateamine, and incubated at 
30 °C with agitation. After 24 h, cells were recovered by centrifugation, washed three 
times with ddH2O, resuspended in 2 ml of ddH2O, 100 µl was spread onto YPD agar plates 
and incubated 30 °C for 3 days. 
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3.3.7 Phenol-chloroform-IAA DNA extraction 
Phenol-chloroform-isoamyl alcohol DNA extraction was performed according to standard 
molecular biology methods (Ausubel 1988). Briefly, an equal volume of 25:24:1 Tris 
buffered (10 mM, pH 8) saturated aqueous phenol:chloroform:isoamyl alcohol was added 
to the sample and vortexed for 30 s. Following micro-centrifugation (13.2k rpm, 
Centrifuge 5415R, Eppendorf, Hamburg, Germany) for 5 min, the aqueous layer was 
removed and added to an equal volume of 24:1 chloroform:isoamyl alcohol, vortexed for 
30 s and returned to the micro-centrifuge for 5 min. The aqueous layer was removed and 
retained. 
 
3.3.8 Ethanol precipitation 
When described in methods below, ethanol precipitation was performed according to 
standard molecular biology methods (Ausubel 1988). Briefly, sodium acetate was added, 
giving a final acetate concentration of 0.3 M followed by 3 volumes of 95% ethanol (v/v). 
After vortexing this was placed at -20 °C for 15 min. Precipitated DNA was collected by 
micro-centrifugation for 15 min at 2 °C, the resulting pellet was air dried at room 
temperature for 15 min and re-dissolved in ddH2O or TE buffer (1 mM EDTA, 10 mM 
Tris-HCl pH 7.5). 
 
3.3.9 Isopropanol precipitation 
When described in methods below, isopropanol precipitation of DNA was performed 
according standard molecular biology methods (Ausubel 1988). Briefly, ammonium 
acetate was added giving a final acetate concentration of 2 M, followed by 0.7 volumes of 
isopropanol. After 15 min incubation at room temperature precipitated DNA was recovered 
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by micro-centrifugation and the pellet air-dried at room temperature for 15 min and 
re-dissolved in ddH2O or TE buffer (1 mM EDTA, 10 mM Tris-HCl pH 7.5). 
 
3.3.10 E. coli plasmid preparation 
Isolation and purification of plasmid DNA from DH5α E. coli was performed with the 
Zyppy™ Mini-prep kit (Zymo Research, Orange, CA, USA) according to the 
manufacturers’ instructions. DNA was quantified using the Nano-Drop ND-1000 
spectrophotometer (Thermo Scientific, Wilmington, DE) according to the standard 
protocol (Ausubel 1988), and purity and size assessed with agarose gel electrophoresis 
(Method 3.3.11). 
 
3.3.11 DNA electrophoresis 
All DNA electrophoresis was performed according to standard molecular biology methods 
(Ausubel 1988). Briefly, all electrophoresis was performed in 1% agarose gels, run in TBE 
buffer (89 mM Boric Acid, 2 mM EDTA disodium dihydrate, 89 mM Tris Base pH 8.3) 
with 0.5 µg/ml ethidium bromide. All samples were dissolved in either ddH2O or TE 
buffer and mixed 5:1 with 6x sample loading buffer (30% glycerol (v/v), 0.25% (w/v) 
bromophenol blue, 0.25% (w/v) cyanol xylene) prior to loading onto the gel. 
Electrophoresis was performed at a constant 100 V and visualized on a transilluminator at 
365 nm (UVItec, Cambridge, UK). 
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3.3.12 EMS mutagenesis 
The double deletion tif1Δ::NatR, erg6Δ::KanR strain was inoculated into YPD medium 
with 200 µg/ml G418 and 100 µg/ml clonNAT and grown overnight in a shaking incubator 
at 30 °C. The overnight culture was diluted to an OD600 of 0.05, returned to the shaking 
incubator and grown to an OD600 of 0.7. Cell concentration was determined using a 
haemocytometer (Amberg, Burke et al. 2005), aliquots containing 2 x 10
8
 cells were 
collected by centrifugation, washed three times with 0.1 M sodium phosphate buffer pH 
7.0, resuspended in 1 ml of the same buffer containing 4% EMS (v/v) (ethyl methane 
sulfonate) and returned to the incubator for 1 h. Cells were recovered by 
micro-centrifugation, washed three times with 0.2 ml of 20% (v/v) sodium thiosulfate, 
re-suspended in 5 ml of YPD and incubated at 30 °C overnight without shaking. Cells were 
recovered by centrifugation and resuspended in 20 ml of YPD with 200 µg/ml G418 and 
100 µg/ml clonNAT and 50 µM pateamine and incubated for at 30 °C with shaking. After 
48 h, 0.5 ml of the culture was spread on YPD agar with 200 µg/ml G418 and 100 µg/ml 
clonNAT and 50 µM pateamine and incubated for three days at 30 °C. Five resulting 
colonies, referred herein as PAR1-5, were picked and pateamine resistance confirmed by 
streaking onto YPD agar with µg/ml G418 and 100 µg/ml clonNAT and 10 µM pateamine 
and incubation at 30 °C for three days. 
 
3.3.13 S. cerevisiae plasmid preparation 
Plasmids were recovered from S. cerevisiae according to standard yeast molecular genetics 
methods (Amberg, Burke et al. 2005). Briefly, a single colony of the plasmid bearing strain 
was inoculated into SD –Ura with 200 µg/ml G418, or 200 µg/ml G418 and 100 µg/ml 
clonNAT depending on the strain, and incubated at 30 °C overnight with shaking. The 
cells were recovered by centrifugation, washed three times with sterile ddH2O, and 
resuspended in 0.2 ml of a solution containing 2% (v/v) Triton X-100, 1% SDS (w/v) 
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(sodium dodecyl sulphate), 0.1 M NaCl, 1 mM disodium EDTA, 10 mM Tris-HCl pH 8.0. 
An equal volume of Zirconia beads (Applied Biosystems/Ambion, Austin, TX, USA) was 
added, followed by the 0.2 ml of 25:24:1 tris buffered saturated aqueous 
phenol:chloroform:isoamyl alcohol (Method 3.3.7) and vortexed for 2 min, followed by 
micro-centrifugation for 5 min. Nucleic acids were recovered from the aqueous layer by 
ethanol precipitation (Method 3.3.8), the resulting pellet was then dissolved in TE buffer 
containing 10 µg/ml RNase A (Sigma-Aldrich, St Louis, MO, USA) and incubated at 
30 °C for 15 min. Plasmid DNA was recovered by phenol-chloroform-IAA (Method 3.3.7) 
extraction followed by ethanol precipitation (Method 3.3.8). The resulting pellet was 
dissolved in TE buffer and purity and size assessed by agarose gel electrophoresis in 
1% agarose gels (Method 3.3.11). 
 
3.3.14 Transformation of S. cerevisiae  
Transformation of S. cerevisiae was performed using the lithium acetate/single stranded 
carrier DNA/PEG method (Gietz and Schiestl 2007) with minor modifications. Prior to 
transformation a single colony of each strain to be transformed was inoculated into YPD 
media and incubated overnight at 30 °C with shaking. The next day the culture was diluted 
to an OD600 of 0.05 in YPD media and returned to the incubator until the OD600 had 
reached 0.7 – 1. Cell density was measured using a haemocytometer, the volume of culture 
corresponding to 1 x 10
8
 cells was removed; the cells recovered by centrifugation 
(4000 rpm, Centrifuge 5810, Eppendorf), washed three times with ddH2O and resuspended 
in transformation mix (33.33% PEG 3350 (w/v), 0.27 mg/ml single stranded salmon sperm 
DNA, 0.1 M lithium acetate) containing approximately 1 µg of plasmid DNA. This was 
incubated at 42 °C for 40 min, followed by micro-centrifugation for 1 min, after which the 
transformation mix was removed; the cells were washed with 1 ml of 30 °C YPD and 
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spread onto SD – Ura agar plates with 200 µg/ml G418, or 200 µg/ml G418 and 100 µg/ml 
clonNAT depending on the strain, to select for successful transformants. 
 
3.3.15 TIF1-TAP plasmid digestion and purification 
Purified pBG1805-TIF1 plasmid was digested with AceII, HindIII and EcoRI restriction 
enzymes and the resulting large fragment was purified using gel permeation 
chromatography. Briefly, 0.5 mg of plasmid was digested with 1000 units of HindIII and 
EcoRI in 0.5 ml NEbuffer 2 (50 mM NaCl, 10 mM MgCl2, 1 mM DTT, 10 mM Tris-HCl 
pH 7.9, New England Biolabs, Ipswich, MA, USA) overnight at 37 °C. Complete digestion 
was confirmed by electrophoresis in a 1% agarose gel in 0.5x TBE buffer (Method 3.3.11). 
Digested plasmid was isolated and purified by phenol-chloroform-IAA extraction (Method 
3.3.7) and ethanol precipitation (Method 3.3.8). The purified digest mixture was 
resuspended in NEbuffer 4 (50 mM potassium acetate, 20 mM Tris acetate, 10 mM 
magnesium acetate, 1 mM DTT, pH 7.9, New England Biolab) and further digested with 
AatII overnight at 37 °C, and the resulting digested plasmid was purified by 
phenol-chloroform-IAA extraction (Method 3.3.7) and ethanol precipitation (Method 
3.3.8). To ensure isolation of only the large digest fragment for transformation, after 
ethanol precipitation of the AatII digest, DNA was dissolved in ddH2O, gel electrophoresis 
loading buffer was added to 1x, and the mixture was then applied to a 2 x 120 cm glass 
Econo-Column (Bio-Rad, Hercules, CA, USA) packed with Bio-Gel A-15m (Bio-Rad) and 
allowed to enter the resin by gravity after which TE buffer was applied. Fractions were 
collected and DNA content assayed using the Nano-Drop spectrophotometer following 
standard procedures (Ausubel 1988). DNA containing fractions were analyzed by 
electrophoresis on 1% agarose and only those fractions containing the large digest product 
were combined, and precipitated with isopropanol (Method 3.3.9). The precipitate was 
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recovered by centrifugation, dissolved in TE buffer and purity was assessed 
electrophoretically in 1% agarose gels (Method 3.3.11). 
 
3.3.16 Gap-repair allelic recovery 
The pateamine resistant clones PAR1-5 were transformed with the large tif1 plasmid 
fragment prepared using Method 3.3.15 using the lithium acetate/single stranded carrier 
DNA/PEG method (Method 3.3.14), with 100 µg of the large digest product. Selection was 
performed on SD – Ura agar plates with 200 µg/ml G418 and 100 µg/ml clonNAT. 
Re-circularized plasmids were recovered according to method 3.3.13. 
 
3.3.17 Serial spot dilution assay 
Strains generated using Method 3.3.16 were inoculated into YPD or YPGal media with the 
appropriate antibiotic (200 µg/ml G418 or 100 µg/ml clonNAT) and grown overnight in a 
shaking incubator at 30 °C. The overnight culture was diluted to an OD600 of 
approximately 0.05, returned to the shaking incubator and grown to an OD600 of 1, this 
culture was added to a sterile 96-well plate and serially diluted ten-fold at least 5 times. A 
multi-channel pipette was used to apply 2.5 – 5 µl of each dilution of the above culture 
onto YPD or YPGal agar plates containing 50 µM pateamine or 0.1% (v/v) DMSO as a 
carrier control, after absorption by the agar the plate was incubated at 30 °C for 3 days 
(Parsons, Brost et al. 2004). 
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3.3.18 TIF1 sequencing 
The plasmids pBG1805-PAR1 – 5, originating from the PARt1-5 clones, produced using 
Method 3.3.16 were sent to the Allan Wilson Centre Genome Service for DNA sequencing 
of the TIF1 coding region (Allan Wilson Centre, Massey University, Palmerston North). 
 
3.3.19 De novo protein and RNA synthesis assay 
The strain his3Δ::KanR was inoculated into YPD medium with 200 µg/ml G418 and 
grown overnight in a shaking incubator at 30 °C. The overnight culture was diluted to an 
OD600 of approximately 0.05 in SC medium, returned to the shaking incubator and grown 
to an OD600 of 0.7. Cells were diluted to an OD600 of 0.5 in either SD - Ura or SD - Leu 
containing pateamine (two-fold serial dilution from 40 µM to 0.31 µM of pateamine or a 
0.1% (v/v) DMSO carrier control), and incubated for 30 min at 30 °C with shaking, after 
which the OD600 was measured and 1 µCi of [5-
3
H] uridine or L-[4,5-
3
H] leucine (GE 
Healthcare, Amersham Biosciences, Uppsala, Sweden), was added and incubated at 30 °C 
for 15 min. Cells were recovered by centrifugation, the supernatant removed, protein and 
RNA were precipitated with the addition of ice-cold aqueous 10% TCA (w/v) 
(trichloroacetic acid, Sigma-Aldrich) and recovered by filtration on GF/B glass fibre filters 
(Whatman Ltd., Kent, England), which were washed three times with ice-cold 10% TCA 
(w/v), followed by ice cold 95% ethanol (v/v). Filters were dried at 60 °C for 1 h, 
incubated at room temperature overnight in the dark to reduce background 
chemoluminescence, and radioactivity measured in Biodegradable Scintillation Cocktail 
(GE Health Sciences) on a liquid scintillation counter (Wallac 1409, Pharmacia-LKB, 
Piscataway, NJ, USA). An IC50 was determined using SigmaPlot Ver 10.0 (Systat Software 
Inc., Richmond, CA, USA) for each individual assay, the results from three independent 
assays were then averaged, standard errors determined and error values propagated to final 
derived data through standard methods.  
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3.4 Results 
3.4.1 Pateamine reversibly inhibits the growth of S. cerevisiae 
A liquid growth assay was used to establish an inhibitory concentration of pateamine 
against wild-type haploid MATa S. cerevisiae a liquid growth assay was performed. Figure 
3.1 shows pateamine inhibits the growth of yeast over a 24 h period with an IC50 of 
approximately 3 µM. In contrast to the inhibitory effect of pateamine on protein synthesis 
(Bordeleau, Matthews et al. 2005), and cytotoxicity in mammalian cells (Figure 2.1) the 
effect in yeast is reversible. Figure 3.2 shows that in contrast to acetic acid, a known 
inducer of yeast apoptosis (Madeo, Herker et al. 2004), cells treated with pateamine are 
able to recover after the drug has been removed. However, in contrast to cycloheximide 
treated cells, which recover at the same rate as untreated cells, the recovery from 
pateamine induced growth inhibition is delayed by 6 and 24 h for 10 and 50 µM pateamine 
respectively. A colony forming unit assay was performed to determine whether the 
observed delay in recovery was due to a small population of cells that remain viable, or the 
slow recovery of the entire treated population. Figure 3.3b confirms the latter option, with 
all pateamine treated cells remaining viable but are stalled in their ability to recover from 
pateamine rather than non-viable as occurs after acetic acid treatment (Figure 3.3a). 
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Figure 3.1 Yeast dose-response experiments. The sensitivity of the Δhis3 strain to pateamine, in 
liquid and solid media containing 200 µg/ml G418. For liquid assays, the IC50 calculated from three 
independent experiments performed in triplicate with an average of 2.85 ± 0.13, this was calculated 
by fitting to a sigmoidal curve, presented is a representative dose-response curve. The solid media 
assay was performed in a 24-well plate with a 1 ml volume of agar containing the concentration of 
pateamine in µM indicated above each well. Presented is a representative dose-response 
experiment, the average MIC after 2 days incubation at 30°C from three assays was 12.5 µM. 
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Figure 3.2 Growth inhibition recovery assay. Recovery of the Δhis3 strain after 24 h exposure 
to pateamine, cycloheximide or acetic acid induced growth inhibition was assessed by inoculating 
washed cells into YPD medium containing 200 µg/ml G418. Growth was measured 
spectrophotometrically at 600 nm, each data point is an average of three independent experiments. 
 
 
Figure 3.3 Colony forming unit assay. Subsequent to incubation at 30 °C for 24 h in YPD 
medium containing 200 µg/ml G418 and A. 250 mM acetic acid or B. 50 µM pateamine. Δhis3 cells 
were washed with water and an equal volume of each spread onto YPD agar containing 
200 µg/ml G418. Plates were incubated at 30 °C for 3 days. 
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3.4.2 Multi-drug resistance pump and ergosterol pathway deletions 
sensitize to pateamine 
A number of haploid yeast deletion strains were tested by serial spot dilution assay 
(Method 3.3.17) for enhanced sensitivity to pateamine in order to minimize the amount of 
pateamine used for the resistant mutant generation, and also to impart a strong selection 
pressure for the most resistant mutant. The strains tested were deficient in either ergosterol 
synthesis pathway components or the major drug efflux pump Pdr5p, that have been 
previously found to enhance sensitivity to a number of bioactive compounds 
(Mukhopadhyay, Kohli et al. 2002; Parsons, Brost et al. 2004). Figure 3.4 shows that the 
deletions of all of these genes results in enhanced sensitivity to 10 µM pateamine in YPD 
medium, however, the deletion of ERG2, ERG3 or ERG6 conferred the most sensitivity. 
Due to this enhanced sensitivity compared to the Δpdr5 strain, the Δerg6 strain was chosen 
as the starting strain, it is also presumed that in this strain any mutation that up-regulates 
the expression of an efflux pump will not confer resistance as the increase in efflux will be 
negated by the increased permeability of the cell wall. For reasons outlined later, all of the 
strains tested were also deficient in TIF2 (tif2Δ::NatR) the gene that contributes the 
majority of eIF4A to the intercellular pool (Prat, Schmid et al. 1990). This deletion does 
not significantly increase the sensitivity to the concentration of pateamine used in this 
assay, beyond that of the surrogate wild-type Δhis3 strain (Figure 3.4). 
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Figure 3.4 Serial spot dilution assay of strains deficient in ergosterol pathway components 
and the Pdr5p drug efflux pump. Overnight cultures were diluted to OD600 = 1, which was 
serially diluted 10 fold, 4 times, and an equal volume of each strain and dilution was spotted onto 
YPD agar plates containing 200 µg/ml G418 and either 0.1% DMSO or 10 µM pateamine, and 
incubated at 30 °C for 3 days.  
 
3.4.3 Pateamine resistance 
The Δtif2, Δerg6 strain was mutagenized using EMS and, in order to isolate the most 
resistant mutant, clones were enriched first by exposure in liquid culture to 50 µM 
pateamine (a concentration that completely inhibits the growth of yeast over 24 h, the 
resulting culture was plated onto YPD agar plates containing 50 µM pateamine. Five 
resistant clones (PAR1-5) were isolated and confirmed by serial spot dilution assay. Figure 
3.5 shows these clones are able to grow on YPD agar containing 10 µM pateamine 
whereas the strain they were derived from was not. 
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Figure 3.5 PAR clone resistance to pateamine confirmation by serial spot dilution. 
Pateamine resistant clones PAR1-5 and the strain they were derived from (Δtif2, Δerg6) were 
grown overnight in YPD medium containing 100µg/ml clonNAT and 200 µg/ml G418. Each culture 
was diluted to OD600 = 1, then diluted serially 10 fold, 3 times, and an equal volume of each strain 
and dilution was spotted onto YPD agar plates containing 100 µg/ml clonNAT and 200 µg/ml G418 
and 0.1% DMSO or 10 µM pateamine. Plates were incubated at 30 °C for three days. 
 
3.4.4 Gap repair-mediated recovery of tif1 allele 
It was proposed the strongest resistance conferring mutation would occur in one of the 
genes encoding the yeast orthologues of mammalian eIF4AI/II, designated TIF1 and TIF2. 
Gap-repair mediated allelic recovery was used to recover the sequence at the TIF1 locus in 
order to establish whether mutation at that site conferred pateamine resistance. To allow 
the unambiguous recovery of the sequence from the TIF1 locus, the parental strain also 
carried a deletion of TIF2 (tif2Δ::NatR). There are only six nucleotide differences between 
TIF1 and TIF2 all of which occur outside of the restriction sites used in the plasmid 
digestion, the choice of the deletion of TIF2 was for due to the fact that it contribute the 
greater proportion of eIF4A to the intracellular pool (Prat, Schmid et al. 1990), though this 
did not appear to affect pateamine sensitivity at the concentrations presented here. The 
plasmid BG1805-TIF1 was digested first with HindIII and EcoRI (Figure 3.6, Lane D) to 
remove a fragment 639 base pairs in size. To ensure that this fragment was not repaired 
back into the plasmid on transformation into yeast; the small fragment was further digested 
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with AatII and separated from the large fragment by size exclusion chromatography 
(Method 3.3.15) (Figure 3.6, Lanes E – L). 
 
 
Figure 3.6 Large BG1805 plasmid fragment production by restriction digestion. 
Electrophoresis was performed on 1% agarose gels and run in TBE buffer. Lane: A. 1kb Ladder; B. 
Undigested BG1805-TIF1 plasmid; C. HindIII digestion; D. EcoRI and HindIII digestion; E. HindIII, 
EcoRI and AatII digestion; F. Purified digestion reaction; H – K. Size exclusion chromatography 
elution fractions; L. Purified and concentrated, pooled size exclusion eluate. 
 
The clones, PAR1-5, were transformed with the large digest fragment generated by 
restriction enzyme digestion of the pBG1805-TIF1 plasmid (Methods 3.3.16). Repaired 
plasmids were isolated and transformed into the parental pateamine--sensitive Δtif2, Δerg6 
strain. A serial spot dilution assay confirmed that plasmids bearing the tif1 alleles 
recovered from PAR1-5 confer pateamine resistance (Figure 3.7), while plasmids 
containing wild type TIF1, the yeast eIF4AIII orthologue FAL1, or an empty vector 
carrying the URA3 selectable marker were unable to do so (Figure 3.8). 
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Figure 3.7 Clones bearing gap-repaired TIF1 plasmids recovered from PAR1-5 clones confer 
pateamine resistance to the Δtif2, Δerg6 strain. Transformants containing the indicated 
plasmids were grown overnight, diluted to OD600 = 1, then serially diluted 10 fold, 3 times. Equal 
volumes of each strain and dilution was spotted onto YPGal agar plates containing either 
0.1% DMSO or 15 µM pateamine, and incubated at 30 °C for 3 days. 
 
 
Figure 3.8 Pateamine resistance is not due to the URA3 selection marker presence. 
Overnight cultures were streaked onto YPGal medium containing 15 µM pateamine or 
0.1% DMSO. Clones contain the following plasmids: A. pBG1805-TIF1; 
B - F. pBG1805-PAR1 - PAR5; G. pBG1805-FAL1; H. pRS316 empty vector. Plates were 
incubated for 3 days at 30 °C. 
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3.4.5 Sequencing of tif1 allele reveals a single point mutation 
Inspection of the sequence recovered by gap-repair shows the presence of a single point 
mutation in the plasmids recovered from PAR1-5 – a thymidine to cytosine transition at 
nucleotide 440 which, in turn leads to a proline to leucine substitution at position 147 of 
the resulting protein (Figure 3.9). 
.  
Tif1p            MSEGITDIEESQIQTNYDKVVYKFDDMELDENLLRGVFGYGFEEPSAIQQRAIMPIIEGH 60 
tif1p-P147L      MSEGITDIEESQIQTNYDKVVYKFDDMELDENLLRGVFGYGFEEPSAIQQRAIMPIIEGH 60 
                 ************************************************************ 
 
Tif1p            DVLAQAQSGTGKTGTFSIAALQRIDTSVKAPQALMLAPTRELALQIQKVVMALAFHMDIK 120 
tif1p-P147L      DVLAQAQSGTGKTGTFSIAALQRIDTSVKAPQALMLAPTRELALQIQKVVMALAFHMDIK 120 
                 ************************************************************ 
 
Tif1p            VHACIGGTSFVEDAEGLRDAQIVVGTPGRVFDNIQRRRFRTDKIKMFILDEADEMLSSGF 180 
tif1p-P147L      VHACIGGTSFVEDAEGLRDAQIVVGTLGRVFDNIQRRRFRTDKIKMFILDEADEMLSSGF 180 
                 ************************** ********************************* 
 
Tif1p            KEQIYQIFTLLPPTTQVVLLSATMPNDVLEVTTKFMRNPVRILVKKDELTLEGIKQFYVN 240 
tif1p-P147L      KEQIYQIFTLLPPTTQVVLLSATMPNDVLEVTTKFMRNPVRILVKKDELTLEGIKQFYVN 240 
                 ************************************************************ 
 
Tif1p            VEEEEYKYECLTDLYDSISVTQAVIFCNTRRKVEELTTKLRNDKFTVSAIYSDLPQQERD 300 
tif1p-P147L      VEEEEYKYECLTDLYDSISVTQAVIFCNTRRKVEELTTKLRNDKFTVSAIYSDLPQQERD 300 
                 ************************************************************ 
 
Tif1p            TIMKEFRSGSSRILISTDLLARGIDVQQVSLVINYDLPANKENYIHRIGRGGRFGRKGVA 360 
tif1p-P147L      TIMKEFRSGSSRILISTDLLARGIDVQQVSLVINYDLPANKENYIHRIGRGGRFGRKGVA 360 
                 ************************************************************ 
 
Tif1p            INFVTNEDVGAMRELEKFYSTQIEELPSDIATLLN 395 
tif1p-P147L      INFVTNEDVGAMRELEKFYSTQIEELPSDIATLLN 395 
                 *********************************** 
Figure 3.9 Recovered pBG1805-PAR1 - 5 amino acid sequence alignment with wild-type 
TIF1. The plasmids recovered from tPAR1 – 5 all contained the single nucleotide transversion at 
nucleotide position 440 (colored red), which results in proline to leucine substitution at position 147.  
 
3.4.6 Pateamine inhibits protein and RNA synthesis in yeast 
While an exhaustive genome-wide mapping of the pateamine resistance mutant was not 
performed, the isolation of a tif1 mutant that confers pateamine resistance strongly 
suggests that eIF4A is a target of pateamine in yeast. Consistent with the role of eIF4A in 
mammalian cells, yeast eIF4A has been shown to be an ATP dependent RNA helicase 
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involved in translation initiation. In order to assess the impact of pateamine treatment on 
protein and RNA synthesis an in vivo metabolic labeling experiment was performed. 
Figure 3.10 shows representative dose-response curves for the incorporation of 
radio-labeled leucine (A) and uridine (B), which indicate pateamine is able to inhibit both 
protein and RNA synthesis with IC50 values of 4.4 ± 0.4 and 8.7 ± 0.5 respectively. 
 
Figure 3.10 Pateamine inhibits in vivo macromolecule synthesis in yeast. The Δhis3 strain 
was grown to mid-log growth phase in SC medium, diluted to OD = 0.5 in either SD – Leu or 
SD - Ura medium, and exposed to a twofold serial dilution of pateamine for 30 min at 30 °C. 
Radiolabeled leucine or uridine was added and incubated at 30 °C for 15 min, after ice-cold TCA 
precipitation, incorporated radioactivity was measured using liquid scintillation counting. Each 
experiment was repeated three times in triplicate, presented is representative curves for; A. leucine 
incorporation and B. uridine incorporation. IC50 values were calculated after fitting to a sigmoidal 
curve to be 4.4 ± 0.4 µM and 8.7 ± 0.5 µM for radiolabeled leucine and uridine incorporation 
respectively. 
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3.4.7 Predicting a putative pateamine binding site 
To postulate a potential binding site for pateamine on eIF4A it was reasoned that such a 
site would be conserved on the known pateamine targets (human eIF4AI, eIF4AII, 
eIF4AIII and yeast Tif1p) but absent in Ded1p, which has been shown to be insensitive to 
pateamine in vitro. Also, that this site would not be a part of the RNA, ATP or eIF4G 
binding sites, as others have shown that pateamine enhances RNA binding, ATP binding 
and hydrolysis (Bordeleau, Matthews et al. 2005) and the interaction with eIF4G of human 
eIF4AI (Bordeleau, Cencic et al. 2006), and enhances ATP hydrolysis in human eIF4AIII 
and yeast Tif1p (Low, Dang et al. 2007). Given that eIF4AI is only able to hydrolyse ATP 
when bound to RNA (Lorsch and Herschlag 1998) the ATP and RNA binding surfaces as 
well as the of eIF4A can also be excluded as a possible binding site. Furthermore it could 
be suggested that this site should also be in close proximity to the resistance conferring 
mutation in yeast Tif1p identified in this work and occurs at least predominantly on the 
N-terminal lobe, which has been shown to bind, albeit weakly to pateamine (Low, Dang et 
al. 2005).  
 
In order to identify possible positions for this binding site the amino acid sequences of the 
known targets of pateamine (human eIF4AI, eIF4AII, eIF4AIII and yeast Tif1p) were 
aligned with each other and the sequences of Ded1p and Fal1p, which was included due to 
its high degree of homology to all the verified pateamine targets (Figure 3.11). An 
immediate observation is that the sequence surrounding and including the resistance 
mutation (P147L in Tif1p which corresponds to P164 in eIF4AIII, underlined in red) is 
highly conserved in all of the sequences aligned here regardless of whether the protein is a 
pateamine target: this suggests it is not the exact site. Closer inspection of residues within 
15 Å of P147/164 (numbering referring to Tif1p/eIF4AIII) that are retained in the 
pateamine sensitive eIF4A homologues but not in Ded1p reveals a conserved cysteine 
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residue (C124 and C140 in Tif1p and eIF4AIII respectively) that is replaced by a valine in 
the equivalent position in Ded1p. This cysteine is embedded in a sequence (HACI) that is 
followed by a sequence of four amino acids whose position changes significantly upon the 
binding of eIF4AIII to RNA. This was established by fitting the crystal structure of the 
N-terminal lobe of eIF4AIII bound to RNA (Nielsen, Chamieh et al. 2009) to the 
N-terminal lobe structure of apo-eIF4AIII and coloring the former by RMS (Figure 3.12).  
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eIF4AI           --------------------------------------------------MSASQDSRSR 10 
eIF4AII          -------------------------------------------------MSGGSADYNRE 11 
Tif1p            ------------------------------------------------------------ 
tif1p-P147L      ------------------------------------------------------------ 
eIF4AIII         --------------------------------------------MATTATMATSGSARKR 16 
Fal1p            -----------------------------------------------------------M 1 
Ded1p            RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI 120 
                                                                              
 
eIF4AI           DNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGY 70 
eIF4AII          HGGPEGMDPDGVIESNWNEIVDNFDDMNLKESLLRGIYAYGFEKPSAIQQRAIIPCIKGY 71 
Tif1p            MSEGITDIEESQIQTNYDKVVYKFDDMELDENLLRGVFGYGFEEPSAIQQRAIMPIIEGH 60 
tif1p-P147L      MSEGITDIEESQIQTNYDKVVYKFDDMELDENLLRGVFGYGFEEPSAIQQRAIMPIIEGH 60 
eIF4AIII         LLKEEDMTKVEFETSEEVDVTPTFDTMGLREDLLRGIYAYGFEKPSAIQQRAIKQIIKGR 76 
Fal1p            SFDREEDQKLKFKTSKKLKVSSTFESMNLKDDLLRGIYSYGFEAPSSIQSRAITQIISGK 61 
Ded1p            NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR 180 
                               ..  .    *    *   **..:    *  *:.:*. ::    .*  
 
eIF4AI           DVIAQAQSGTGKTATFAISILQQ---------------IELDLKATQALVLAPTRELAQQ 115 
eIF4AII          DVIAQAQSGTGKTATFAISILQQ---------------LEIEFKETQALVLAPTRELAQQ 116 
Tif1p            DVLAQAQSGTGKTGTFSIAALQR---------------IDTSVKAPQALMLAPTRELALQ 105 
tif1p-P147L      DVLAQAQSGTGKTGTFSIAALQR---------------IDTSVKAPQALMLAPTRELALQ 105 
eIF4AIII         DVIAQSQSGTGKTATFSISVLQC---------------LDIQVRETQALILAPTRELAVQ 121 
Fal1p            DVIAQAQSGTGKTATFTIGLLQA---------------IDLRKKDLQALILSPTRELASQ 106 
Ded1p            DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ 240 
                 *::* :*:*:***. * :  *.                :        *::::****** * 
 
eIF4AI           IQKVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKY 175 
eIF4AII          IQKVILALGDYMGATCHACIGGTNVRNEMQKLQAEAPHIVVGTPGRVFDMLNRRYLSPKW 176 
Tif1p            IQKVVMALAFHMDIKVHACIGGTSFVEDAEGLRDAQ--IVVGTPGRVFDNIQRRRFRTDK 163 
tif1p-P147L      IQKVVMALAFHMDIKVHACIGGTSFVEDAEGLRDAQ--IVVGTLGRVFDNIQRRRFRTDK 163 
eIF4AIII         IQKGLLALGDYMNVQCHACIGGTNVGEDIRKLDYGQ-HVVAGTPGRVFDMIRRRSLRTRA 180 
Fal1p            IGQVVKNLGDYMNVNAFAITGGKTLKDDLKKMQKHGCQAVSGTPGRVLDMIKKQMLQTRN 166 
Ded1p            IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGC-DLLVATPGRLNDLLERGKISLAN 299 
                 * .    :         .  **. .  : . :       : .* **: * :.:  :     
 
eIF4AI           IKMFVLDEADEMLSR--GFKDQIYDIFQKLNSN----TQVVLLSATMPSDVLEVTKKFMR 229 
eIF4AII          IKMFVLDEADEMLSR--GFKDQIYEIFQKLNTS----IQVVLLSATMPTDVLEVTKKFMR 230 
Tif1p            IKMFILDEADEMLSS--GFKEQIYQIFTLLPPT----TQVVLLSATMPNDVLEVTTKFMR 217 
tif1p-P147L      IKMFILDEADEMLSS--GFKEQIYQIFTLLPPT----TQVVLLSATMPNDVLEVTTKFMR 217 
eIF4AIII         IKMLVLDEADEMLNK--GFKEQIYDVYRYLPPA----TQVVLISATLPHEILEMTNKFMT 234 
Fal1p            VQMLVLDEADELLSETLGFKQQIYDIFAKLPKN----CQVVVVSATMNKDILEVTRKFMN 222 
Ded1p            VKYLVLDEADRMLDMG--FEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLS 357 
                 :: ::*****.:*.    *: ** .:            *.::.***:  :: .:: .*:  
 
eIF4AI           DPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLT 289 
eIF4AII          DPIRILVKKEELTLEGIKQFYINVEREEWKLDTLCDLYETLTITQAVIFLNTRRKVDWLT 290 
Tif1p            NPVRILVKKDELTLEGIKQFYVNVEEEEYKYECLTDLYDSISVTQAVIFCNTRRKVEELT 277 
tif1p-P147L      NPVRILVKKDELTLEGIKQFYVNVEEEEYKYECLTDLYDSISVTQAVIFCNTRRKVEELT 277 
eIF4AIII         DPIRILVKRDELTLEGIKQFFVAVEREEWKFDTLCDLYDTLTITQAVIFCNTKRKVDWLT 294 
Fal1p            DPVKILVKRDEISLEGIKQYVVNVDKEEWKFDTLCDIYDSLTITQCVIFCNTKKKVDWLS 282 
Ded1p            DYIFLSVGRVGSTSENITQKVLYVENQ-DKKSALLDLLSASTDGLTLIFVETKRMADQLT 416 
                 : : : * :   : *.* *  : *:.:  * . * *: .: :    :** :*:: .: *: 
 
eIF4AI           EKMHARDFTVSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDL 349 
eIF4AII          EKMHARDFTVSALHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDL 350 
Tif1p            TKLRNDKFTVSAIYSDLPQQERDTIMKEFRSGSSRILISTDLLARGIDVQQVSLVINYDL 337 
tif1p-P147L      TKLRNDKFTVSAIYSDLPQQERDTIMKEFRSGSSRILISTDLLARGIDVQQVSLVINYDL 337 
eIF4AIII         EKMREANFTVSSMHGDMPQKERESIMKEFRSGASRVLISTDVWARGLDVPQVSLIINYDL 354 
Fal1p            QRLIQSNFAVVSMHGDMKQEERDKVMNDFRTGHSRVLISTDVWARGIDVQQVSLVINYDL 342 
Ded1p            DFLIMQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDL 476 
                   :   .* . :::.*  *.**:  :  **:* : :*::* : ***:*: :*: :***** 
 
eIF4AI           PTNRENYIHRIGRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI--- 406 
eIF4AII          PTNRENYIHRIGRGGRFGRKGVAINFVTEEDKRILRDIETFYNTTVEEMPMNVADLI--- 407 
Tif1p            PANKENYIHRIGRGGRFGRKGVAINFVTNEDVGAMRELEKFYSTQIEELPSDIATLLN-- 395 
tif1p-P147L      PANKENYIHRIGRGGRFGRKGVAINFVTNEDVGAMRELEKFYSTQIEELPSDIATLLN-- 395 
eIF4AIII         PNNRELYIHRIGRSGRYGRKGVAINFVKNDDIRILRDIEQYYSTQIDEMPMNVADLI--- 411 
Fal1p            PEIIENYIHRIGRSGRFGRKGVAINFITKADLAKLREIEKFYSIKINPMPANFAELS--- 399 
Ded1p            PSDVDDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSA 536 
                 *   : *:***** ** *..*:*  :... :   :: :.   .   : :*  .        
108 
 
                     
Figure 3.11 Potential pateamine binding site proposition by sequence alignment. Amino acid 
sequences of verified pateamine sensitive eIF4A proteins (human eIF4AI, eIF4AII, eIF4AIII, yeast 
eIF4A (Tif1p), pateamine resistant Tif1p (Tif1p-P147L), pateamine insensitive Ded1p and a 
potential yeast pateamine target Fal1p were aligned using the Clustal-W algorithm. Presented is 
the sequence alignment corresponding to the region of human eIF4AI from amino acid 52 to 246 
and constitutes the majority of the N-terminal lobe of all sequences pictured. The position of the 
pateamine resistance conferring mutation in Tif1p (P147L) is in red, and part of the potential 
pateamine binding site (surrounding C124) is in green. 
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Figure 3.12 eIF4AIII bound to RNA abstracted from the crystal structure of the EJC 
(3ex7.pdb). N-terminal is on the left and colored by RMS calculated relative to the apo-eIF4AIII 
crystal structure, poly-U and ATP are indicated by blue arrows, the side-chain of C124 is colored 
magenta and indicated by the magenta arrow and the red arrow indicates the sequence 
immediately C-terminal to the HACI motif which changes position upon RNA binding. Shown are 
two views from the (A) front and (B) back. 
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3.5 Discussion 
 
3.5.1 Pateamine inhibits the growth of yeast in a but does not kill them 
Consistent with previously published results regarding the sensitivity of yeast and fungal 
species sensitivity to pateamine (Northcote, Blunt et al. 1991) the growth of S. cerevisiae 
was inhibited in both liquid and agar media, with an IC50 of approximately 3 µM in liquid 
media and a MIC of 12.5 µM in solid. Compounds that affect the growth of yeast generally 
inhibit their growth rather than kill them, a relatively small number of compounds that 
show inhibitory activity towards yeast induce a cell death process analogous to mammalian 
apoptosis (Almeida, Silva et al. 2008).  
 
While pateamine irreversibly induces apoptosis in human cell lines (Hood, West et al. 
2001; Miller, Rouwe et al. 2004; Low, Dang et al. 2005), it reversibly inhibits cell division 
in yeast. Yeast treated with pateamine in liquid culture require more time to recover than 
those treated with cycloheximide, the reason for this may be that the interaction between 
pateamine and its target in yeast is of high affinity, the inability of mammalian eIF4A to be 
eluted from the pateamine affinity resin, by any means other than completely denaturing 
and reducing conditions, may be indicative of a high affinity or covalent interaction. An 
alternative explanation that the compound accumulates intracellularly, due to low levels of 
efflux though the hypersensitivity of Δpdr5 deletion strain suggests this is not the case.  
 
If the interaction between pateamine and eIF4A is covalent this may explain the slow 
recovery from pateamine exposure, in this case the adduct would have to be cleared by 
proteolytic degradation. Yeast eIF4A has been identified as a protein that is degraded via 
the proteasome after ubiquitination (Tagwerker, Flick et al. 2006). Given the large number 
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of ubiquitinated proteins, and the fact that inactivation of eIF4A (in this case by pateamine) 
prevents protein synthesis, the resolution of the adduct and the production of new eIF4A 
and ubiquitination would be slow, which could account for the considerably increased 
recovery time. 
 
3.5.2 Multi-drug resistance pump and ergosterol pathway deletions 
sensitize to pateamine 
The major drug efflux pump expressed in S. cerevisiae is Pdr5p; the deletion of the gene 
that encodes this pump confers sensitivity to pateamine, indicating this pump recognizes it 
as a substrate and removes it from the cell. The recognition of pateamine by Pdr5p raises 
the possibility that resistance to pateamine may be generated by up regulation of this or 
other efflux pumps, such as Snq2p or Yor1p (Balzi and Goffeau 1995). Alternatively a 
mutation may occur in the substrate recognition domain of a pump that pateamine is not a 
substrate for, making it now a substrate (Tutulan-Cunita, Mikoshi et al. 2005). Deletion of 
a number of genes in the ergosterol pathway also sensitize to pateamine, most likely due to 
increased permeability and fluidity of the plasma membrane, because of decreased 
ergosterol levels, that allows greater diffusion of the compound into the cell 
(Mukhopadhyay, Kohli et al. 2002; Abe and Hiraki 2009). Pateamine resistance of these 
strains is less likely to occur because of efflux pump up-regulation since this would not 
lower the concentration of the drug in the cytosol, the increased permeability of the cell 
negates increasing efflux. For this reason the deletion of ERG6 was used to generate 
pateamine resistant clones. 
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3.5.3 Pateamine resistance 
Given that pateamine treatment causes growth arrest, if it is presumed the target in yeast is 
a protein, it is possible to speculate as to the nature of its target in limited terms: pateamine 
may target an essential gene product; or the functionally redundant product of two 
non-essential duplicated genes; alternatively a lethal function of a non-essential gene 
product in a essential pathway may be agonized. Given the high degree of homology 
between human eIF4AI, the target in human cells, and yeast Tif1/2p (Linder 2003), it is not 
unreasonable to suggest this is the target in yeast. Consistent with the above speculations 
regarding the nature of the pateamine target, yeast Tif1/2p is the product of two duplicated 
non-essential genes, TIF1 and TIF2, which are functionally redundant and display a 
synthetic lethal genetic interaction (Linder and Slonimski 1989). In order to simplify the 
recovery of a mutation in one of these genes conferring pateamine resistance, the parental 
strain used to generate the resistant clones was deficient in both ERG6, for reasons stated 
above, and TIF2. The deletion of TIF2 was chosen since it contributes the majority of 
eIF4A present in yeast (Prat, Schmid et al. 1990), removal of one of the genes encoding 
eIF4A simplifies the recovery of the sequence at the other locus by gap-repair. 
 
In order to isolate the most pateamine resistant mutant following the incubation of the 
mutagenized Δtif2, Δerg6 strain in YPD, to allow the expression of any mutant genes, the 
cells were exposed to a high (50 µM) concentration of pateamine in liquid media, and 
allowed to grow to OD corresponding to mid-log growth phase. This allowed the relative 
increase of the strongest mutant, and may explain why all of the TIF1 sequences recovered 
from the pateamine resistance mutants all contained the same point mutation (see below). 
Of note is that all mutants retained pateamine-resistance after growth in non-selective 
media (YPD) (Figure 3.5), which suggests the observed resistance is not due to the 
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temporary up-regulation of drug efflux pumps, for instance Pdr5p for which the deletion of 
was shown to confer pateamine sensitivity (Figure 3.4). 
 
3.5.4 Gap repair mediated recovery of tif1 allele 
Typically once a clone resistant to the drug of interest is generated classical yeast 
molecular genetics approaches are used to determine broad characteristics of the mutation. 
For instance, the dominant or recessive nature of this mutation with respect to the 
wild-type gene is determined by mating the resistant clone with the opposite mating type of 
the parental from which it was derived and quantifying the drug sensitivity of the resulting 
diploid clones. Whether the resistance observed is due to a single genetic locus is 
determined after sporulation of the above diploid and quantifying the drug sensitivity of 
the resulting haploid progeny. Whether all of the clones generated belong to the same 
complementation group, that is whether they map to the same position, is determined by 
quantifying the drug sensitivity of the haploid progeny resulting from mating the drug 
resistant haploid clones (Miyamoto, Machida et al. 2002). However, given the 
identification of the eIF4A family of proteins as putative mammalian targets of pateamine 
and the high degree of homology between eIF4AI and Tif1/2p (Linder 2003), the ability of 
the TIF1 locus from the clones PAR1-5 was to confer resistance to the parental 
Δtif2, Δerg6 strain was assessed directly. 
 
The sequence recovered from the TIF1 locus of all of the PAR clones by gap-repair 
mediated allelic recovery was able to confer resistance to the parental strain when 
over-expressed from a 2-micron plasmid driven by a galactose inducible promoter, 
whereas the wild-type TIF1 gene when over-expressed failed to confer resistance upon the 
parental strain, as did the over-expression of Fal1p. This suggests a sequence difference in 
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the TIF1 allele recovered from the PAR1-5 clones compared to wild-type TIF1 and that 
this confers pateamine resistance, and represents the major target in yeast. 
 
3.5.5 Sequencing of tif1 allele reveals a single point mutation 
Primers designed outside of the HindIII and EcoRI restriction sites were used to determine 
the sequence of the DNA recovered from the TIF1 locus of the PAR clones. This revealed 
the presence of a single point mutation within the coding region of TIF1 that results in a 
proline to leucine substitution at position 147. In the wild type protein P147, as is 
commonly seen in other proteins, causes a sharp kink in the peptide back-bone at the end 
of an alpha helix which facilitates the tight turn required to place the next helix in the 
correct position (Caruthers, Johnson et al. 2000), and is close in proximity to the RNA 
binding portion of the N-terminal of eIF4A. Given this scenario it is possible that 
substitution of a leucine may prevent this tight kink and therefore have dramatic and far 
reaching consequences on the overall structure of the domain. However, there are a 
number of crystal structures reported in the literature that contain a leucine in an equivalent 
sequence to the P147 in wild-type yeast eIF4A motif Ib, whilst still retaining the kink 
characteristic of the eIF4A proline-containing motif (Figure 7.4, Appendix B) (Stec, Rao et 
al. 1995; Matias, Soares et al. 2001), which indicates that leucine is capable of maintaining 
the kink in the peptide back-bone that the proline does. Also, since the only source of 
Tif1/2p in the original PAR clones, which evidenced no growth defect, was the pateamine 
resistant form bearing this mutation, it is obviously functional, arguing against a 
large-scale change to protein structure due to this mutation. It is currently unclear whether 
this mutation confers resistance to pateamine by abrogating the binging event or by 
uncoupling the binding event from the structural change that pateamine induces upon 
binding.  
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It is of interest to note that the position at which this point mutation occurs is highly 
conserved across almost all DEAD-box helicase enzymes, known as motif Ib (Linder 
2006), yet pateamine seems to be a specific eIF4A inhibitor, since it does not affect Ded1p 
function in vitro, or any of the helicases involved in the mammalian splicing reaction 
in vitro (Bordeleau, Matthews et al. 2005). The ubiquitous presence of motif Ib in DEAD-
box helicase enzymes suggest that this position does not constitute the exact pateamine 
binding site, however, given the stimulatory activity of pateamine on mammalian eIF4AI 
helicase and RNA binding activity, this might suggest the P147L mutation uncouples the 
pateamine binding event from the stimulation of RNA binding, possibly by decreasing the 
affinity the N-terminal lobe has for RNA, or perhaps prevents the formation of a 
pateamine-eIF4A covalent adduct.  
 
3.5.6 Pateamine inhibits protein and RNA synthesis in yeast 
Consistent with the role of Tif1/2p in translation initiation in yeast, pateamine inhibits the 
incorporation of tritiated leucine at concentrations comparable to those that inhibit growth 
in liquid culture. The incorporation of tritiated uridine was also inhibited at slightly higher 
concentrations suggesting an effect of pateamine treatment on RNA synthesis. 
Temperature sensitive mutants that are defective in translation display lowered rates of 
uridine incorporation when grown at the non-permissive temperature (Gross and Pogo 
1976), as do cells treated with high concentrations of the protein synthesis inhibitors edeine 
and cycloheximide (Gross and Pogo 1974; Gross and Pogo 1976), which suggests a control 
mechanism that relates the rate of RNA synthesis to the protein synthetic ability of the cell. 
It has been proposed that some protein factor, presumably of short half-life, is essential for 
RNA transcription and is not synthesized in the presence of cycloheximide (Gross and 
Pogo 1974). The concentration of cycloheximide seen to decrease RNA synthesis far 
exceeds that required to inhibit protein synthesis. Given that the majority of the RNA 
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synthesized by yeast cells at any one time is rRNA (Michels and Hernandez 2006), and the 
high degree of homology shared between Tif1/2p and Fal1p (Kressler, de la Cruz et al. 
1997), the two-fold difference between the EC50 values for leucine and uridine 
incorporation may suggest a functional effect of pateamine on Fal1p and hence ribosome 
biogenesis, or that rRNA synthesis in yeast is more susceptible to inhibition of protein 
synthesis by targeting the initiation phase than it is by targeting elongation.  
 
While the effect on RNA synthesis is more marked in the case of pateamine treatment, 
compared to cycloheximide, and that it is possible that this is due to an effect on Fal1p 
function, it must be noted that the P147L point mutation in Tif1p is sufficient in conferring 
pateamine resistance in the presence of, presumably, wild-type Fal1p. This indicates that 
any direct effect on Fal1p by pateamine may only occur at exceedingly high 
concentrations, or that Fal1p is not strictly essential, meaning that even though there may 
be a functional effect by pateamine, the contribution of this to the decreased fitness in the 
presence of pateamine is minor. This is supported by the observations that the 
heterozygous deletion is not haploinsufficient in rich media (Deutschbauer, Jaramillo et al. 
2005) and clones containing FAL1 driven by either a tetracycline repressible promoter or 
the GAL1 promoter displays negligible fitness defect in the presence of doxycycline 
(Mnaimneh, Davierwala et al. 2004), or glucose respectively, despite the isolation of 
temperature sensitive mutants of FAL1 that display reduced fitness at the non-permissive 
temperature (Kressler, de la Cruz et al. 1997). 
 
3.5.7 Putative pateamine binding site on eIF4A 
It could be presumed the pateamine resistance conferring mutation identified in this work 
would not cause a large change in the surface properties of eIF4A, despite the increase in 
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amino acid side chain size from proline to leucine, the flexibility of the leucine side chain 
would not necessarily abrogate the binding of pateamine, although a thorough in silico 
assessment of this proposition is probably required to say for sure. Given this mutation 
occurs in a region that is highly conserved amongst both pateamine sensitive eIF4A 
homologues and other DEAD-box helicases it could be presumed it does not represent the 
exact binding site. The presence of the cysteine that is conserved amongst the verified 
eIF4A pateamine targets and not in the pateamine insensitive Ded1p, and resides within 
15 Å of the resistance conferring mutation in combination with the presence of the 
conjugated diene in pateamine at C19 – C22 which is directly connected to one of the 
carbonyl carbon (C18) of one of the lactone groups, raises the possibility that the thiol 
group of the cysteine, may be involved in creating a covalent adduct of pateamine and 
eIF4A as have been found to be formed by andrographolide and NF-κB (Xia, Ye et al. 
2004).  
 
This may explain the considerable lag period in the recovery of yeast treated with 
pateamine and also requirement for reducing conditions in the recovery of eIF4A and not 
β-tubulin or actin in the affinity isolation experiments. While this is highly speculative, and 
requires verification, it may be that the P147L mutation causes a slight change in 
orientation of the cysteine side-chain preventing such an addition reaction to occur, 
alternatively the mutation may cause subtle changes in the surface of eIF4A that may alter 
the relative position of the diene with respect to the cysteine thiol. As mentioned in the 
previous chapter the potential eIF4A-pateamine covalent can be investigated with mass 
spectrometry.  
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3.6 Conclusions 
Pateamine has been shown to inhibit the growth of yeast in a reversible manner and 
deletion of the major drug efflux pump, Pdr5p, or ergosterol synthesis pathway 
components increases its potency, despite a recent publication stating the pateamine is not 
a substrate for the human PgP drug efflux pump which share significant homology with 
Pdr5p (Kuznetsov, Xu et al. 2009). A pateamine resistant mutant was isolated and the basis 
of this resistance was shown to be a single point mutation, P147L, in the TIF1 gene which 
encodes the yeast orthologue of the mammalian pateamine target eIF4AI. The P147L 
mutation might be expected to cause significant structural changes, however since the 
mutant protein was the only source of eIF4A in the original pateamine resistant clones this 
appears to not be the case. Consistent with the role of eIF4A in yeast translation, pateamine 
inhibits protein synthesis. While it was not assessed whether the genes encoding actin or β-
tubulin were altered in the drug resistant mutant, the likelihood of a second mutation 
outside of the TIF1 gene that confers additional resistance is low, furthermore, 
reintroducing only the TIF1 mutation into a yeast background without mutation elsewhere, 
albeit at high copy number, was sufficient to provide resistance on its own.  
 
The position of the resistance conferring mutation in a motif highly conserved amongst 
DEAD-box helicase suggests this might not be the precise binding site of pateamine, but 
may uncouple the drug binding event from the structural changes normally induced upon 
drug-binding, or possibly prevent the formation of a covalent adduct. The relatively potent 
effect of pateamine, compared to other protein synthesis inhibitors, on RNA synthesis, 
might suggest a role for the inhibition of the eIF4A like protein, Fal1p, albeit in a non-
covalent manner given the presence of an isoleucine at the equivalent position to the 
cysteine in the HACI motif, in the growth inhibitory effects of this compound in 
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S. cerevisiae, or the effect on uridine incorporation may be as a result of the effect of 
pateamine on translation initiation. 
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4 Chemogenomic profiling with pateamine 
 
4.1 Introduction 
The use of yeast in drug target identification or mode-of-action studies has markedly 
increased with the advent of chemogenomic screening methods. These methods aim to 
identify yeast deletion mutants, from a genome-wide collection, that display altered 
sensitivity to the compound of interest, and infer the mode-of-action or mechanism of that 
compound based on the function of those genes (Luesch 2006; Boone, Bussey et al. 2007). 
The completion of the Saccharomyces cerevisiae genome sequencing program (Goffeau, 
Barrell et al. 1996), and the subsequent designation of putative open reading frames 
(ORFs), coupled with robotic nucleic acid synthesis technology and the ease at which 
homologous recombination occurs in this yeast (Baudin, Ozierkalogeropoulos et al. 1993), 
facilitated the Saccharomyces Gene Deletion Project, the aim of which was to create a 
deletion strain for each putative ORF found in S. cerevisiae (Winzeler, Shoemaker et al. 
1999). The immediate output of this program was the designation of each putative ORF as 
essential or non-essential in rich media conditions, as well as the production of four yeast 
deletion libraries: the hemizygous MATa and MATα, deletion sets, in which each strain 
has a non-essential gene replaced with an antibiotic resistance cassette; the homozygous 
deletion set which is a result of mating the two hemizygous sets to produce a diploid 
library of deletion strains; and the heterozygous deletion set where the one copy of each 
gene in the diploid organism has been replaced with the antibiotic resistance cassette.  
 
Each of these libraries has been used in the literature in an attempt to identify drug targets, 
or ascribe a mode-of-action to a biologically active compound. Various screen formats 
have been published including the discrete screening of each deletion mutants in liquid 
media in 96 or 384 well plates (Butcher and Schreiber 2004), or arrayed to high density on 
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agar media (Chan, Carvalho et al. 2000; Xie, Jin et al. 2005), both of which often require 
considerable amounts of the drugs of interest. In contrast, the parallel or competitive 
growth assay allows an entire deletion library to be screened in a culture volume of 5-10 
ml, this method takes advantage of a unique DNA barcode included in each deletion 
cassette which allows the relative abundance of each strain in the pooled culture to be 
quantified by microarray analysis (Shoemaker, Lashkari et al. 1996; Giaever, Chu et al. 
2002). While the screening procedure for the homozygous and heterozygous deletion sets 
is essentially identical, the theoretical basis of their use and the interpretation of the results 
differ somewhat. 
 
4.1.1 The heterozygous deletion library 
The use of this library in drug target identification relies on the notion that reducing the 
copy number of the drug-target encoding gene will cause hypersensitivity to an inhibitory 
compound. It was reported that increasing the copy number of a drug-target encoding gene 
decreases the sensitivity of that yeast to the corresponding drug (Rine, Hansen et al. 1983; 
Launhardt, Hinnen et al. 1998), and the converse, reducing the copy number of the gene by 
half, by generating a heterozygote deletion strain, leads to hypersensitivity to a drug that 
targets that gene product (Giaever, Shoemaker et al. 1999). Therefore, it was reasoned that 
screening a library of heterozygous genes deletion strains of every essential gene with an 
inhibitory compound, should identify the gene product targeted by that compound, by 
virtue of the hypersensitivity of the target deletion strain to that compound. In this way, the 
heterozygous deletion strain of DFR1, the gene that encodes dihydrofolate reductase, the 
target of methotrexate, was found to be the most sensitive strain to that compound, and the 
heterozygous deletion strains of both HMG1 and HMG2, which encode the target of 
atorvastatin, HMG-CoA reductase, were the most sensitive in its presence (Giaever, 
Flaherty et al. 2004). While it is not always the most sensitive heterozygous deletion 
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strains that encodes the drug target, for instance the YFL032W deletion strain is more 
sensitive to tunicamycin than the deletion strain of its target, ALG7 (Kuo and Lampen 
1974), it appears the target gene is often within the top ten sensitive strains and other 
hypersensitive strains are often within the same pathway. For instance terbinafine targets 
the ergosterol synthesis pathway by inhibiting Erg1p, the heterozygous deletion of ERG1 
displays hypersensitivity along with the deletion of NCP1 which acts as a NADH cofactor 
binding subunit for ERG11, also within the ergosterol synthesis pathways (Lum, Armour et 
al. 2004). Hence it has been proposed that heterozygous deletion set screens may provide 
information regarding all of the functionally relevant target interactions for a drug, 
including potential secondary targets (Giaever, Flaherty et al. 2004). 
 
The use of the heterozygous yeast deletion library has allowed characterization of a 
number of novel bioactive compounds. For instance: dihydromotuporamine was shown to 
affect sphingolipid biosynthesis (Baetz, McHardy et al. 2004) and was later used as a tool 
to identify the cellular effects of inhibiting sphingolipid biosynthesis; cincreasin was 
shown to inhibit the Mps1p protein kinase (Dorer, Zhong et al. 2005); and tenovin-6, 
indentified as an activator of p53 was shown to target the histone deacetylase Sir2p (Lain, 
Hollick et al. 2008). Given the potential to identify every functionally relevant drug-target 
interaction, this library has also been used to further elucidate the mechanism of nitrogen-
containing bisphosphonates, which are used clinically to treat diseases which involved 
excess bone resorption and are suspected to act through a variety of mechanisms (Bivi, 
Romanello et al. 2009). However, by far the most powerful use of the heterozygous 
deletion set in determining drug mode-of-action has been its use in concert with the 
homozygous deletion set. 
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4.1.2 The homozygous deletion library 
The use of the homozygous deletion library in determining the mode-of-action of a 
compound is based on the observation that recessive mutants that display hyper-sensitivity 
to a drug can identify genes involved in that drug target’s function (Umesono, Toda et al. 
1983). Stearns and co-workers used EMS to increase genetic variation of a population of 
yeast then individually screened 20,000 clones for sensitivity to the microtubule 
depolymerizing agent benomyl (Stearns, Hoyt et al. 1990). Subsequent characterization of 
these genes showed mutations in the tubulin encoding genes, TUB1, TUB2 and TUB3 as 
well as three other unlinked genetic loci, named CIN1, CIN2 and CIN4 which were also 
identified in an independent screen for decreased chromosome stability (Hoyt, Stearns et 
al. 1990). The authors showed that of the CIN genes genetically interact with TUB1 in a 
synthetic lethal manner, and that mutation in the TUB2 gene can suppress the hyper-
sensitivity of the Δcin1 and Δcin4 strains to benomyl, indicating a functional relationship 
between microtubules and the CIN genes. Since their discovery the CIN genes have been 
shown to be essential for the folding of β-tubulin (Lopez-Fanarraga, Avila et al. 2001). 
Importantly the authors noted that deletion of CIN1 and CIN2 gave rise to the same level of 
benomyl sensitivity as the spontaneous mutations isolated in the original screen, and while 
the deletion of CIN4 was not as sensitive to benomyl as the spontaneous mutant, it was still 
more sensitive than wild-type. 
 
Hitherto a common approach to drug target identification in yeast was to isolate drug 
resistant yeast mutants, the isolation of hypersensitive mutants is considerably more 
laborious since their identification is based on negative rather than positive selection, 
which means potential hypersensitive mutants must be screened individually against the 
compound of interest. One advantage of the hyper-sensitivity screen is that the resulting 
mutation can be mapped by complementation with the wild-type gene in a plasmid library. 
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However both resistance and hyper-sensitivity mutation screens both suffer from the 
considerable draw-back that mapping of the mutations is often laborious. Given the 
observation that hypersensitivity conferring mutations in non-essential genes are mimicked 
by the complete deletion of those genes (Stearns, Hoyt et al. 1990), the homozygous 
deletion set can be screened for the gene deletions that confer hypersensitivity, which will 
be functionally related to the target and are already mapped. This approach was used to 
identify components of the TOR signaling pathway by screening 2,216 haploid deletion 
strains for hypersensitivity or resistance to rapamycin. In this way a number of known 
TOR pathway components were identified as well as genes involved in other pathways and 
processes such as vacuolar function and protein synthesis (Chan, Carvalho et al. 2000).  
 
In the same way, the yeast DNA damage response pathway has been extensively studied in 
screens for hypersensitivity to UV radiation (Birrell, Giaever et al. 2001), γ-rays (Bennett, 
Lewis et al. 2001; Game, Birrell et al. 2003), methyl methanesulfonate (Begley, Rosenbach 
et al. 2002; Chang, Bellaoui et al. 2002; Hanway, Chin et al. 2002) and numerous clinically 
relevant DNA damaging agents (Birrell, Brown et al. 2002; Wu, Brown et al. 2004). In a 
truly chemical-genetic fashion, the inhibitor PS-341 was used to study the cellular effects 
of proteasome inhibition (Fleming, Lightcap et al. 2002), wortmannin was used to propose 
novel functions of the phosphatidylinositol pathway (Zewail, Xie et al. 2003), the role of 
the Rho-PKC-MAPK in cell wall biosynthesis was revealed by virtue of caspofungin 
hypersensitivity (Markovich, Yekutiel et al. 2004) and the cellular functions of the 
chaperone Hsp90p was demonstrated with geldanamycin, in combination with an 
assessment Hsp90p’s genome-wide synthetic lethal interactions and physical interactions 
(Zhao, Davey et al. 2005). Although all of these studies used well characterized 
compounds they show the power in this approach not only to identify genes directly 
involved in the same process affected by a drug, but also other cellular processes that may 
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be required for resistance to that drug or response to its presence, and that the function of 
these hypersensitive mutants could aid in the elucidation of the mode-of-action of an 
uncharacterized drug.  
 
In support of this supposition it was shown that the profile of deletion mutants that display 
hypersensitivity to compounds with a similar mode-of-action are significantly correlated, 
as in the cases of the immunosuppressants cyclosporine A and FK506 and the DNA 
damaging agents hydroxyurea and camptothecin. Furthermore it was shown the drug-
specific hypersensitivity profiles for cyclosporine and FK506 were highly correlated with 
negative-genetic interactions of their target gene, CNB1, likewise the profile of benomyl 
was very similar to the synthetic lethal genetic interaction profile of a temperature sensitive 
TUB2 allele, and they form a cluster in hierarchical cluster analysis (Parsons, Brost et al. 
2004). The authors propose linking drugs to their targets by this chemical-genetic – 
synthetic-lethal genetic interaction correlation, a proposition that relies on the notion that 
an active compound mimics a loss-of-function mutation in its target encoding gene. Most 
of the compounds that were shown to cluster with the genetic interaction profile of their 
targets (fluconazole, cyclosporine A, FK506 and benomyl) inhibit their targets (Erg11p, 
Cnb1p and Tub1/2p), camptothecin on the other hand requires the enzymatic activity of 
topoisomerase I in order to be toxic, so the lack of correlation with the TOP1 genetic 
interaction profile in understandable, nevertheless its chemical-genetic profile clustered 
with that of hydroxyurea and genes known to be involved in DNA replication and repair. It 
must be noted that the wide-spread application of this approach hinges on the existence of 
a database of genome-wide synthetic lethal interactions which will presumably be 
available in the next few years with the development of high throughput synthetic-genetic 
array analysis (Tong, Evangelista et al. 2001; Tong and Boone 2006; Costanzo, 
Baryshnikova et al. 2010). 
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The development of parallel or competitive growth assays (Shoemaker, Lashkari et al. 
1996; Giaever, Chu et al. 2002) has lead to a large number of chemical genetic profiles for 
drugs of diverse structure and activity (Parsons, Lopez et al. 2006; Hillenmeyer, Fung et al. 
2008). These datasets have reaffirmed the concept that similar drugs generate similar 
profiles, albeit in an arguably mode-of-action dependant manner (Hillenmeyer, Ericson et 
al. 2010), as well as further defining genes whose deletions cause hypersensitivity to 
numerous active compounds, known as multi-drug sensitizing (MDS) gene deletions. This 
has highlighted the importance of vesicular trafficking in drug efflux function as well 
explaining these genes’ presence in a number of profiles (Hillenmeyer, Fung et al. 2008). 
While homozygous deletion set profiling can be informative in terms of identifying the 
cellular processes required for resistance to the compound of interest, it rarely identifies 
drug targets directly, since essential drug targets are not present in this library, and the 
majority of drugs that are inhibitory in yeast target essential genes. This creates difficulties 
in interpreting the results of a screen with a compound that is truly novel. A more powerful 
approach is to screen both deletion libraries with the compound of interest (Hillenmeyer, 
Fung et al. 2008; Yu, Lopez et al. 2008; Kemmer, McHardy et al. 2009) and in 
combination with a multi-copy plasmid borne random genomic library to incorporate 
increased and decreased gene dosage effect (Hoon, Smith et al. 2008). 
 
In chapter 3 it was shown that a single point mutation in the eIF4A encoding TIF1 gene, 
when over-expressed conferred resistance to a relatively high concentration of pateamine 
whereas over-expression of the wild-type TIF1 failed to. More than 25 genes encoding 
DEAD-box helicases are present in S. cerevisiae they are involved at almost every step of 
RNA metabolism and translation (Linder 2006), while the entire super-family is highly 
conserved structurally, Fal1p has high sequence homology to eIF4A (Kressler, de la Cruz 
et al. 1997), and therefore represents a distinctly possible secondary target for pateamine. 
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Indeed its gene name arises from the fact that it produces a Four A-Like (FAL) protein 
product. We sought to identify possible effects of pateamine, independent of its effects on 
eIF4A via a chemogenomic approach. 
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4.2 Aims and Objectives 
The aim of this work is to establish the breadth of target specificity of pateamine, that is to 
identify every functionally relevant interaction that pateamine takes part in. To this end 
multiple genome-wide yeast deletion libraries screens were performed to identify both 
essential genes that exhibit haploinsufficiency and non-essential genes that exhibit 
hypersensitivity when deleted, in the presence of pateamine, which is indicative of the 
biological processes affected by pateamine and hence it’s targets. The profiles of gene 
deletions strains hypersensitive to pateamine will be assessed for functional enrichment 
and their similarity to previously published profiles attained for biologically and 
chemically diverse compounds. 
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4.3 Materials and Methods 
Yeast strains were maintained according to standard practices previously described. The 
MATa haploid homozygous yeast deletion library (Thermo Scientific-Open Biosystems) 
was incubated for 3 days at 30 ºC in 96 well plates in YPD containing 200 µg/ml G418, 
shaken every 12 h, and stored at 4 ºC prior to use.  
 
4.3.1 Serial spot dilution assay 
Deletion strains were grown to saturation in YPD overnight and diluted to an OD600 of 1 
prior to use. One hundred µl of OD adjusted cultures were added to 96 well plates and 
serially diluted ten-fold, after which they were transferred in quadruplicate to rectangular 
petri dishes containing YPD agar with either 17 µM pateamine, 50 µM anisomycin, 
3.5 µM cycloheximide or 0.1% DMSO using the 96-pin hand pinning tool (V & P 
Scientific Inc., San Diego, CA, USA). Plates were incubated for three days at 30 °C, before 
pictures were taken. 
 
4.3.2 Pateamine haploid hyper-sensitivity screen  
The screen for MATa haploid deletion strains that display hyper-sensitivity to pateamine 
was performed in 384 well plates, using YPD containing 16 µM pateamine, this 
concentration was determined to correspond approximately to the EC20 of the Δhis3 
control strain. The BioTek Precision XS liquid handler (BioTek Instruments, Winooski, 
VT, USA) was used to dilute the starting culture plates approximately 1000-fold before 
being inoculated in quadruplicate into 384 well plates. The plates were returned to the 
incubator for 30 h and optical density at 590 nm measured using the Wallac EnVision 2102 
plate-reader (Perkin-Elmer). A deletion strain was deemed hypersensitive if it showed 
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greater than 25% increase in sensitivity with respect to the control Δhis3 strain in all three 
screen repeats. Candidate pateamine hypersensitive deletion strains were confirmed using a 
24 h, end-point assay turbidity in triplicate performed in 96 well plates at 16 µM pateamine 
in YPD. 
 
4.3.3 Confirmation of altered pateamine sensitivity 
Deletion strains hypersensitive to pateamine in the pateamine hyper-sensitivity screen 
(Method 4.3.2) were further confirmed with the use of an end point liquid growth assay. 
Strains were picked from the MATa haploid yeast deletion library (Thermo Scientific-
Open Biosystems), inoculated into 96-well plates containing YPD containing 200 µg/ml 
G418 and incubated for 3 days at 30 ºC. The 96-pin hand pinning tool (V & P Scientific 
Inc., San Diego, CA, USA) was used to inoculate in duplicate from the stationary phase 
culture into fresh YPD containing 200 µg/ml G418 containing 4 µM pateamine or 0.1% 
DMSO and returned to the incubator for 18 h, after which the plates were shaken and their 
absorbance read at 600 nm on the Wallac EnVision 2102 plate-reader. Values analogous to 
the ε-scores used to establish genetic interactions (Schuldiner, Collins et al. 2005) were 
calculated, this was done by calculating the drug induced growth inhibition of the control 
Δhis3 strain, and expressing the growth of each strain relative to the Δhis3 control, the 
multiplication of these values gives the predicted growth inhibition if the deletion strain 
displays no drug hyper or hypo-sensitivity. The growth of each strain in the drug was 
expressed as a proportion of the growth in the untreated sample, this value was subtracted 
from the expected score calculated above, if this number is negative the strain is hypo-
sensitive to the drug, a positive values indicates hyper-sensitivity. 
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4.3.4 Pateamine HIPHOP assay 
The homozygous diploid non-essential gene deletion library and the heterozygous diploid 
essential gene deletion library were used to perform a haploinsufficiency 
profiling/homozygous profiling (HIPHOP) screen using the pooled microarray method 
(Pierce, Fung et al. 2006) by members of the Giaever and Nislow group at the University 
of Toronto Terrence Donnelly Centre for Cellular and Biomolecular Research. The screen 
was performed four times, twice at 28 nM pateamine and twice a 38.5 nM in YPD for 
20 generations, concentrations that were established as being minimally inhibitory in the 
HIPHOP screen format. Herein the homozygous aspect of these screens are referred to as: 
HOP screen 1 (38.5 nM pateamine), HOP screen 2 (28 nM pateamine), HOP screen 3 
(28 nM pateamine) and HOP screen 4 (38.5 nM pateamine); and the heterozygous aspect 
as: HIP screen 1 (38.5 nM pateamine), HIP screen 2 (28 nM pateamine), HIP screen 3 
(28 nM pateamine) and HIP screen 4 (38.5 nM pateamine). 
 
4.3.5 Functional enrichment analysis 
Enrichment of function in the chemogenomic datasets was assessed by gene ontology term 
analysis performed with the BiNGO 2.41 plug-in (Maere, Heymans et al. 2005) for 
Cytoscape (version 2.7.0) (Shannon, Markiel et al. 2003) using the current S. cerevisiae 
gene annotation file (released 07/2010) and gene ontology file (downloaded 19/07/2010) 
from the GO Consortium website (www.geneontology.org). Over-representation of genes 
corresponding to GO terms was assessed using a hypergeometric test with a Benjamini and 
Hochberg false discovery rate correction (Benjamini and Hochberg 1995), significance 
was assigned to P-values less than 0.05. 
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4.3.6 Hierarchical cluster analysis 
Two-dimensional agglomerative hierarchical cluster analysis was performed using the 
clustergram function in Matlab Version 7.8.0.347 (R2009a) (Mathworks Inc.) with two 
large scale chemical-genetic profiling datasets previously published (Parsons, Lopez et al. 
2006; Hillenmeyer, Fung et al. 2008). Prior to clustering, previously identified MDS genes 
were removed, as well as those genes that do not display hyper- or hypo-sensitivity in the 
presence of any of the conditions in the datasets. Four datasets were used in the cluster 
analysis with the supplementary literature data from Hillenmeyer et al.:  
Dataset 1: log2 ratio data;  
Dataset 2: log2 ratio data for hypersensitive and resistant (hyposensitive) strains 
after the application of a threshold (resistant = log2 < -1.5, sensitive = log2 > 0.5);  
Dataset 3: log2 data of just the hypersensitive strains after the application of the 
threshold described for dataset 2;  
Dataset 4: Dataset 3 converted to a binary form, where a 1 indicates 
hypersensitivity.  
Clustering with the Parsons et al. supplementary data was performed only with the 
sensitive strain data but the same threshold as described for dataset 2 above was applied. 
The log2 ratio data was clustered using both the centered and uncentered Pearson distance 
metric and the binary data set was clustered using the Jaccard distance metric, in all cases 
the average linkage method was used to form clusters.  
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4.3.7 Protein synthesis inhibitor sensitive strain overlap  
The overlap of protein synthesis inhibitor chemogenomic datasets was visualized in 
Cytoscape (version 2.7.0) with the binary profiles of: hygromycin, verrucarin, 
streptovitacin, cycloheximide, neomycin sulfate, anisomycin (Hillenmeyer, Fung et al. 
2008), emetine, anisomycin (Parsons, Brost et al. 2004), anisomycin, verrucarin, 
neomycin, emetine (Parsons, Lopez et al. 2006) supplemented with focused screen data on: 
sordarin (Botet, Rodriguez-Mateos et al. 2008), hygromycin B (Banuelos, Moreno et al. 
2010), and paromomycin (Alamgir, Eroukova et al. 2008). 
. 
4.3.8 Network analysis 
Physical and genetics interaction present in the SGD database for hits from all pateamine 
screens performed (the haploid screen, HOP screen 1 – 4 and HIP screen 1 - 4), were 
downloaded and merged, in Cytoscape, with a network consisting of individual nodes for 
each screen with edges connecting these nodes to nodes representing each hit in each of the 
screens. The pateamine screen nodes were selected, each node directly connected by these 
nodes (the screen hits) were selected and all other nodes were deleted. This left a network 
consisting of pateamine screen nodes, connected to their respective gene hits and the 
inter-hit interactions. This network was then searched with the MCODE algorithm for 
sub-networks of increased edge density; the resulting sub-networks were then assessed for 
enriched function using the BiNGO plug-in as described in Method 4.3.5. 
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4.4 Results 
4.4.1 eIF4F component sensitivity to pateamine 
The sensitivity of various eIF4F complex members to pateamine was assessed in YPD 
using a serial spot dilution assay. The MATa strains bearing deletion of the eIF4F complex 
members eIF4A (Δtif1 and Δtif2) and one of the isoforms of eIF4G (Δtif4632), as well as 
the yeast homologues of human eIF4E-BP (Δcaf20) and eIF4B (Δtif3) were tested for 
hypersensitivity to pateamine and the ribosome targeting protein synthesis inhibitors 
cycloheximide and anisomycin (Figure 4.1). Each strain was serially diluted ten-fold twice 
and pinned in quadruplicate onto YPD agar media containing the drugs at a concentration 
that slightly inhibited the growth of the surrogate wild-type deletion strain (Δhis3) at the 
greatest cell dilution. Deletion of either TIF1 or TIF2 conferred a slight increase in 
pateamine sensitivity, whereas the Δtif3 strain was extremely sensitive to pateamine. While 
the deletion of TIF3 also caused hypersensitivity to both anisomycin and cycloheximide it 
was not to the same extent as to pateamine, it is also interesting to note that the Δtif2 and 
not Δtif1 strain was hypersensitive to anisomycin, more so than it was to pateamine. The 
deletion of TIF4632 and CAF20 had a negligible effect on pateamine and cycloheximide 
sensitivity but conferred slight hypersensitivity to anisomycin. 
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Figure 4.1 Serial spot dilution assay of eIF4F component deletion strains. Overnight cultures 
of the deletion strains of eIF4F components (Δtif1, Δtif2 and Δtif4632) as well as the yeast 
homologues of human eIF4B (Δtif3) and 4E-BP (Δcaf20) and the surrogate wild-type strain (Δhis3) 
were diluted to an OD of 1, and serially diluted 10-fold twice in 96 well plates. A hand pinning tool 
was used to spot each dilution in quadruplicate onto YPD agar containing either: 17 µM pateamine; 
50 µM anisomycin; 3.5 µM cycloheximide; or 0.1% DMSO as a carrier solvent control. 
 
The growth of the Δtif1 and Δtif2 strains in the presence of pateamine was quantified in 
liquid YPD, hypersensitivity must be defined as a growth inhibition that is greater than is 
to be expected when taking into account the growth defect conferred by the gene deletion 
in combination with that caused by the drug treatment, to this end ε-scores were calculate 
according to method 4.3.3. In the presence of 15 µM pateamine the average ε-score of 
three independent experiments performed in triplicate was 0.087 and -0.096 for the both 
Δtif1 and Δtif2 strains respectively, a score of 0 indicates that the growth rate of the 
deletion strain when treated with the drug is equal to what would be expected if the 
deletion does not confer hypersensitivity, that is the growth inhibition of both TIF1 and 
TIF2 deletion and pateamine treatment combine in an additive fashion. The same analysis 
was performed on the heterozygous deletion strain of FAL1, here the average ε-score from 
three independent experiments performed in triplicate was -0.013, indicating FAL1 is not 
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haploinsufficient in the presence of pateamine, this is also illustrated in Figure 4.2 which 
shows the growth over time of the wild-type BY4743 and the FAL1 heterozygous deletion. 
While it appears the FAL1 heterozygous deletion strain grows slightly slower in the 
presence of 5 µM pateamine, it is still within the error of the untreated curve. It would 
appear that the homozygous deletion TIF1 and TIF2 strains and the heterozygous FAL1 
deletion strain are not hypersensitive to pateamine treatment and therefore would not be 
expected as hits in the HOP and HIP screens respectively.  
 
Figure 4.2 Pateamine sensitivity of the heterozygous Δfal1 deletion strain. Wild-type diploid 
BY4743 and the heterozygous Δfal1 strains were harvested from exponential growth phase 
cultures in YPD and diluted to an OD of 0.1 in YPD. Pateamine was added at the indicated 
concentrations in triplicate and 0.5 % DMSO served as a carrier. OD 590 nm was measured using 
the Wallac EnVision 2102 plate-reader at the indicated time points, data points correspond to the 
average of the triplicates and errors bars correspond to the standard deviation. 
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4.4.2 Pateamine haploid hyper-sensitivity screen  
The MATa haploid deletion library was screened in 384 well plates for strains displaying 
hypersensitivity to 16 µM pateamine in YPD. This screen was performed three times and 
strains that displayed hypersensitivity in all three screens were reassessed in 96 well plates 
at the same concentration of pateamine. A total of 247 haploid strains were found to be 
greater than 20% more sensitive to pateamine in these conditions (Sheet 1, Supplementary 
File 2), of which 17 carried deletions of uncharacterized genes and 63 have been 
previously shown to be multi-drug sensitizing (MDS) deletions in at least one of three 
large scale chemogenomic screening papers published (Parsons, Brost et al. 2004; Parsons, 
Lopez et al. 2006; Hillenmeyer, Fung et al. 2008) indicating not only that pateamine is a 
substrate of the membrane bound drug efflux pump, Pdr5p as observed previously (Section 
3.4.2), but also that vacuolar acidification may play a role in resistance to it or its 
detoxification.  
 
Assessment of functional enrichment by GO term analysis of those deletion strains that 
have not been identified as multi-drug sensitizing shows statistically significant enrichment 
of gene deletions involved in the ribosome (P = 2.4 x 10
-3
), the eIF4F translation initiation 
complex (P = 3.4 x 10
-4
) and stress granules (P = 3.0 x 10
-2
), as well as genes involved in 
protein poly-ubiquitination (P = 4.6 x 10
-2
), the Golgi apparatus function (P < 9.0 x 10
-3
), 
RNA processing (P < 1.5 x 10
-3
) and RNA polymerase II dependant transcription 
(P < 2.7 x 10
-2
) (Sheet1, Supplementary File 3), processes that could be expected to be 
sensitive to, or whose disruption could sensitize to, a perturbation of eIF4A activity or 
protein synthesis. 
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During the re-screen it was apparent that the effective concentration of pateamine in this 
format was significantly lower than that observed in the primary screen format. Given this, 
the deletion strains hypersensitive to 16 µM pateamine were retested for hypersensitivity to 
4 µM pateamine, a concentration that inhibited the Δhis3 surrogate wild-type strain by 
10%. Hyper-sensitivity to 4 µM pateamine was established with a ε-score of less than                                             
-0.15. A total of 27 deletion strains were deemed hypersensitive to 4 µM pateamine, seven 
of which bear MDS deletions, and one which is uncharacterized (Sheet 1, Supplementary 
File 2). Those strains not bearing MDS deletions were analyzed for functional enrichment; 
however no statistically significant GO term enrichment was found. It is of note that 
consistent with the previously performed serial spot dilution assay (Figure 4.1) the Δtif3 
deletion strain retained pateamine hypersensitivity at the lower pateamine concentration 
yet the other eIF4F component encoding gene deletions do not. While no statistically 
significant enrichment of translation or RNA metabolism GO terms was found it is also of 
note that nine of the 21 non-MDS deletion strains that retain hypersensitivity to 
4 µM pateamine are all described as being involved in these processes (Sheet 1, 
Supplementary File 2). 
 
The haploid deletion strains hypersensitive to pateamine were analyzed for overlap with 
previously published strains sensitive to the known protein synthesis inhibitors: 
cycloheximide (Cooper, Banthorp et al. 1967); paromomycin (Jacoby and Gorinl 1968); 
neomycin sulfate (Shimma and Uno 1990); anisomycin (Grollman 1967); emetine (Gupta 
and Siminovitch 1977); sordarin (Capa, Mendoza et al. 1998); hygromycin B (Cabanas, 
Vazquez et al. 1978); verrucarin (Fried and Warner 1981); and streptovitacin (Felicett, 
Colombo et al. 1966). A total of 133 from the 247 pateamine sensitive haploid strains 
where also sensitive to at least one previously screened protein synthesis inhibitor (Sheet 2, 
Supplementary File 2), however a significant proportion of these (46/133) were also 
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previously identified as MDS deletion strains. Functional enrichment analysis of this 
overlap, minus the MDS deletion strains, gave statistically significant enrichment of genes 
involved in: RNA metabolism (P < 3.2 x 10
-2
); regulation of transcription (P < 1.8 x 10
-3
); 
the ribosome (P < 1.9 x 10
-2
); regulation of translation (P = 1.1 x 10
-3
); the Golgi apparatus 
(P < 1.9 x 10
-2
); and the eIF4F complex (P = 1.2 x 10
-3
) (Sheet 2, Supplementary File 3), 
this is consistent with the notion that these process could be sensitive to disruption of 
protein synthesis or translation initiation. 
 
4.4.3 Heterozygous essential gene deletion library results 
The library of heterozygous deletion strains of essential genes was screened for those that 
are haploinsufficient in the presence of pateamine, the screen was performed four times, 
with a range of correlation scores of the dataset both before and after the application of a 
log2 ratio threshold of 0.5 (Table 8.1, Appendix C). The application of the log2 ratio 
threshold serves to highlight the false increase in correlation observed when non-
significant log2 ratio values are included in these calculations, it should be noted that this 
level of correlation is common amoungst HIP screen replicates previously published 
(Hillenmeyer, Fung et al. 2008; Hillenmeyer, Ericson et al. 2010). 
 
In total, 49 heterozygous deletion strains (Sheet 3, Supplementary File 2) were identified to 
be haploinsufficient in the presence of pateamine in three of the four screens performed, of 
these, two (Δmed7 and Δglc7) have been previously identified as displaying 
haploinsufficiency in the presence of a number of compounds (Hillenmeyer, Fung et al. 
2008). These strains were therefore omitted from further analysis, as were the three 
dubious open-reading-frame deletions that exhibited haploinsufficiency. Consistent with 
the results of the growth rate experiments with the Δfal1 heterozygous deletion strain 
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(Figure 4.2) it did not appear to be haploinsufficient in the presence of pateamine in any of 
the four heterozygous screen replicates. 
 
It has been previously noted that often the heterozygous deletion strain of a drug target 
encoding genes appears within the top-ten most sensitive strains to that drug (Lum, 
Armour et al. 2004). Since TIF1 and TIF2 are non-essential genes the heterozygous 
deletions were not amongst those tested for haploinsufficiency in the presence of 
pateamine. The previous growth assays of the FAL1 heterozygous deletion strains showed 
a lack of haploinsufficiency and as such it is not surprising that this strain is not in the 
top-ten list of hits in any of the screen replicates (Table 4.1 and Sheet 4, Supplementary 
File 2). Only two heterozygous deletion strains were consistently within the top-ten most 
pateamine-sensitive, these genes encode the mRNA splicing factor, Prp3p (Vijayraghavan, 
Company et al. 1989) and the MAP kinase scaffold protein Ste5p which is involved in the 
pheromone response and mating (Elion 2001), neither of which have been implicated as 
potential pateamine targets 
HOP 1 
log2 
ratio HOP 2 
log2 
ratio HOP 3 
log2 
ratio HOP 4  
log2 
ratio 
PRP3 1.20563 SHQ1 2.81491 SHR3 1.31592 PRP3 1.63675 
STE5 1.18035 CFT2 2.56481 PRP3 1.29605 RHO1 1.31886 
SHR3 1.10247 MED7 2.54759 ERG1 1.19322 STE5 1.29398 
SHQ1 1.07347 MGE1 2.2001 STE5 1.09775 TLG1 1.26767 
YNL114C 1.06204 PRP3 1.9873 NBP35 1.07074 SHR3 1.22015 
ERB1 0.902135 CDC37 1.98417 GCD11 0.952337 INH1 1.01295 
ERG1 0.885164 KRE5 1.91341 CWC2 0.921177 NBP35 0.994744 
YNL247W 0.865951 ERG8 1.89348 PSE1 0.896843 ERB1 0.977173 
NBP35 0.841353 STE5 1.76521 YGR114C 0.893818 YNL114C 0.937676 
ERG8 0.819469 GCR1 1.71899 KRE5 0.88745 ASA1 0.883253 
Table 4.1 Top-ten haploinsufficient strains from four pateamine HIP replicates and their log2 
ratio scores. HOP screens 1 – 4 were performed in the presence of 38.5, 28, 28 and 38.5 nM 
pateamine respectively, in YPD medium. Bold gene names indicate the only two strains to appear 
in the top-ten hits of all screen replicates.  
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Functional enrichment of the top ten hits from each screen was assessed using the BiNGO 
plug-in available for Cytoscape (Maere, Heymans et al. 2005), Sheet 3, Supplementary File 
3 shows the GO terms which are found to be significantly over-represented. In HIP screen 
1 the top ten hits were enriched for ncRNA metabolic process and ergosterol biosynthetic 
process (P = 4.59 x 10
-2
 and P = 3.38 x 10
-2
 respectively). The ten most sensitive 
heterozygotes in HIP screen 4 were enriched for signal transduction regulation 
(P = 3.22 x 10
-2
) and MAPKKK cascade regulation (P = 7.51 x 10
-3
), as was HIP screen 2, 
there were no significant GO terms represented in HIP screen 3. 
 
It is not too surprising that there is little GO term enrichment in the top ten hits of these 
screen replicates given there were a total of 53, 80, 74, and 90 hits above a log2 ratio of 0.5 
in HIP screens 1 - 4 respectively. While the Pearson correlation score of the four screen 
replicates with a log2 ratio threshold shows a reasonably high degree of correlation 
between the replicates (Table 8.2, Appendix C), if the overlap of hits in each screen 
replicate is assessed using the Jaccard distance measure, the congruence of the four screens 
is lowered considerably (Table 8.2, Appendix C). Given the broad range of correlation 
scores for the screen replicates it may be more appropriate to look at the GO term 
enrichment of heterozygous deletion strains that display haploinsufficiency in each of the 
four screen replicates separately. Sheets 4 – 7 of Supplementary File 3 show the significant 
GO term enrichment for each of the four screen replicates. While there is a reasonable 
degree of variation in the GO term enrichment results for each screen (Table 8.2, Appendix 
C), what is striking is the significant enrichment of almost every aspect of RNA 
metabolism including: mRNA transcription, splicing and polyadenylation; tRNA 
aminoacylation; and DNA polymerase II transcription and termination, and ribosome 
biogenesis; as well as the conspicuous absence of terms directly describing translation. 
Given the variation in replicate screen results, if only those heterozygotes that appear 
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haploinsufficient in the presence of pateamine in three of the four screen replicates is 
assessed, only the terms RNA metabolic process and ncRNA (non-coding RNA) metabolic 
process appear significantly enriched (P = 3.5 x 10
-3
 and P = 3.52 x 10
-2
 respectively); 
though it must be noted that ncRNA is a daughter term of RNA metabolic process and 
consequently includes all of the genes mapped to this term as well. 
 
In order to establish the protein synthesis inhibitor specificity of the HIP results, the 
overlap between the pateamine sensitive heterozygous strains, and those known to be 
haploinsufficient in the presence of known protein synthesis inhibitors (Hillenmeyer, Fung 
et al. 2008), and that of resveratrol, which has recently been proposed to target eIF4A 
(Lomenick, Hao et al. 2009), was assessed (Sheet 5, Supplementary File 2). A total of 18 
out of 49 heterozygote strains appear haploinsufficient in three of the four pateamine 
screen replicates. The presence of the Δste5 and Δcdc37 heterozygous strains in this 
overlapping set caused the statistically significant detection of the GO term regulation of 
MAPKKK cascade (P = 1.1 x 10
-4
) (Sheet 12, Supplementary File 3), however given there 
are only 18 genes ascribed to this term this significance may be misleading. The overlaps 
of the four individual HIP screens with known protein synthesis inhibitors was also 
assessed, in this case 19/53, 42/88, 24/74 and 37/90 of the pateamine haploinsufficient 
strains overlap with known protein synthesis inhibitors respectively (Sheet 5, 
Supplementary File 2). Functional enrichment of these overlaps shows statistically 
significant enrichment of RNA metabolism related process in all but screen replicate 3, as 
seen with the full individual screen results (Sheets 9 – 11, Supplementary File 3), which 
suggests they may be indicative of a set of chemogenomic interactions that are specific to 
protein synthesis inhibitors. None of the overlaps identified included genes that have been 
identified as being multi-drug haploinsufficient heterozygous gene deletions, thus 
strengthening their attribution as protein synthesis inhibitor specific nature.  
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In order to establish whether the profile of pateamine haploinsufficient strains was similar 
to any other drugs screened, hierarchical cluster analysis was performed with the four 
haploinsufficiency profiles of pateamine and the essential gene heterozygous deletion 
dataset from Hillenmeyer et al (2008). Prior to clustering, those heterozygous strains 
shown to be haploinsufficient in the presence of multiple compounds were removed, as 
were those strains that did not display haploinsufficiency to any of the conditions screened. 
Clustering was undertaken using a number of different approaches:  Raw log2 ratio dataset 
clustered using the centered correlation; Raw log2 ratio dataset clustered using the 
uncentered correlation distance metric; threshold dataset 2 (see method 4.3.6), sensitive 
strains are log2 ratio > 0.5, resistant are log2 < -1.5 clustered using the centered correlation 
distance metric; threshold dataset 2, clustered using the uncentered correlation distance 
metric; threshold dataset 3, sensitive strains are log2 ratio > 0.5 clustered using the centered 
correlation distance metric; threshold dataset 3 (see method 4.3.6), sensitive strains are log2 
ratio > 0.5 clustered using the uncentered correlation distance metric; binary representation 
of dataset 3, known as dataset 4, clustered with the Jaccard distance metric; binary 
representation of gene deletions that were sensitive in three of four screen replicates, 
clustered with dataset 4 using the Jaccard distance metric, all clustering was performed 
using the average linkage method to form clusters.  
 
In each case, despite the overlap with the heterozygous deletion strain profiles of other 
protein synthesis inhibitors previously discussed, the haploinsufficiency profiles of 
pateamine failed to cluster with any other profiles of drugs or environmental conditions 
present in the dataset. Figure 4.3 provides an example clustergram, and complete 
clustergrams are presented in Figure 8.1 – 8.7, Appendix C. Of particular note is the lack 
of cluster with resveratrol despite it sharing the most overlaps with the pateamine 
haploinsufficient heterozygotes, also of note is the lack of coherent clusters formed by any 
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of the protein synthesis inhibitors observed in previous analyses on this dataset 
(Hillenmeyer, Fung et al. 2008; Hillenmeyer, Ericson et al. 2010), this suggests that 
although there seems to be a set of protein synthesis inhibitor specific haploinsufficient 
genes, there is not enough similarity in the overall profiles to cause cluster formation with 
the methods used here. 
 
 
Figure 4.3 Heterozygous diploid (HIP) pateamine screen results hierarchically clustered with 
the essential heterozygous deletion screen dataset from Hillenmeyer et al with dataset 2 
using the uncentered correlation distance metric. This was performed with a variety of distance 
metrics and dataset thresholds (see Figure 8.1 - Figure 8.7, Appedix C for complete clustergrams). 
Pateamine screens are underlined with red where all four screen replicates were clustered. 
 
4.4.4 Homozygous deletion library screen results 
The library of homozygous diploid deletion strains was screened for those that conferred 
hypersensitivity to pateamine, the screen was performed four times with a broader range of 
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correlation between screens, both before and after the application of a log2 ratio threshold 
of 0.5, than was observed for the heterozygous screen (Table 8.3, Appendix C). The four 
HOP screens identified 231, 306, 386 and 407 pateamine hypersensitive deletions strains, 
of which: 30, 38, 41 and 51 were annotated as dubious open reading frames; 26, 47, 48 and 
63 were annotated as uncharacterized open reading frames; and 16, 16, 23 and 20 were 
previously identified as MDS deletion strains respectively. A total of 198 strains displayed 
hypersensitivity to pateamine in three of the four screens performed, of which nine were 
previously identified as MDS deletion strains, 25 of which are annotated as dubious open 
reading frames, and 40 of which were annotated as uncharacterized. Nineteen pateamine 
hypersensitive haploid deletion strains were also identified in at least one HOP screen 
(Supplementary File 2, Sheet 9). 
 
Functional enrichment analysis of each screen replicate and the hits from three of the four 
screens yielded no statistically significant results with the exception of the first screen 
replicate in which the GO terms: protein insertion into ER membrane (P = 4 x 10
-3
); M 
phase (P = 3.2 x 10
-2
); and cell cycle process (P = 4 x 10
-2
) were found to be enriched 
(Sheet 13, Supplementary File 3). The application of a more stringent log2 ratio threshold 
also failed to reveal any significant GO term enrichment (data not shown). 
 
The overlap of the strains hypersensitive to pateamine and other protein synthesis 
inhibitors was assessed for each screen replicate and for those that appeared hypersensitive 
to three of the four screen replicates. A significant proportion of the overlaps in each case 
were due to the presence of MDS deletion strains (Sheet 7, Supplementary File 2) as was 
seen in the previous haploid deletion set screen. Those overlapping hypersensitive strains 
that were not MDS strains were not significantly enriched for any functional category, with 
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the exception of the overlap with screen one which showed enrichment for the GO term 
protein insertion into the ER membrane (P = 3.7 x 10
-3
) (Sheet 14, Supplementary File 3), 
as was noted in the same analysis on the complete hit list (Sheet 13, Supplementary File 3).  
This suggests that gene deletions that sensitize to multiple protein synthesis inhibitors do 
not fall into a discreet biological process. 
 
Following removal of MDS-related hits, the homozygous diploid chemogenomic profiles 
obtained for the four pateamine screens were clustered with two previously published 
datasets, referred to as the Hillenmeyer (Hillenmeyer, Fung et al. 2008) and Parsons 
(Parsons, Lopez et al. 2006) datasets respectively (Figure 8.8 – Figure 8.14, Appendix C). 
The Hillenmeyer homozygous dataset variations used in this clustering experiment were 
the same as those for the heterozygous datasets from the same publication mentioned in the 
above section (Section 4.4.3), and included data pertaining to both sensitive and resistant 
strains in the various conditions screened, the Parsons dataset on the other hand contained 
only strains that were deemed as being hypersensitive to the compounds screened.  
 
Once again, despite the overlaps between the pateamine hypersensitive deletions and those 
hypersensitive to known protein synthesis inhibitors, in each variation of the cluster 
analysis pateamine failed to cluster with any of the previously published profiles in either 
the Hillenmeyer (Figure 4.4) or Parsons (Figure 4.5) datasets, regardless of the type of data 
included with respect to sensitive and resistant strains or the application of the described 
thresholds on the data. The clustering methods, with respect to the choice of distances 
metric and threshold, have been previously applied to successfully identify clusters of 
compounds of similar modes of action (Parsons, Brost et al. 2004; Parsons, Lopez et al. 
2006; Hillenmeyer, Fung et al. 2008; Hillenmeyer, Ericson et al. 2010), furthermore the 
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clustering performed here has successfully recapitulated clusters of drugs previously 
published, specifically DNA damaging agents and oxidative stress inducing agents 
clusters, reaffirming the robustness and applicability of the methods performed. As was 
noted in the clustering of the heterozygous datasets, the few protein synthesis inhibitors 
that are present in the datasets fail to form a distinct cluster with any of the variations in 
dataset or clustering method employed here, as has been noted in previous analyses 
(Hillenmeyer, Fung et al. 2008; Hillenmeyer, Ericson et al. 2010). 
 
 
Figure 4.4 Homozygous diploid (HOP) pateamine screen results hierarchically clustered 
with the essential heterozygous deletion screen dataset from Hillenmeyer et al with dataset 2 
using the uncentered correlation distance metric. This was performed with a variety of distance 
metrics and dataset thresholds (see Figure 8.8 – 8.14, Appendix C for complete clustergrams). 
Pateamine screens are underlined with red where all four screen replicates were clustered. 
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Figure 4.5 Homozygous diploid (HOP) pateamine screen results hierarchically clustered 
with the homozygous deletion screen dataset from Parsons et al using the uncentered 
correlation distance metric. This was performed with a variety of distance metrics and dataset 
thresholds (see Figure 8.15 – Figure 8.17, Appendix C for complete clustergrams). Pateamine 
screens are underlined with red where all four screen replicates were clustered. 
  
4.4.5 Network analysis 
Given the lack of significant functional enrichment in the pateamine HOP results and the 
failure to find other conditions or drugs that the pateamine profiles would cluster with, an 
alternative analysis was performed taking into account the known genetic and physical 
interactions of the genes whose deletions conferred hypersensitivity to pateamine. This 
allows gene deletions to be grouped according to empirically defined interactions rather 
than shared functional annotation. In this analysis the genetic and physical interactions of 
all of the pateamine hits from each of the screens described above were downloaded from 
SGD, a bipartite network was constructed where nodes correspond to each of the 
pateamine screens which are connected by an edge to nodes that correspond to their hits 
(Figure 8.18, Appendix C), this network was merged with the networks corresponding to 
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genetic and physical interactions, this network consists of 5,390 nodes and 80,209 
interactions (Figure 8.18, Appendix C), so was simplified by removing all nodes that 
correspond to genes which did not appear in any of the pateamine screens. The resulting 
network consists exclusively of pateamine hypersensitive or haploinsufficient gene 
deletions and the interactions they share with each other, and contains of 1,063 nodes and 
19,179 interactions (Figure 8.18, Appendix C). The size of the network makes manual 
visual analysis challenging, therefore the Cytoscape plug-in MCODE was used to identify 
significant sub-networks characterized by localized areas of interaction density, which 
should be indicative of related function or shared pathway membership. While MCODE 
has been primarily used (Bader and Hogue 2003) to identify protein complexes from large-
scale protein-protein interaction datasets it treats all forms of interactions as equivalent and 
therefore can be applied to this scenario.  
 
It must be noted that the physical and genetic interaction data present in the SGD database 
in a mixture of those derived from large-scale studies (for instance genome-wide affinity 
mass spectrometry defined protein-protein interactions (Collins, Kemmeren et al. 2007) 
and genetic interactions defined by genome-wide epistatisis analysis (Costanzo, 
Baryshnikova et al. 2010) a large number of which are not verified, and interactions that 
have been studied and verified individually. The interactions used in this analysis were not 
filtered for reliability on the premise that novel unverified interactions may be informative 
and those verified interactions exist as multiple interactions between nodes which will be 
recognized and scored more highly by the MCODE algorithm. Previously identified MDS 
genes were retained in this analysis, it is presumed that those related to detoxification or 
drug efflux will be identified as sub-networks and therefore do not compromise the 
interpretation of the results. A total of 13 sub-networks with more than five nodes were 
identified using MCODE, seven of which were significantly functionally enriched, those 
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that were not were generally scored lower by the algorithm (Sheet 8, Supplementary 
File 2).  
 
Each sub-network consists of nodes corresponding to genes from at least one of the five 
screens performed (HIP and HOP screens 1 - 4 and the homozygous haploid screen; Table 
8.4, Appendix C) and was functionally enriched in a manner that appears more specific to 
the known mode-of-action of pateamine, translation inhibition, than the compiled list of all 
hits from all screens (compare Sheet 22 to Sheets 15 – 21, Supplementary File 3). 
Sub-network one (Figure 4.6) was enriched for processes related to RNA polymerase II 
related transcription (P < 2.2 x 10
-6
), translation (P < 2.1 x 10
-3
), tRNA metabolism 
(P < 1.4 x 10
-2
) and protein ubiquitination (P < 2.4 x 10
-2
) and includes most of the eIF4F 
complex (P < 1.3 x 10
-7
). Sub-network two (Figure 4.7) was enriched for processes related 
to RNA transport (P < 1.9 x 10
-2
), mitosis (P < 4.5 x 10
-2
), transcription (P < 1.3 x 10
-2
), 
DNA repair (P = 3.4 x 10
-4
) and vacuolar acidification (P < 2.9 x 10
-2
). Sub-network three 
(Figure 4.8) was enriched for various terms surrounding translation including the large and 
small ribosome subunits (P < 2 x 10
-5
), ribosome biogenesis (4.2 x 10
-2
), regulation of 
transcription (1.4 x 10
-2
), particularly the mediator complex (P = 2.9 x 10
-6
), and translation 
initiation (2.6 x 10
-6
). Four other sub-networks were enriched in similar process to those 
mentioned above (Figure 8.21 - Figure 8.24, Appendix C) further highlighting the role of 
RNA centered biological processes in the sensitivity to pateamine. 
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Figure 4.6 Sub-network one is enriched for processes related to RNA polymerase II related 
transcription, translation, tRNA metabolism and protein ubiquitination. Blue interactions are 
physical, magenta are genetic. Yellow nodes are MDS gene deletions; black node borders are 
homozygous strains sensitive to pateamine in at least one of the screens performed; grey node 
borders are heterozygous strains that display haploinsufficiency in the presence of pateamine. 
 
 
Figure 4.7 Sub-network two is enriched for processes related to RNA transport, mitosis, 
transcription, DNA repair and vacuolar acidification. Blue edges are physical interactions, 
magenta are genetic interactions and black are pateamine hypersensitive. Green node is the 
HIPHOP pateamine screen 4; Yellow nodes are MDS gene deletions; black node borders are 
homozygous strains sensitive to pateamine in at least one of the screens performed; grey node 
borders are heterozygous strains that display haploinsufficiency in the presence of pateamine. 
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Figure 4.8 Sub-network three is enriched for large and small ribosome subunits, ribosome 
biogenesis, regulation of transcription and translation initiation. Blue edges are physical 
interactions, magenta are genetic interactions and black are pateamine hypersensitive. Green 
nodes are the pateamine screens as labeled; Yellow nodes are MDS gene deletions; black node 
borders are homozygous strains sensitive to pateamine in at least one of the screens performed; 
grey node borders are heterozygous strains that display haploinsufficiency in the presence of 
pateamine. 
 
The results of this network based analysis of the pateamine screen data have shown that, in 
contrast to looking simply at GO term enrichment, incorporation of empirically defined 
genetic and physical interactions with chemogenomic datasets allows a greater statistical 
significance to be ascribed to the presence of certain functional groups of hits. The most 
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striking outcome of this analysis was the occurrence of genes related to RNA polymerase 
II mediated transcription, which was also seen in the functional analysis of the haploid 
screen and HIP assays. By analyzing all of the screen results as a single set it has been 
possible to ascribe significant functional enrichment to genes that appeared in the HOP 
assay, where previous analysis of the HOP screens discretely failed to do so. 
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4.5 Discussion 
The motivation behind this work was to discover the breadth of functional specificity of 
pateamine. Given the clear evidence that both yeast eIF4A and human eIF4AI/II and 
eIF4AIII are targeted by pateamine in vivo and the strong degree of homology between 
yeast eIF4A and Fal1p (Kressler, de la Cruz et al. 1997) there exists the distinct possibility 
that it too is targeted by pateamine. To this end the newly developed approach of 
chemogenomic profiling was employed with the hope it would reveal whether Fal1p was 
in fact targeted by pateamine. Additionally the eIF4A family of proteins is a part of the 
much larger DEAD-box helicase super-family, all of which share significant sequence and 
structural homology (Linder 2006) and hence are also potential pateamine targets. 
 
4.5.1 eIF4F component deletion fitness in the presence of pateamine 
Initially the sensitivity of homozygous deletions of the various eIF4F complex members, 
namely TIF1 and TIF2 which encode yeast eIF4A (Linder and Slonimski 1989), TIF4632 
which encodes a yeast eIF4G homologue (Goyer, Altmann et al. 1993), and TIF3 and 
CAF20, the yeast homologues of eIF4B (Coppolecchia, Buser et al. 1993) and eIF4E-BP 
(Altmann, Krieger et al. 1989) respectively, were assessed individually. Given the verified 
effect of pateamine on the function of the eIF4F complex, through perturbation of eIF4A 
function, this was performed in order to establish whether these gene deletions strains were 
likely to appear in the large-scale genome-wide deletion set screen to be performed later. 
The deletions of TIF1 and TIF2 had only very slight effects on pateamine sensitivity, with 
TIF2 deletion strain being slightly more sensitive than TIF1. This is not surprising given 
the duplicate nature of these genes, which encode identical protein products and display a 
synthetic lethal genetic interaction, indicating an essential gene product; the slight 
additional sensitivity of TIF2 may be explained by the observation that it contributes the 
slight majority of eIF4A (Prat, Schmid et al. 1990). This slight increase in sensitivity was 
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only observed when the assay was performed on YPD agar, suggesting the potential of 
differential requirements or expression of TIF1 and TIF2 on solid media, and in high 
concentrations of pateamine in liquid YPD since lower concentrations failed to cause 
hypersensitivity. It is interesting to note that the deletion of TIF2 caused a greater 
hypersensitivity to anisomycin and not cycloheximide, two well characterized ribosome 
targeting, translation elongation inhibitors. The difference in sensitivity may be due to 
slight differences in the mechanism by which anisomycin and cycloheximide inhibit the 
ribosome, where anisomycin inhibits the ribosome A-site and cycloheximide binds to a 
position near the E-site and arrests and stabilizes the translocating ribosome on the mRNA 
being translated (as reviewed in Section 1.4).  
 
While the deletions of TIF1 and TIF2 caused slight, and arguably negligible, 
hypersensitivity to pateamine, the deletion of TIF3 caused a significant decrease in fitness 
in the presence of pateamine, and while it also increased sensitivity to anisomycin and 
cycloheximide it was not nearly to the same extent. This hypersensitivity was retained in 
liquid media and both high and low concentrations of pateamine, and falls in line with the 
literature which shows that over-expression of TIF3 suppresses the growth defect of a 
temperature sensitive TIF1 allele (Coppolecchia, Buser et al. 1993). Tif3p shares a 
moderate but significant degree of homology with human eIF4B and eIF4H which have 
been shown to support the function of eIF4AI/II both in vitro and in vivo (Altmann, Muller 
et al. 1993), allowing it act as a processive helicase when present (Lorsch and Herschlag 
1998), it has been suggested that this occurs due to its RNA binding properties (Altmann, 
Wittmer et al. 1995). Therefore the absence of Tif3p would be expected to sensitize 
particularly to conditions that perturb eF4A function, such as pateamine treatment. 
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While the literature shows there exists numerous genetic interactions between TIF4632 and 
TIF1 and TIF2 (Neff and Sachs 1999; He, von der Haar et al. 2003; Watanabe, Murai et al. 
2010), it may not be surprising that it does not cause pateamine hypersensitivity given the 
presence of TIF4631 which also encodes an isoform of eIF4G, also in contrast to Tif3p, 
recruitment by eIF4G to the eIF4F complex is required before eIF4A can exert is role in 
translation initiation. The deletion of CAF20 did not cause a fitness defect in the presence 
of pateamine, which is also not surprising given that it’s physiological role is to attenuate 
translation initiation by binding to eIF4E subsequent to being phosphorylated, and 
represents one of the many proteins involved in translation that is phosphorylated in 
response to various growth inhibiting stimuli or conditions (Zanchin and McCarthy 1995).  
 
4.5.2 FAL1 haploinsufficiency in the presence of pateamine 
Due to the significant homology of Fal1p to yeast eIF4A it represents a most likely 
additional target for pateamine. Like the eIF4A protein, Fal1p is an essential gene product, 
given that it exists a single copy in the yeast genome it is hence an essential gene, therefore 
the heterozygous deletion of FAL1 was assessed for haploinsufficiency in the presence of 
pateamine. Given previous observations that the heterozygous deletion of an inhibitor-
target encoding gene is haploinsufficient in the presence of said inhibitor (Giaever, 
Shoemaker et al. 1999) if pateamine does inhibit Fal1p then the heterozygous deletion 
should display haploinsufficiency in the presence of pateamine. This was not observed, the 
growth of the heterozygous Δfal1 strain was not significantly different from the isogenic 
wild-type control. The success of haploinsufficiency profiling to identify drug targets relies 
on the premise that the heterozygous deletion of the target results in less gene product due 
to gene dosage effects, while it is possible that in this case the gene product is not 
significantly decreased in abundance by the heterozygous deletion of the gene this is 
argued against by the reporting of several conditions that do cause haploinsufficiency of in 
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the Δfal1 strain (for instance treatment with miconazole, lovastatin and camptothecin 
(Hillenmeyer, Fung et al. 2008)). This result explains the absence of the Δfal1 
heterozygous deletion strain in the pateamine haploinsufficiency profiling results and 
argues it is not targeted by pateamine, or that the affect of pateamine on eIF4A masks the 
haploinsufficiency of the Δ fal1 strain. 
 
4.5.3 Homozygous deletion library screens 
In order to further establish whether Fal1p, or any other DEAD-box helicase, is a potential 
pateamine target two complementary homozygous deletion library screens were 
performed; one at VUW in an individual 384-well format with a relatively high 
concentration of pateamine on the MATa haploid deletion library; the other at the 
University of Toronto by members of the Giaever and Nislow group, at a much lower 
concentration with the homozygous diploid library which was multiplexed with the 
haploinsufficiency profiling screen, a system known as the HIPHOP assay (Pierce, Fung et 
al. 2006).  
 
It is well established that homozygous deletion profiling with biologically active small 
molecules has the potential to reveal genes that are functionally related to the target protein 
or biological processes, and hence may be used to infer a drug target or a drug targeted 
process (Parsons, Brost et al. 2004; Parsons, Lopez et al. 2006). It is accepted that this 
screening procedure identifies “friends of the target” in contrast to haploinsufficiency 
profiling which was originally conceived to identify drug targets directly. These “friends of 
the target” often display hypersensitivity to the compound in question by virtue of 
synthetic lethal genetic interactions with the target, or by compromising the biological 
process in question, in the case of non-protein targeting compounds such as DNA 
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damaging agents or lipid targeting drugs. As such, pateamine hypersensitive deletion 
strains may be directly related to the known target (i.e. eIF4A), as seems to be the case 
with the Δtif3 strain, or may be related to one of the various biologically processes that 
members of the DEAD-box helicase super-family are known to be involved in (i.e. 
ribosome biogenesis in the case of Fal1p), or possibly related to the combined perturbation 
of all targets. However, a complicating factor in the interpretation of these screen results is 
the existence of so-called multi-drug sensitizing (MDS) deletions, while a significant 
proportion of the MDS deletions are the drug efflux pumps themselves (such as PDR5 and 
SNQ2) or related to their regulation (such as the PDR1 and PDR3 transcription factors and 
genes involved vesicular transport and the recycling of the drug efflux pumps), also present 
in this list is genes involved in vacuolar function, in particular its acidification. However, a 
considerable proportion are genes that display a slow growth phenotype, which are often 
involved in the ribosome and its biogenesis (Parsons, Brost et al. 2004; Parsons, Lopez et 
al. 2006; Hillenmeyer, Fung et al. 2008), which may complicate the use of this approach in 
characterizing novel protein synthesis inhibitors. 
 
The most simple analysis of homozygous deletion library screen results involves 
establishing whether any particular functional group of genes is over-represented (after the 
removal of MDS genes), the most common approach to this has been the utilization of the 
output of the Gene Ontology Project, hence it was applied here also.  
 
It appears that pateamine is a substrate of the drug efflux pump Pdr5p and compromised 
vacuolar acidification also causes hypersensitivity. Subsequent to the removal of 
previously identified MDS gene deletions, it is apparent that genes involved in translation, 
particularly ribosomal proteins and the eIF4F complex, RNA processing, RNA polymerase 
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II transcription and protein ubiquitination are significantly enriched amongst the pateamine 
hypersensitive strains in the high concentration screen. The presence of translation related 
genes can be explained by the effect of pateamine on eIF4A, also related to this may be the 
presence of ubiquitination genes given that ubiquitin has an extremely short half-life 
protein and it has been previously shown that deletions in ubiquitin related genes sensitize 
to cycloheximide (Hanna, Leggett et al. 2003). The presence of RNA processing and RNA 
polymerase II transcription related genes could also be explained by an effect of pateamine 
on translation initiation, however these enrichments may also be contributed to by an effect 
on ribosome biogenesis via Fal1p, or indeed an effect on one of the many DEAD-box 
helicases that are involved in multiple facets of transcription, mRNA splicing, and RNA 
metabolism (Linder 2003; Linder 2006).  
 
When yeast DEAD-box helicase sequences are aligned, it is notable that only one has an 
equivalently positioned cysteine residue to that proposed in section 3.4.7 as being a 
possible pateamine binding site. This protein, Prp5p has been characterized as a 
DEAD-box helicase that is required for pre-spliceosome formation (Xu, Newnham et al. 
2004) and this raises the possibility that Prp5p, and not Fal1p, may be responsible for the 
RNA processing-related hits identified in these screens. In preliminary analysis, the Δprp5 
heterozygous deletion strain showed increased sensitivity to pateamine compared to the 
effect found following either cycloheximide or anisomycin treatment (data not shown), 
which could indicate that it is a target for pateamine, however despite the existence of 
DDX46, the mammalian homologue of Prp5p (Will, Urlaub et al. 2002) pateamine does 
not inhibit mammalian in vitro cell splicing reactions (Bordeleau, Matthews et al. 2005). 
Therefore it is unlikely Prp5p is a pateamine target in yeast and the haploinsufficiency 
shown by the Δprp5 heterozygote is likely reflective of a functional link between mRNA 
splicing and translation initiation  
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The likely intimate functional relationships between Fal1p and eIF4A, and of course many 
other DEAD-box helicase makes a clear distinction difficult. This is not helped by the lack 
of any significant functional enrichment in the results from either the low concentration 
secondary screen performed on the haploid deletion hits, or the low concentration HOP 
screens performed at the University of Toronto.  
 
An alternative to functional enrichment analysis, which depends on the deleted genes being 
characterized, cluster analysis has been used to assess chemogenomic profile similarity and 
hence group compounds of similar biological activity. Various clustering and partitioning 
methods have been employed to ascertain profile similarity, the most common, and 
arguably the most successful has been the application of hierarchical cluster analysis 
(Parsons, Brost et al. 2004; Parsons, Lopez et al. 2006; Hillenmeyer, Fung et al. 2008; 
Hillenmeyer, Ericson et al. 2010), which was popularized by its use in mRNA microarray 
data interpretation. Given the lack of significant functional enrichment in the low 
concentration HOP screen results, hierarchical clustering was employed to assess their 
similarity to other screened conditions.  
 
Two large-scale genome-wide chemogenomic datasets have been previously published, 
which screened the homozygous diploid library for hypersensitivity to 178 and 82 unique, 
biologically and chemically diverse compounds and conditions respectively, and hence 
were used in clustering experiments with the pateamine HOP screen results (Parsons, 
Lopez et al. 2006; Hillenmeyer, Fung et al. 2008). However in each variation of the 
clustering method employed (as outlined in method 4.3.6) the pateamine HOP screen 
results failed to cluster with any drug or condition, despite the significant overlap between 
its hypersensitive deletion strains and those hypersensitive to other known protein 
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synthesis inhibitors. There are two possible interpretations of this result: 1. the pateamine 
HOP profile is truly novel, which may not be surprising since there are no translation 
initiation specific inhibitors, only translation elongation inhibitors, present in either of the 
datasets; 2. Protein synthesis inhibitor HOP profiles do not form coherent clusters, 
indicated by the lack of a “protein synthesis inhibitor cluster” in either this cluster analysis 
or the original analyses performed on these datasets. This result may suggest there is not a 
global response to protein synthesis inhibition in yeast but rather an inhibitor-mechanism 
dependant one, this is reflected by the observation that deletions in ubiquitin related genes 
sensitize to cycloheximide, and anisomycin but not to hygromycin B (Hanna, Leggett et al. 
2003). Previous studies have shown that a compound’s chemogenomic profile will cluster 
with the synthetic lethal interaction profile of its target (Parsons, Brost et al. 2004), there is 
small number overlap between the pateamine screens performed here and the negative 
genetic interactions of TIF1, TIF2 and FAL1 present in the literature (Figure 8.25, 
Appendix C), however this type of analysis suffers from the paucity of genetic interaction 
known for these three genes, due to their duplicate nature (in the case of TIF1 and TIF2) 
and the lack of large-scale geteic interaction data, as in the case of FAL1. 
 
A subsequent analysis of the Hillenmeyer dataset published recently revealed that strains 
with gene deletions involved in translation, ribosome biogenesis and RNA metabolism also 
fail to form functionally enriched clusters across the many drugs and conditions screened 
(Hillenmeyer, Ericson et al. 2010), which may be reflective of an evolved genetic 
redundancy in these systems given their importance to fitness. Given a significant 
proportion of biologically active natural products target protein synthesis, this redundancy 
may have evolved in part to deal with numerous assaults on these systems by natural 
products produced by competing organisms. Ultimately the inability of the HOP approach 
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to resolve the biological activities of pateamine likely reflects a broader problem of the 
application of this methodology to defining the activity of protein synthesis inhibitors. 
 
4.5.4 Haploinsufficiency profiling of pateamine  
Early analysis of haploinsufficiency profiling assays involved analyzing the top- ten most 
sensitive heterozygous deletions strains that showed haploinsufficiency in the presence of a 
compound, and that the drug target was often present (Lum, Armour et al. 2004). As 
already mentioned the Δfal1 heterozygote is not haploinsufficient in the presence of 
pateamine and hence does not appear in the top-ten hits of any of the screen replicates, also 
absent from these lists are any DEAD-box helicases, however two gene deletions strains 
were consistently within the top-ten hits for each screen, the mRNA splicing factor PRP3 
and STE5 a MAP kinase scaffold protein, neither of which have been implicated as 
potential pateamine targets. The haploinsufficiency caused by the heterozygous deletion of 
STE5 is not immediately explainable; however the growth defect of PRP3 once more is 
likely due to the relationship between translation and mRNA splicing. More recent studies 
have assessed functional enrichment as might be done for homozygous deletion set results 
(Baetz, McHardy et al. 2004; Kemmer, McHardy et al. 2009), this analysis performed on 
the top ten hits from each pateamine HIP screen revealed little evidence of an effect on 
either eIF4A or Fal1p, hence the analysis was performed on the entire haploinsufficient 
strain list for each screen. This revealed enrichment in numerous aspects of RNA 
metabolism, which, for reasons mentioned previously do not aid in determining whether 
any gene product other than eIF4A is affected by pateamine.  
 
In more recent publications haploinsufficiency profiles have been clustered in the same 
manner as those for homozygous deletion sensitivity profiles (Hillenmeyer, Fung et al. 
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2008). As was observed with the clustering of the pateamine homozygous profiles, the 
pateamine induced haploinsufficiency profiles failed to cluster with any other condition or 
drug present in the dataset, again despite overlap in the strains haploinsufficient in the 
presence of other protein synthesis inhibitors. Unlike the profile datasets used in the HOP 
cluster analysis, there was one compound that has been shown to potentially target 
translation initiation, specifically eIF4A. Resveratrol has recently been shown to physically 
interact with eIF4A in vitro, and also inhibit protein synthesis and the growth of yeast, 
albeit with a much lower potency that pateamine (Pan, Agarwal et al. 2008). However, 
despite sharing the greatest overlap out of any of the protein synthesis inhibitors with 
pateamine it too failed to cluster with pateamine.  
 
According to prior literature, if eIF4A is a target of pateamine the heterozygous deletion of 
TIF1 and TIF2 should cause haploinsufficiency in its presence, since only essential genes 
were screened in this work the TIF1 and TIF2 heterozygous strains were absent from the 
pool, also the lack of Δfal1 haploinsufficiency seen in both the large-scale screen (Table 
4.1 and Sheet 3, Supplementary File 2) and when assessed individually (Figure 4.2) argues 
that Fal1p is not a functionally relevant target for pateamine. 
 
4.5.5 Interactions of pateamine with other proposed targets 
The affinity chromatography and biochemical assays presented in chapter 2 raised the 
possibility that pateamine might interact functionally with actin and tubulin. Kuznetsov, 
Xu et al. (2009) also report the in vitro inhibition of DNA polymerases  and  by 
pateamine. None of these putative targets, all of which are proposed to require a higher 
concentration of pateamine than inhibition of the eIF4A proteins, have become apparent 
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during the chemogenomic screens performed here. Inhibitors of tubulin (benomyl and 
nocodazole) and actin (latrunculin and cytochalasin) are present in each of the datasets the 
pateamine profiles were clustered with, and provide chemogenomic profiles that clearly 
identify their interactions with these targets, though the same cannot be said for inhibitors 
of DNA polymerase, since none appear in the either datasets. In contrast to protein 
synthesis inhibitors, actin and tubulin targeting compounds group together during 
hierarchical cluster analysis (Parsons, Brost et al. 2004; Parsons, Lopez et al. 2006; 
Hillenmeyer, Fung et al. 2008; Hillenmeyer, Ericson et al. 2010). Thus, although final 
clarification regarding DEAD-box helicase protein selectivity has not been fully 
established in the screens reported here, confirmation has been obtained that other putative 
targets are not involved in the mode of action of pateamine, at least in yeast. 
 
4.5.6 Pateamine-hit interaction network analysis 
The network analysis attempted here makes use of the large number of known physical and 
genetic interactions that have been enumerated for a significant proportion of the yeast 
genome. This provides an alternative to the more traditional approaches to analyzing 
chemogenomic screen data presented above. These traditional approaches rely on the 
functional annotation of genes whose deletion confers hypersensitivity to a drug or display 
haploinsufficiency in its presence, in the case of GO term enrichment, or on the existence 
of significantly similar deletion hypersensitivity profiles, as in the case of cluster analysis. 
 
There are several disadvantages of functional enrichment analysis, first it relies on the 
genes of interest being annotated with GO terms, and while the vast majority of the 
genome has been functionally annotated there is considerable variation regarding the 
specificity of these annotations. The gene ontology system is hierarchically structured, 
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with parent and daughter term relationships, this hierarchical structure can make the clear 
assessment of the results of a functional enrichment analysis difficult, with the significant 
enrichment of numerous GO terms occurring because of the same set of genes, the 
question is which term is the most informative or accurate? This can been seen in all of the 
GO term enrichment analysis results presented here (Supplementary File 3) where multiple 
GO terms are enriched due to presence of the same genes, a judgment must be made as to 
which to report, making what should be an objective analysis somewhat more subjective.  
  
Another issue associated with GO term analysis is the effect of noisy datasets and the 
number of genes ascribed to certain terms. The methods that are used to assess statistical 
significance take into account the size of the dataset being analyzed, the proportion of that 
dataset that contains genes annotated to a certain term, the total number of genes in the 
genome annotated to that term relative to and the proportion of that total that is present in 
the dataset. Misleadingly low p-values can be found for the enrichment of a GO term if 
that term only has one or two genes annotated to it in the whole genome, and one of these 
is present in the dataset, as was seen with the enrichment of MAP kinase related terms in 
the HIP screen.  
 
This problem is considerably exacerbated by the high level of noise present in 
chemogenomic data, where it is often not known what the p-value of specific hit is. Even 
when this is calculated, and found to be significant, the considerable variation in hits from 
different screen formats, i.e. pooled microarray methods vs. agar based screens, and from 
different labs using the same methods makes it difficult to assess the true validity of the 
hit. Therefore the same drug screened in different ways can give significantly different 
results; a good example of this is rapamycin, arguably the most screened compound. 
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Comparing the list of hits from all of the screens performed just on agar based media 
shows considerable variation, the overlap between these datasets is even worse when liquid 
and pooled microarray assays are considered (Chan, Carvalho et al. 2000; Parsons, Brost et 
al. 2004; Xie, Jin et al. 2005; Parsons, Lopez et al. 2006). Even seemingly replicate screens 
often have significant variation in the hits that appear (Hillenmeyer, Fung et al. 2008), 
these variations affect not only functional enrichment but also cluster analysis results. 
 
Cluster analysis suffers from separate but related issues, while it does not rely on the 
functional annotation of genes of interest its success is dependent on the presence of 
compounds of similar mode-of-action to the compound of interest being present in the 
dataset that is being clustered. Furthermore it relies on the notion that compounds with a 
similar mode-of-action will have a similar chemogenomic profile. As has been noted here, 
protein synthesis inhibitors as a class of drugs fail to form distinct clusters with each other, 
arguably this may be as a consequence of the fact that there are many ways to inhibit 
protein synthesis and therefore different gene deletions sensitize to different types of 
protein synthesis inhibitors depending on their exact mechanism and the consequence of 
their interaction with the ribosome. For instance emetine, anisomycin are both ribosomal 
A-site inhibitors have been shown to cluster together with the exclusion of hygromycin 
which also interacts with this site on the ribosome (Parsons, Lopez et al. 2006). This is, at 
least in part, due to the over-simplification in terms of ascribing a broad mode-of-action to 
a class of compounds such as protein synthesis inhibitors. 
 
The removal of MDS deletions strains has become common-place prior to cluster analysis, 
this is due to the observation that the inclusion of these genes serves to make clusters 
“drug-hungry” (Parsons, Brost et al. 2004), meaning the formation of clusters is 
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predominantly influenced by the presence of these genes. However, there may be 
information specific to a certain drug that is lost by excluding these results. For instance, 
vesicular mediated transport type genes are often excluded since they are presumed to act 
in a relatively non-specific manner with respect to their role in drug efflux pump recycling, 
however one wonders what would result from the exclusion of these genes if a drug was 
screened that affected this process directly. A more specific example to the case of protein 
synthesis inhibitors is that a number of these MDS genes are designated as such because 
they show a growth defect in rich media, and therefore often appear being sensitive to 
many compounds since the manner in which their fitness is defined in the presence of the 
drug does not take into account the additive effect of the drug and the gene deletion on 
fitness. For instance the Δtif3 deletion strain grows particularly slowly in rich media, 
causing it to erroneously appear as a hit in many screens and is therefore in the MDS 
deletion list; however the extreme sensitivity of this strain to pateamine is informative with 
respect to the mode-of-action of pateamine, perturbing the function of eIF4A, and this 
extreme sensitivity is not seen with other protein synthesis inhibitors. For these reasons 
removal of MDS genes should be approached with caution and with knowledge of whether 
the drug in question is subject to pump mediated efflux. 
 
In the interaction-based approach trialed in this study, rather than relying on grouping 
genes on the basis of shared functional annotation they are grouped on the basis of 
empirically defined physical or genetic interactions. A considerable advantage of using 
S. cerevisiae as a model organism in these experiments is the large amount of data 
available for this type of analysis. Aside from the full-genome sequence, there have been 
numerous genome-wide assays performed on it, for instance a number of large-scale 
protein-protein interaction studies. There also exists a wealth of genetic interaction data 
from both targeted studies and at least partially genome-wide epistatic or genetic 
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interaction studies. Additionally numerous biochemical activity screens have been 
documented, for instance the enumeration of kinase and phosphatase substrates, RNA 
binding protein specificity for mRNAs, transcription factor binding (CHiP on Chip assays) 
etc… All of this information can be used to establish functional and physical relationships 
between the hits found in a chemogenomic screen, enabling them to be grouped in a way 
that is similar the grouping of genes by shared GO term annotation. The advantage over 
GO term analysis is that all of the data used has been experimentally defined, while this 
suffers from the level of noise present in each dataset, true interactions are more likely to 
be present in multiple datasets and therefore represented by multiple links in the resulting 
network. Therefore a method that identifies related gene clusters in a chemogenomic 
dataset on the basis localized density of interactions should score sub-networks consisting 
of the “real” interactions more highly, thereby negating the potentially high level of 
spurious interactions. One such method is implemented by the MCODE algorithm which 
was originally used to identify protein complexes for large-scale protein-protein interaction 
datasets by searching for localized areas of high interaction density (Bader and Hogue 
2003). 
 
In this work, a network was constructed that consisted of all of the hits from each 
pateamine screen performed, and their physical and genetic interactions with each other. 
Inter-hit interactions were obtained from the SGD database and represent genetic and 
physical interactions established through a variety of means (see Table 8.5 and Table 8.6 
for a description of each), MCODE was used to find localized regions of interaction 
density, which were presumed to represent biological processes or systems that are 
functionally related to the target(s) of pateamine or, due to inclusion of MDS strains, 
detoxification mechanisms employed in its presence. It was hoped by the inclusion of these 
inter-hit interactions that noise in the datasets would be negated as only those hits that 
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share interactions with other hits would be present in any resulting sub-networks, thereby 
allowing a more appropriate application of functional analysis assessments, or a less 
ambiguous interpretation of the results. It must be noted that some of the interactions 
present in the network analyzed by MCODE are directional, for instance positive epistatic 
and RNA binding interactions, however the directions were ignored, the presence of an 
interaction is all that matters in this analysis, MCODE ignores edge directionality. 
 
Seven sub-networks were identified from the pateamine-hit interaction network that were 
significantly functionally enriched. Not only did this analysis highlight biological 
processes required for resistance to pateamine, it also drew relationships between those 
processes on the basis of literature interactions. For instance, sub-network one was 
enriched for components of the eIF4F complex, RNA polymerase II transcription, tRNA 
processing all of which can be directly associated with translation, and protein 
ubiquitination which is also related in that many proteins involved in translation are 
ubiquinated. Sub-networks two and five (Figure 8.22, Appendix C) on the other hand show 
significant enrichment for vacuolar function, which may be related to the detoxification of 
pateamine, or to recycling of drug efflux pumps. Sub-network three appears enriched for 
proteins involved in translation, especially ribosome components and initiation factors and 
members of the mediator complex which is directly related to the transcription of RNA 
polymerase II. The MAP kinase enrichment of sub-network four (Figure 8.21, Appendix 
C) might reflect signaling pathways employed in the presence of pateamine to modulate 
response to its presence, or they may be reflective of a general stress response. 
 
By undertaking this analysis it was hoped to clearly delineate pateamine-sensitizing 
deletions related to the inhibition of translation initiation (and thus eIF4A) or ribosome 
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biogenesis (related to Fal1p inhibition), the significant enrichment of genes in sub-network 
six (Figure 8.23, Appendix C) related to rRNA processing may well be reflective of an 
inhibitory effect on Fal1p, though this interpretation must be approached with caution 
given the intimate link between ribosome biogenesis and translation. Sub-network seven 
(Figure 8.23, Appendix C)was another network in which genes relating to the transcription 
by RNA polymerase II were significantly enriched, this has been seen in a number of other 
sub-networks and also in the functional analysis of the HIP screen results.  
 
RNA polymerase II is responsible for the transcription of all ribosomal gene mRNA which 
represents ~50% of all mRNAs that it is responsible for transcribing. Therefore deletions 
that affect its function will impact the production of ribosomes (Hampsey 1998), which 
could in turn aggravate inhibition of translation initiation or ribosome biogenesis. 
However, ribosome biogenesis is also impacted by the synthesis of rRNA, which are 
transcribed by RNA polymerase III, it might be expected if a direct effect on rRNA 
synthesis by pateamine occurs there would also be a number of genes related to the 
function of RNA polymerase III, and other genes directly related to the processing of 
rRNA. There is a lack of a clear enrichment of these genes in any of the screens lists or 
sub-networks within the pateamine-hit interaction network. Therefore, it could be 
suggested that pateamine does not affect Fal1p function and that all of the RNA 
metabolism enrichment seen above is as a result of a direct effect on yeast eIF4A. 
   
Interpretation of these results must be done with caution, since they are dependent on 
interactions present in the literature there will be a bias as to which processes are most 
represented in the data, predominantly due to the presence of a small set of highly focused 
epistatic interaction datasets. The so-called EMAP (epistatic mini-array profiling) studies 
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performed in the Weissman laboratory at the University of California, San Francisco, 
involve pre-selecting genes on the basis of previously known annotations and localizations 
and establishing positive and negative epistatic interaction within this restricted list of 
genes (Schuldiner, Collins et al. 2005). For instance the relative fitness of double mutants 
of all genes that have been annotated to the early secretory pathway as well as those that 
have been localized to structures associated with it, were measured and epistatic 
relationships established within this subset of the genome. The same analysis has been 
performed on: RNA processing genes (Wilmes, Bergkessel et al. 2008); chromatin 
function (Schuldiner, Collins et al. 2006); protein kinases and phosphatases (Fiedler, 
Braberg et al. 2009); and the early secretory pathway (Schuldiner, Collins et al. 2005) 
therefore the literature has an over-representation of the interactions in which these genes 
partake. While there is a program underway to delineate these interactions on a genome-
wide basis (Costanzo, Baryshnikova et al. 2010), it is yet to be completed, therefore a 
significant proportion of the genome is under-represented in the genetic interaction 
databases.  
 
The network analysis presented here is of a pilot nature, further refinements would include 
a way of correcting for the over/under representation of genetic interactions analysis of the 
identified sub-networks due to literature biases. Also, this analysis only takes into account 
interaction data in the literature, the deletion set has been used in conjunction with 
numerous phenotypic assays, to identify genes contributing to these phenotypes. For 
instance gene deletion impact on: glycogen levels (Wilson, Wang et al. 2002), ncRNA 
abundance , basal unfolded protein levels (Jonikas, Collins et al. 2009); cell size and shape 
(Giaever, Chu et al. 2002; Jorgensen, Nishikawa et al. 2002; Zhang, Schneider et al. 2002); 
lipid droplet number and size (Fei, Alfaro et al. 2008); CPY export (Bonangelino, Chavez 
et al. 2003); and type II intron splicing (Luban, Beutel et al. 2005) has been assessed for 
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most of the non-essential yeast deletion library. The inclusion of these gene deletion 
attributes may allow another level of grouping of chemogenomic data based on shared 
phenotype. Additionally there are numerous datasets identifying proteins that are 
post-translationally modified by phosphorylation, isoprenylation, ubiquitination, 
SUMOylation, glycosylation and methylation that could also been included in this analysis 
that might reveal further relationships between the hits in a chemogenomic screen. Other 
information that may be incorporated would be data pertaining to protein and mRNA 
abundance, half-life or stability, as well as mRNA 5` and 3` UTR structure (which may be 
particularly illuminating in the case of pateamine with its verified effect on eIF4A 
activity). This type of analysis is most likely beyond a simple network density analysis 
presented here, but would take into account the deletion phenotypes, post-translation 
modifications and protein and mRNA characteristics listed, as node attributes which could 
be analyzed in a similar way as GO term annotation, or in combination with it. 
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4.6 Conclusions 
The motivation behind this work was to identify possible targets of pateamine in yeast 
other than eIF4A. The yeast genome encodes 25 DEAD-box helicase enzymes that share a 
significant degree of homology with eIF4A, therefore the distinct possibility that one or 
more of these may represent potential non-eIF4A targets for pateamine. The use of the 
homozygous and heterozygous deletion libraries has failed to clearly discern whether any 
of these, or in fact any other gene products are targeted by pateamine. This could be 
explained in a number of ways: 1. The close relationship between the pathways and 
processes in which the DEAD-box helicase enzymes function makes it difficult to 
disentangle the effect on one system or process from another; 2. The poor performance of 
these assays in discerning similarities in the response of yeast to protein synthesis 
inhibition by chemical agents; 3. The paucity of data derived from the use of chemical or 
genetic perturbation of each process in which a DEAD-box helicase plays a role. 
 
The ambiguity in the data caused by the intimate link between ribosome biogenesis and 
translation can be cleared experimentally in a number of ways, the most obvious of which 
would be an assay of the ATPase activity of Fal1p in the presence of pateamine, which 
would establish whether it is able to interact with pateamine in vitro, also the pateamine 
resistance conferring mutation identified in eIF4A in the previous chapter could be 
incorporated into FAL1 and this strain tested for resistance to pateamine. The same 
mutation in eIF4A could be incorporated into the deletion set and the haploid screen 
performed again, any gene deletions related to eIF4A functions would not be sensitive in 
this screen and any resulting hits should be directly related to Fal1p, or any other 
secondary target. In conclusion, it cannot be definitively stated whether pateamine only 
targets eIF4A in yeast, however it is clear its effects are centered on one or more aspects of 
translation, ribosome biogenesis or RNA metabolism and are distinct from other putative 
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targets, including actin, tubulin. Similarly there is little obvious evidence from the screen 
performed for the role of the inhibition of DNA polymerases, despite the lack of a 
chemogenomic profile corresponding to this condition it would expected that a 
considerable number of non-essential genes involved in DNA replication would sensitize 
to pateamine if DNA polymerase was targeted. 
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5 Discussion 
 
5.1 Pateamine targets the eIF4A helicase family in mammalian cell 
lines 
Pateamine is a potent inducer of mammalian apoptosis in a variety of mammalian cell lines 
(Hood, West et al. 2001), the initial affinity chromatographic approach to identifying the 
targets of pateamine in these cell line was undertaken, by and large, for reasons of ease. 
The existence of the reactive primary amine group afforded a simple means by which to 
conjugate pateamine to a solid phase support, additionally there was ample evidence to 
suggest that derivatisation at this position was tolerated in terms of biological activity 
(Romo, Rzasa et al. 1998; Romo, Choi et al. 2004). This lead to the identification of three, 
high abundance proteins that specifically interact with the pateamine affinity resin, two of 
which (β-tubulin and actin) are well characterized targets of numerous natural products and 
synthetic agents that are also known to induce apoptosis in mammalian cell lines and hence 
were possible targets (Jordan and Wilson 2004; Rao and Li 2004). The third protein, 
eIF4A, was at the time, an unknown target for any drug studied at that time, however, 
evidence from the Pelletier group at McGill University suggested that pateamine was able 
to specifically inhibit cap-dependent translation initiation in vitro so therefore may be the 
target process of pateamine.  
 
Subsequently two classes of compounds have been shown to target the eIF4A family of 
proteins. One series, known as the hippuristanols, isolated from the gorgonian Isis hippuris 
(Higa, Tanaka et al. 1981), have been shown to inhibit eIF4AI, II and III ATP hydrolysis 
activity in vitro, by preventing them from binding RNA, at least in the case of murine 
eIF4AI (Lindqvist, Oberer et al. 2008). The other class is the cyclopenta[b]benzofuran 
flavaglines, of which silvestrol is a representative member, was also shown to inhibit cap-
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dependent translation in vitro, and increase the RNA binding activity of eIF4A in both its 
free form, and as a part of the eIF4F complex (Bordeleau, Robert et al. 2008; Cencic, 
Carrier et al. 2009). 
 
The results of the affinity chromatography experiments suggested that the interaction 
between eIF4A and the pateamine affinity resin was either covalent or at least of higher 
affinity than that of β-tubulin and actin, as its binding was largely insensitive to a high salt 
wash and only able to be disrupted under strong denaturing, basic and reducing conditions, 
which would be harsh enough to reverse a possible conjugate addition reaction. 
Additionally, the in vitro polymerization assays with bovine microtubules and rabbit 
muscle microfilaments showed that the concentration of pateamine required to affect 
polymerization far exceeded those of other agents known to target these structures (Jordan, 
Toso et al. 1993; Bollag, McQueney et al. 1995; Hood, West et al. 2002; Usui, Kazami et 
al. 2004). The retention of eIF4AIII, which is of considerably lower cellular abundance 
that the eIF4AI or II isoforms, by the pateamine resin also suggests that this is a high 
affinity, specific interaction. 
 
It has been shown that pateamine is able to inhibit mammalian protein synthesis in vivo at 
concentrations directly comparable to those that induce apoptosis, and that this occurs by 
specifically targeting the initiation step, shown by an absence of polysome formation upon 
pateamine treatment (Bordeleau, Matthews et al. 2005; Low, Dang et al. 2005). These 
studies also showed that, unlike the hippuristanols, pateamine stimulates the helicase 
activity of murine eIF4AI, increases RNA binding, abrogates the requirement of ATP 
binding for RNA binding, increases ATP binding and hydrolysis of murine eIF4AI in a 
RNA-dependent manner. The increase in RNA binding effect of pateamine only manifests 
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in free eIF4AI, that is not when it is a part of the eIF4F complex, in contrast to silvestrol 
that is able to increase RNA binding by eIF4A when it is also a part of the eIF4F complex 
(Cencic, Carrier et al. 2009). Confirmation of the eIF4AI1-specific nature of these effects 
was shown by the lack of inhibition of an in vitro splicing reaction, which involves 
numerous, non-eIF4AI, DEAD-box RNA helicases. The absence of an effect on the related 
yeast DEAD-box helicase, Ded1p, in an in vitro helicase activity and a lack of an effect on 
prokaryotic translation in a cell free bacterial translation system also provides strong 
evidence for the specificity of pateamine for eIF4A (Bordeleau, Matthews et al. 2005). 
 
Confirmation of the physical interaction between eIF4AI and pateamine was shown by an 
independent group with biotinylated-pateamine, derivatized at the same position we 
presume coupling to the epoxy-Sepharose resin occurs at (Figure 2.2), whereas an inactive 
analogue failed to recover eIF4AI from a cell lysate (Low, Dang et al. 2005). The same 
group showed that over-expression of eIF4AI afforded modest resistance to the growth 
inhibitory effect of pateamine in vivo, however they also suggested that pateamine 
stabilized the interaction between eIF4AI and eIF4B, a proposition that has since been 
disputed as it was shown that this observed increase in binding is dependent on the 
presence of RNA and is therefore probably a consequence of pateamine’s ability to 
increase the eIF4AI-RNA interaction (Bordeleau, Cencic et al. 2006). This work has lead 
to the development of a model whereby pateamine causes unscheduled loading of eIF4AI 
onto mRNA in a manner independent of the eIF4G scaffolding protein which is normally 
responsible for eIF4AI being recruited to mRNA. While some reviewers suggest pateamine 
disrupts eIF4F complex function by weakening the interaction between eIF4A and eIF4G 
(Schneider-Poetsch, Usui et al. 2010), this is potentially a misleading statement given there 
is evidence that this interaction is not inhibited directly by pateamine (Bordeleau, Cencic et 
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al. 2006), thus this so-called weakening is most probably a result of the stabilization of 
eIF4A on mRNA sequestering it from taking part in the eIF4F complex. 
 
Pateamine has also been shown to induce the formation of stress granules in mammalian 
cells. The use of biotinylated-pateamine, a derivative that retains biological activity, 
allowed visualization of a punctate cellular distribution that prompted the authors to 
investigate whether eIF4A was localized to stress granules formed by arsenite (Low, Dang 
et al. 2005). Arsenite treatment leads to phosphorylation of eIF2α, which attenuates 
translation initiation and causes a ribonuleoprotein complex known as a stress granule to 
form. These stress granules contain numerous translation initiation factors, RNA binding 
proteins and mRNA and are thought to act as a triage complex, allowing the storage of 
mRNA that is made available for translation after alleviation of the encountered stress 
(Anderson and Kedersha 2006). Unlike previous conditions in which the phosphorylation 
of eIF2α is required for the formation of the stress granules, pateamine treatment did not 
cause the phosphorylation and cells expressing mutant eIF2α that is unable to be 
phosphorylated still formed stress granules upon treatment. In light of pateamine’s ability 
to enhance the interaction between eIF4A and RNA it has been proposed these stress 
granules form as a direct consequence of this enhancement rather than because of its ability 
to inhibit protein synthesis, thus circumventing the requirement for eIF2α phosphorylation 
(Dang, Kedersha et al. 2006).  
 
Co-treatment of cells with pateamine and cycloheximide prevents stress granule formation, 
a phenomena seen with stress granules formed due to arsenite treatment. Cycloheximide 
inhibits stress granule formation by sequestering components essential for their formation 
in polysomes by virtue of its ability to stabilize translating ribosomes on mRNA (Anderson 
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and Kedersha 2008). One interesting characteristic of pateamine-induced stress granules is 
that they are not resolved upon withdrawal of pateamine, however they do dissipate after 
treatment with cycloheximide, suggesting a continuation of dynamic exchange of 
components of the stress granule between itself and polysomes. Though it is not 
immediately obvious why they would resolve only upon cycloheximide treatment 
following pateamine treatment and not simply upon the withdrawal of pateamine, it must 
be noted the authors monitored the TIA-1 component of the stress granules in these 
experiments and not eIF4A, therefore it is possible that it remains bound to mRNA even 
upon cycloheximide treatment and it is the dynamic nature of the other stress granule 
components that cause their dissipation.  
 
The initial affinity chromatographic recovery of eIF4AIII (Bordeleau, Matthews et al. 
2005) was confirmed by an independent group, who also showed that pateamine is able to 
inhibit non-sense mediated mRNA decay in vivo independent of its affect on eIF4AI and 
translation initiation (Dang, Low et al. 2009). In contrast to the stabilization of eIF4AI on 
mRNA previously characterized, which occurs exclusively with the free form of the 
protein when it is not part of the eIF4F complex, in vitro at least, pateamine was shown to 
stabilize the entire EJC complex on premature termination codon (PTC) containing 
transcripts, in a manner independent of the phosphorylation of Upf1, the factor normally 
responsible for the stabilization of this complex on mRNA transcripts that contain a PTC 
(Page, Carr et al. 1999; Ohnishi, Yamashita et al. 2003; Kashima, Yamashita et al. 2006). 
 
In contrast to the compelling evidence for the targeting of the eIF4A family of proteins in 
mammalian cells, little evidence exists to suggest that it may also target actin or tubulin in 
cells at concentrations required to induce apoptosis. While both of these proteins were 
180 
 
isolated from all three cell lines during the affinity chromatography experiments the effect 
of pateamine on their function in vitro was weak, additionally these protein were not 
isolated by biotinylated-pateamine (Low, Dang et al. 2005). While the polymerization of 
each was perturbed by pateamine, the concentrations required to observe an effect far 
exceeded those of known inhibitors, such as taxol, cytochalasin and latrunculin especially 
taking into account the potency of pateamine in inducing apoptosis in these cell lines 
(Hood, West et al. 2001; Hood 2002). In short it is unlikely that if there is an effect on 
either of these targets by pateamine in vivo or that it contributes significantly to the cell 
death process, though it is possible their function may be perturbed at very high 
concentrations of pateamine, a possible risk for high concentration, short-term bioactivity 
assays. Another group has suggested that pateamine is able to inhibit DNA synthesis in 
vivo, more specifically they found inhibitory effects of pateamine against DNA 
polymerases α and γ but not β in an in vitro cell free assay (Kuznetsov, Xu et al. 2009). 
There was no evidence from the affinity chromatography experiments presented here that 
pateamine was able to recover any DNA helicase enzymes from any of the cell lines used.  
 
5.2 Pateamine targets yeast eIF4A 
The generation and characterization of drug resistant mutants in S. cerevisiae has proven 
hugely successful in the past in identifying drug targets. In this respect the characterization 
of a pateamine resistance-conferring mutation that occurs in the yeast eIF4A encoding 
gene TIF1, adds further weight to the argument that pateamine targets the eIF4A family of 
proteins in both yeast and mammalian cell lines, as does the stimulatory effect of 
pateamine on Tif1p ATP hydrolysis observed in vitro (Low, Dang et al. 2007). Consistent 
with this is the inhibitory effect of pateamine on radiolabeled amino acid incorporation at 
concentrations that were directly comparable to those that inhibit growth. However, 
pateamine also appears to inhibit radiolabeled uridine incorporation in yeast at 
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concentrations much closer to those that are growth inhibitory compared to mammalian 
cell lines where, in one study, a significant effect on uridine incorporation was not 
observed at concentrations ~1000-fold higher than those that induce apoptosis (Bordeleau, 
Matthews et al. 2005), and in another study an effect was seen at ~50-fold higher 
concentrations (Low, Dang et al. 2005). 
 
While it is well established that inhibition of protein synthesis in yeast, via chemical or 
genetic means, results in a decrease in uridine incorporation (Foury and Goffeau 1973; 
Gross and Pogo 1974; Gross and Pogo 1976; Gross and Pogo 1976), the concentration at 
which the latter effect manifests with pateamine is much closer to that which inhibits 
leucine incorporation, compared to the respective effective cycloheximide concentrations. 
It is possible that this indicates an effect of pateamine on Fal1p, and that there exists a 
mechanism by which defects in rRNA processing feedback to inhibit transcription, 
especially of RNA polymerase I which is responsible for the production of the 35S pre-
rRNA (Michels and Hernandez 2006). However, without a direct assessment of the effect 
of pateamine on Fal1p in vitro, and the in vivo effect on pre-rRNA processing this cannot 
be resolved. The use of the pateamine resistant eIF4A allele described above would allow 
an assessment of the in vivo effects on rRNA processing in the absence of an effect on 
protein synthesis. 
 
The P147L point mutation in TIF1 that confers pateamine resistance strongly suggests that 
eIF4A is the primary pateamine target in yeast, however it may also indicate the position of 
its binding site. The sequence surrounding this point mutation is highly conserved in both 
pateamine-sensitive and insensitive DEAD-Box helicase, such as Ded1p, and therefore 
probably does not constitute the exact binding site, however taking into consideration the 
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requirements for eIF4A binding to pateamine, and the requirements for an effect on in vitro 
function of eIF4A, coupled with published crystal structures of eIF4AIII, speculation of the 
approximate position of this site is possible. It has been shown that the N-terminal lobe of 
eIF4AI is able to weakly interact with biotinylated-pateamine (Low, Dang et al. 2005) and 
that RNA is required for the binding of full length eIF4AI to biotinylated-pateamine (Low, 
Dang et al. 2007). It has also been shown that the stimulation of ATP binding of eIF4AI by 
pateamine is dependent on the presence of RNA (Bordeleau, Matthews et al. 2005) and 
that pateamine is able to stabilize the EJC complex on PTC containing transcripts (Dang, 
Low et al. 2009).  
 
All of these observations suggest that the full pateamine binding site may not exist on 
eIF4A when it is not bound to RNA, it is reasonable to propose that the binding site of 
pateamine exists on a surface of the protein that changes conformation upon binding to 
RNA. Given the publication of the crystal structure of the EJC, in which eIF4AIII is bound 
to RNA (Bono, Ebert et al. 2006), a comparison of the RNA bound and apo crystal 
structures may reveal this site, and that the amino acid sequence of this site should not be 
conserved in pateamine insensitive DEAD-Box helicases, furthermore it may be in close 
proximity to the amino acid analogous to P147 in Tif1p. The alignment of the sequences of 
the pateamine-sensitive eIF4As and the insensitive Ded1p reveals a motif of four amino 
acids in the N-terminal lobe of eIF4A that is not present in Ded1p, furthermore this HACI 
motif is within 15 Å of P164, the Tif1p P147 analogous amino acid in eIF4AIII, and is 
exposed on the surface of the protein. Analysis of the amino acid sequences that differ in 
position between the apo and RNA bound eIF4AIII crystal structures shows that one of 
these areas immediately precedes the HACI motif. Furthermore, the site is positioned such 
that pateamine bound at this motif could interact with the RNA, for example through an 
ionic interaction between the protonated tertiary amino group at the end of the extended 
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conjugated side arm of pateamine and the phosphate backbone of the RNA. Such an 
interaction would stabilize the binding considerably and, by making RNA part of the 
binding site, would be consistent with the observations of low affinity to eIF4A in the 
absence of RNA, especially the N-terminal lobe. 
 
The presence of a cysteine residue in the HACI sequence, that is also within 15 Å of the 
resistance-conferring point mutation, that is conserved in pateamine-sensitive but not 
insensitive DEAD-box helicases, coupled with the requirement of reducing conditions for 
the elution of human eIF4A from the pateamine affinity resin, and the presence of a 
conjugated diene in pateamine capable of acting as a site for Michael-type addition raises 
the possibility that a covalent adduct may be formed between pateamine and eIF4A. This 
might explain the significantly increased recovery time from pateamine treatment in yeast 
compared to cycloheximide, the irreversible inhibitory effect on protein synthesis and 
stress granule formation, and the irreversible induction of apoptosis in mammalian cell 
lines. Although it could be argued that this is simply the result of a particularly high 
affinity interaction between eIF4A and pateamine, the possibility for a formation of a 
covalent adduct exists and warrants further investigation. 
 
5.3 Functional specificity of pateamine 
Through chemogenomic screens performed it was hoped an appreciation of all of the 
cellular effects of pateamine in yeast would be revealed. What was clear from these results 
was that the effect of pateamine is influenced by the deletion of genes involved in multiple 
facets of RNA metabolism, with the exclusion of results that would suggest a direct effect 
on either actin or tubulin cytoskeletal components or DNA polymerase. 
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While there is clear evidence for the targeting of human and murine eIF4AI/II and 
eIF4AIII and yeast eIF4A by pateamine both in vitro and in vivo, its effect, if any, on Fal1p 
remains to be resolved. The level of homology between Fal1p and the other eIF4A family 
members suggests that it too could be targeted, however the chemogenomic screens 
performed in order to address this failed to provide a clear result. The lack of 
haploinsufficiency of the Δfal1 heterozygote in the presence of pateamine, and the lack of 
any significant functional enrichment of deletions involved in ribosome biogenesis in the 
homozygous deletion screens may suggest it is not a target, however in both the 
heterozygous and homozygous screens there was clearly significant enrichment of 
numerous processes surrounding RNA metabolism. It is possible to imagine an aggravating 
effect of simultaneously inhibiting Fal1p with pateamine and compromised RNA 
metabolism; however it is equally easy to imagine this would also be aggravating with an 
inhibition of translation initiation.  
 
Finally, if a covalent adduct is actually formed between eIF4A and pateamine it might be 
expected that Fal1p is not a target given it has an isoleucine rather than the cysteine residue 
conserved in pateamine sensitive eIF4A isoforms and putatively proposed as a site for 
pateamine covalent modification of the eIF4As. The question of pateamine targeting Fal1p 
may be resolved by investigating whether rRNA processing is perturbed in the strains 
bearing the pateamine resistant form of eIF4A, and whether the introduction of the 
pateamine resistance conferring mutation adds to the resistance seen with the resistant 
eIF4A mutant. Unfortunately attempts to develop an assay for rRNA processing 
undertaken during this work were unsuccessful (data not shown). 
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Prp5p is another DEAD-Box helicase which could act as a target for pateamine given its 
homology to the eIF4A family and the presence of the conserved cysteine seen in 
pateamine sensitive eIF4As. Although the heterozygous deletion of this gene was not 
haploinsufficient in the presence of pateamine, the chemogenomic screen results, as in the 
case of an effect on Fal1p, fail to clearly implicate or absolve Prp5p in mediating the 
inhibitory effect of pateamine in yeast. Though given the overwhelming amount of 
evidence regarding the targeting of eIF4A, any effect on Prp5p, or indeed any other target, 
would likely be masked by the effect on eIF4A and translation initiation. 
 
5.4 Pateamine and apoptosis 
Pateamine was discovered by virtue of its cytotoxicity towards a murine leukemic cell line 
(Northcote, Blunt et al. 1991), further studies have shown that this cytotoxicity is due to 
the induction of apoptosis (Hood, West et al. 2001) that occurs via the intrinsic apoptotic 
pathway involving the induction of caspase 9 (Miller, Rouwe et al. 2004), and this work 
has shown it depends on caspase 3/7 induction. There are a number of potential scenarios 
for the induction of apoptosis by pateamine: 1. Inhibition of protein synthesis via the 
stabilization of eIF4AI/II on mRNA; 2. Inhibition of NMD by the stabilization of the EJC 
on mRNA; 3. A synergistic combination of both; 4. A response to the presence of these 
stabilized RNP complexes that is independent of or synergistic with the inhibitory effects 
on either pathway.  
 
The role of protein synthesis in apoptosis remains controversial. While a number of protein 
synthesis inhibitors are known to induce apoptosis it has been shown that, depending on 
the manner in which apoptosis is induced, some of these inhibitors actually inhibit 
apoptosis. Also the protein synthesis inhibitor didemnin B, which targets eEF1α, rapidly 
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induces apoptosis but the inhibition of protein synthesis is not required for this induction. It 
has been suggested that the inhibition of protein synthesis may induce apoptosis by 
decreasing the pool of ubiquitin available, as occurs in yeast treated with anisomycin or 
cycloheximide (Hanna, Leggett et al. 2003). Other unstable proteins have been implicated 
in the induction of apoptosis by protein synthesis inhibitors in mammalian cell lines, for 
instance Mcl-1 levels have been shown to rapidly decrease after treatment with the protein 
synthesis inhibitors silvestrol (Cencic, Carrier et al. 2010), lycorine (Liu, Jiang et al. 2009), 
homoharringtonine (Tang, Faussat et al. 2006) and cycloheximide (Adams and Cooper 
2007). Mcl-1 is an anti-apoptotic member of the Bcl-2 family of proteins (Gross, 
McDonnell et al. 1999). When its intracellular levels decrease the pro-apoptotic Bcl-2 
family members Bik and Bax are activated (Adams and Cooper 2007), which leads to 
mitochrondrial membrane permeabilisation, release of cytochrome C and activation of 
caspase 9 (Gross, McDonnell et al. 1999).  
 
 A complication to the mechanism proposed above in the case of pateamine is that a 
number of anti-apoptotic proteins arise from transcripts that contain an IRES, which 
according to previous studies would still be translated in the presence of pateamine 
(Bordeleau, Matthews et al. 2005; Low, Dang et al. 2005). Furthermore the simultaneous 
knockdown of eIF4AI and II with siRNA does not seem to induce cell death (Ferraiuolo, 
Lee et al. 2004), arguing that the simultaneous inhibition of eIF4AIII is also required for 
apoptosis induction. However silvestrol, which also targets eIF4A, has been shown to 
reduce Mcl-1 levels and therefore it is presumed that pateamine would as well (Cencic, 
Carrier et al. 2010). 
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The role of NMD in apoptosis is not clear, it is presumed that NMD functions to prevent 
the production of truncated, partially functional protein products that could prove to be 
deleterious in a dominant-negative manner and hence possibly cause cell death. This falls 
in line with the observation that depleting eIF4AIII levels by siRNA causes cell death, 
therefore it is possible that pateamine induced inhibition of this process may cause cell 
death. However, while pateamine may stabilize mRNA containing PTCs these transcripts 
cannot be translated, since translation initiation would also be inhibited. Even in the case of 
IRES-controlled transcripts that contain a PTC it is unclear whether they will be translated 
since the ribosome would probably not be able to displace the pateamine-stabilized EJC 
that occurs at every exon-exon junction, although this is somewhat speculative, as the 
study that showed pateamine to inhibit NMD only measured transcript abundance and not 
their translation (Dang, Low et al. 2009). In that study, while they used IRES-controlled 
NMD reporter constructs they did not measure their translation, and while they validated 
the insensitivity of the IRES to pateamine it was done with a luciferase reporter that did not 
contain introns.  
 
This argues that while simultaneous inhibition of translation initiation and NMD occurs in 
the presence of pateamine, the consequence to the cell may be independent of the result of 
the inhibition of NMD, which would be the production of potentially dominant-negative 
truncated protein products. So, unless a system exists within the cell to detect NMD 
inhibition independent of the production of truncated proteins, no synergy would occur due 
to the simultaneous inhibition of both processes. The question of whether IRES-containing 
transcripts that also contain introns are actually translated in the presence of pateamine 
cannot be answered as each assay that has shown insensitivity of IRES controlled 
transcript translation has used intron-less reporter genes (Bordeleau, Matthews et al. 2005; 
Low, Dang et al. 2005). The incorporation of the pateamine resistance-conferring mutation 
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into eIF4AI and II in mammalian cells in combination with the same mutation in eIF4AIII 
would allow the relative contribution of the inhibition of each of translation inhibition and 
NMD to the induction of apoptosis by pateamine to be assessed. 
 
5.5 Models of pateamine action 
The in vitro stimulatory effect of pateamine on the RNA binding and ATP hydrolysis 
activities of eIF4A could be modeled in two ways:  
 
1. Pateamine locks eIF4A in a confirmation that allows the binding of ATP, its hydrolysis 
and the subsequent release of ADP, but prevents the release of RNA. In this model either 
pateamine first interacts with eIF4A which then binds RNA, or, more likely, pateamine 
binds to eIF4A once it is bound to RNA, and locks both lobes onto RNA while still 
allowing the intra-molecular movement required to bind ATP, hydrolyze it and release 
ADP, allowing another ATP molecule to bind (Figure 5.1). The implication of this model 
is that pateamine is able to stabilize the RNA interaction of both lobes of eIF4A which 
would require direct contact between pateamine and both lobes directly, or indirectly via a 
strong interaction with the RNA substrate. 
 
189 
 
 
Figure 5.1 Pateamine mechanism model 1: Pateamine locks eIF4A onto RNA in a way that 
allows ATP hydrolysis and ADP release. A red cross indicates pateamine binding. 
 
2. Alternatively, pateamine may interact with the N-terminal lobe of eIF4A first, which 
raises its affinity for RNA, ATP binding would occur in concert with the C-terminal lobe 
making contact with the RNA. Once hydrolyzed the C-terminal lobe may lose contact with 
the RNA allowing another ATP molecule to bind, while the N-terminal lobe remains 
bound, possibly due to the direct interaction of pateamine and RNA for instance. The 
newly bound ATP would be hydrolyzed; the energy produced causing the C-terminal to 
lose contact again and the release of ADP (Figure 5.2). This model implies that the 
interaction between the N-terminal eIF4A and RNA is very stable, and does not change 
due to the energy released by ATP hydrolysis. Both models suggest that the increase in 
RNA helicase activity caused by pateamine is due to the increase in RNA binding and the 
uncoupling of RNA release from ATP hydrolysis, as of yet there no evidence that allow 
discrimination between these two models. 
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Figure 5.2 Pateamine mechanism 2: Pateamine stabilizes the interaction between the N-terminal 
lobe of eIF4A and RNA. A red cross indicates pateamine binding. 
 
The order of binding of pateamine, RNA and ATP by eIF4A is currently unclear. Given 
the ATP binding site exists between both lobes (Pause and Sonenberg 1992) and that in 
vitro eIF4A has higher affinity for RNA than it does ATP (Lorsch and Herschlag 1998), it 
is likely that RNA is bound first. Given the weak binding of the N-terminal lobe to 
pateamine it is possible that pateamine binds after, or even co-operatively with RNA. The 
potential for an interaction between RNA and pateamine exists due to the proximity of the 
P147L pateamine resistance-conferring mutation in yeast Tif1p, to the RNA binding site of 
the N-terminal lobe, this interaction may be mediated by the tertiary amine at C17 of the 
trienyl tail of pateamine, given the primary amine at C3 can be removed without a loss of 
activity (Romo, Choi et al. 2004; Low, Dang et al. 2005). 
 
It has been proposed in vivo that pateamine circumvents the requirement of eIF4G for 
eIF4A recruitment to mRNA, in direct parallel to the suggested in vitro mechanisms, and 
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the stabilization of the eIF4A-RNA interaction causes stress granule formation by 
simultaneously inhibiting translation initiation and providing a starting point for the rest of 
the granule to form. This was suggested due to the observation that RNA and ATP binding 
by eIF4A is not increased when it is a part of the eIF4F complex (Bordeleau, Cencic et al. 
2006), though it is of note that this was done with purified eIF4F complex which contains 
at the most a two-fold increase in the amount of eIF4A relative to eIF4G and eIF4E, 
whereas in yeast, eIF4A exists in vivo at approximately 40-fold the level of eIF4GI (von 
der Haar and McCarthy 2002) and at least five-fold the level of eIF4G in HeLa cells 
(Duncan and Hershey 1983; Duncan, Milburn et al. 1987). Also of note is that there is 
much more RNA relative to the amount of eIF4A in the in vitro assays performed 
compared to in vivo, where the relative concentrations of mRNA will be significantly 
lower. In order for pateamine to cause eIF4A to be loaded onto mRNA independent of 
eIF4G, eIF4A must either interact with mRNA at some level, independent of eIF4G 
recruitment, or pateamine must bind to eIF4A first and drastically increase its affinity for 
mRNA. These mechanistic details are yet to be elucidated fully. 
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5.6 Conclusions 
The work presented here, in combination with studies by other groups, has shown that 
pateamine specifically targets the eIF4A family of proteins, resulting in the inhibition of 
protein synthesis in yeast and mammalian cells, and non-sense mediated decay in 
mammalian cells. While the targeting of other proteins has been implicated, it is clear that 
the primary target of pateamine is the eIF4A family of proteins, and hence it is the first 
compound known to specifically and directly inhibit translation initiation and non-sense 
mediated decay. While it is unclear whether inhibiting non-sense mediated decay by 
stabilizing the interaction of the exon-exon junction complex on mRNA would produce a 
cellular consequence, the mechanism by which pateamine induces apoptosis likely 
involves the decrease of the anti-apoptotic protein Mcl-1. The generation of a 
pateamine-resistant form of eIF4A through random mutagenesis has allowed the 
speculation of an approximate binding site for pateamine on the N-terminal lobe of eIF4A, 
close to the RNA binding site. It also raises the possibilities of the formation of a covalent 
adduct between pateamine and eIF4A, and a direct interaction between RNA and 
pateamine. Regardless of the mechanistic details, pateamine has proven to be the first 
compound able to stabilize the interaction between a protein target and RNA. Further 
investigation is required to establish whether the related yeast protein, Fal1p, is targeted by 
pateamine, if so it will also be the first compound able to directly impair rRNA processing. 
If Fal1p is truly not a target it places pateamine in the position to become an invaluable 
reagent for studying eIF4A activity in yeast, allowing chemical access to a proteins’ 
function that has been challenging to access genetically due to its redundant encoding by 
duplicate genes. The study presented here provides the groundwork for the further 
development of pateamine as a specific biological probe of eIF4A.  
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6 Appendix A 
 
Figure 6.1 Replicate MTT assay dose response curves for HeLa, SH-SY5Y, and HL-60 cell 
lines. Each point is the average of triplicate samples, with error bars as standard deviation. 
 
 
194 
 
 
Figure 6.2 Mass spectra close-up images. A. Mass spectrum obtained for gel band one isolated 
from HeLa cell lysate; B. Close up indicating the presence of peptides specific to different isotypes 
of β-tubulin 
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Figure 6.3 Close up of spectrum acquired from gel band two. Isolated from the HeLa cell 
lysate, indicated are peptides specific to eIF4A1, 2 and 3. 
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Figure 6.4 Mass spectrum acquired from gel band three. Isolated from the HeLa cell lysate, 
indicated peptides are common to both β and γ actin. 
 
 
Figure 6.5 LDS-PAGE of purified bovine tubulin. 
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Figure 6.6 Multiple amino acid sequence alignment of actin. Human β actin (ACTB), γ actin 
(ACTG) and rabbit α actin (ACTS). 
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7 Appendix B 
 
 
Figure 7.1 Replicate tritiated leucine and tritiated uridine incorporation dose-response 
curves. Each data point is the average of three replicates and standard deviation as error bars. 
  
Leucine 
incorporation 
Replicate 
1 
Replicate 
2 
Replicate 
3 
Mean 
EC50 (µM) 4.55 4.39 4.36 4.43 
Standard error 0.37 0.50 0.91 0.59 
Uridine 
incorporation 
        
EC50 (µM) 8.90 8.32 8.85 8.69 
Standard error 0.62 1.06 0.96 0.88 
Table 7.1 Summary statistics for leucine and uridine incorporation assays. EC50 values 
defined for the three independent leucine and uridine incorporation assays (Figure 3.10 and Figure 
7.1) 
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Figure 7.2 TPG and TLG sequences are able to assume the same conformation. Yeast eIF4A 
(yellow, pdb: 1FUU) TPG motif was aligned with TLG sequences from beta-purothionin (Blue, pdb: 
1BHP) and [NiFe] hydrogenase from Desulfovibrio desulfuricans (Green, pdb: 1E3D). 
 
 
Figure 7.3 Conformational differences in RNA bound and apo structures. TPG (left) and HACI 
(right) motif conformational differences in the RNA bound (magenta) and apo crystal structures of 
eIF4AIII (green and cyan). Only the side chains for P164 and C124 are shown. 
 
  
200 
 
8 Appendix C 
 
  HIP 
Screen 1 
HIP 
Screen 2 
HIP 
Screen 3 
HIP 
Screen 4 
HIP 
Screen 1 
1 0.74996 0.8505 0.82568 
HIP 
Screen 2 
0.63349 1 0.66916 0.7096 
HIP 
Screen 3 
0.6762 0.4773 1 0.89838 
HIP 
Screen 4 
0.60713 0.50861 0.76653 1 
Table 8.1 Pearson correlation of heterozygous deletion set HIP screen results. Upper right: 
correlation scores of the entire datasets for each screen. Lower left: correlation scores after 
applying the log2 ratio threshold of 0.5 used to identify sensitive strains. 
 
  HIP 
Screen 1 
HIP 
Screen 2 
HIP 
Screen 3 
HIP 
Screen 4 
HIP 
Screen 1 
  0.39 0.43 0.37 
HIP 
Screen 2 
0.34   0.29 0.31 
HIP 
Screen 3 
0.22 0.2   0.56 
HIP 
Screen 4 
0.33 0.46 0.27   
Table 8.2 HIP screen overlaps in hit and GO term enrichment. Upper right: Screen replicate hit 
heterozygous gene deletion overlap measured by Jaccard distance. Lower left: Screen replicate 
GO term overlap measured by Jaccard distance. 
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Figure 8.1 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 1 
(Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HIP screens are indicated in blue. 
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Figure 8.2 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 1 
(Method 4.3.6) was clustered using the uncentered Pearsons distance metric and average 
linkage method. Pateamine HIP screens are indicated in blue. 
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Figure 8.3 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 2 
(Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HIP screens are indicated in blue. 
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Figure 8.4 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 2 
(Method 4.3.6) was clustered using the uncentered Pearsons distance metric and average 
linkage method. Pateamine HIP screens are indicated in blue. 
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Figure 8.5 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 3 
(Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HIP screens are indicated in blue. 
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Figure 8.6 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 3 
(Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HIP screens are indicated in blue. 
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Figure 8.7 Complete clustergram resulting from the hierarchical clustering of pateamine HIP 
screens with the essential heterozygous screen data from Hillenmeyer et al 2008. Dataset 4 
(Method 4.3.6) was clustered using the Jaccard distance metric and average linkage method. 
Pateamine HIP screens are indicated in blue. 
 
 
  HOP 
Screen 1 
HOP 
Screen 2 
HOP 
Screen 3 
HOP 
Screen 4 
HOP 
Screen 1 
1 0.34 0.59 0.47 
HOP 
Screen 2 
0.17 1 0.07 0.27 
HOP 
Screen 3 
0.38 -0.05 1 0.67 
HOP 
Screen 4 
0.34 0.17 0.55 1 
Table 8.3 Pearson correlation of homozygous deletion set HOP screen results. Upper right: 
correlation scores of the entire datasets for each screen. Lower left: correlation after applying the 
log2 ratio threshold of 0.5 used to identify sensitive strains. 
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Figure 8.8 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
1 (Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HOP screens are indicated in blue. 
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Figure 8.9 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
1 (Method 4.3.6) was clustered using the uncentered Pearsons distance metric and average 
linkage method. Pateamine HOP screens are indicated in blue. 
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Figure 8.10 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
2 (Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HOP screens are indicated in blue. 
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Figure 8.11 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
2 (Method 4.3.6) was clustered using the uncentered Pearsons distance metric and average 
linkage method. Pateamine HOP screens are indicated in blue. 
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Figure 8.12 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
3 (Method 4.3.6) was clustered using the centered Pearsons distance metric and average 
linkage method. Pateamine HOP screens are indicated in blue. 
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Figure 8.13 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
3 (Method 4.3.6) was clustered using the uncentered Pearsons distance metric and average 
linkage method. Pateamine HOP screens are indicated in blue. 
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Figure 8.14 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Hillenmeyer et al 2008. Dataset 
4 (Method 4.3.6) was clustered using the Jaccard distance metric and average linkage 
method. Pateamine HOP screens are indicated in blue. 
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Figure 8.15 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Parsons et al 2006. Log2 ratio 
data after the application of the described threshold (Method 4.3.6) was clustered using the 
centered Pearsons distance metric and average linkage method. Pateamine HOP screens are 
indicated by the red bar. 
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Figure 8.16 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Parsons et al 2006. Log2 ratio 
data after the application of the described threshold (Method 4.3.6) was clustered using the 
uncentered Pearsons distance metric and average linkage method. Pateamine HOP screens 
are indicated by the red bar. 
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Figure 8.17 Complete clustergram resulting from the hierarchical clustering of pateamine 
HOP screens with the homozygous diploid screen data from Parsons et al 2006. Log2 ratio 
data after the application of the described threshold (Method 4.3.6) was clustered using the 
uncentered Pearsons distance metric and average linkage method. Pateamine HOP screens 
are indicated by the red bar. 
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Figure 8.18 Pateamine hypersensitive and haploinsufficient gene deletion network. Green 
nodes correspond to pateamine screens, red nodes correspond to gene deletions that confer 
hypersensitivity or haploinsufficiency from all screen performed. 
 
 
Figure 8.19 Pateamine screen hit interaction network. This network consists of nodes 
corresponding to individual pateamine screens (green), connected to their hits, which are further 
connected to genes in the SGD database with which they interact physically or genetically. 
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Figure 8.20 Pateamine screen hit interactions with other hits. This network is the same as 
Figure 8.19 but the genes that interact with the hits, according to SGD, have been removed. The 
remaining physical and genetic interactions occur only between genes that are haploinsufficient or 
hypersensitive to pateamine in one or more of the screens performed. 
 
 
Figure 8.21 Sub-network four. Blue interactions are physical, magenta are genetic. Yellow nodes 
are MDS gene deletions; black node borders are homozygous strains sensitive to pateamine in at 
least one of the screens performed; grey node borders are heterozygous strains that display 
haploinsufficiency in the presence of pateamine. Sub-network four is enriched for numerous MAP 
kinase related terms (P < 1.1 x 10
-2
) and terms related to the unfolded protein response (P < 1.9 x 
10
-2
). 
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Figure 8.22 Sub-network five. Blue edges are physical interactions, magenta are genetic 
interactions and black are pateamine hypersensitive. Green nodes are the pateamine screens as 
labeled; Yellow nodes are MDS gene deletions; black node borders are homozygous strains 
sensitive to pateamine in at least one of the screens performed; grey node borders are 
heterozygous strains that display haploinsufficiency in the presence of pateamine. Sub-network five 
is enriched for similar terms but also vacuolar function, particularly its acidification (P < 1.8 x 10
-3
) 
and the ergosterol biosynthesis pathway (P = 3.8 x 10
-2
). 
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Figure 8.23 Sub-network six. Blue interactions are physical, magenta are genetic. Yellow nodes 
are MDS gene deletions; black node borders are homozygous strains sensitive to pateamine in at 
least one of the screens performed; grey node borders are heterozygous strains that display 
haploinsufficiency in the presence of pateamine. Sub-network six was significantly enriched for 
genes involved in RNA metabolism in part by the inclusion of three POP (Processing Of Precursor 
RNAs) genes, which, as a part of the RNase MRP and RNase P complexes, cleave pre-rRNA and 
tRNA precursors (Houser-Scott, Xiao et al. 2002).  
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Figure 8.24 Sub-network seven. Blue edges are physical interactions, magenta are genetic 
interactions and black are pateamine hypersensitive. The green node is the 16 µM pateamine 
haploid screen; Yellow nodes are MDS gene deletions; black node borders are homozygous 
strains sensitive to pateamine in at least one of the screens performed; grey node borders are 
heterozygous strains that display haploinsufficiency in the presence of pateamine. Sub-network 
seven was enriched in genes involved in transcription (P < 4.1 x 10
-3
) specifically from RNA 
polymerase II promoters (P < 4.4 x 10
-4
) and various aspects of chromosome biology, including the 
spindle (P < 2.9 x 10
-2
), the kinetochore (P = 1.5 x 10
-7
) and chromatin remodeling (P = 2.9 x 10
-3
). 
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Sub-
network 
Haploid 
Screen 
HIPHOP 
Screen 1 
HIPHOP 
Screen 2 
HIPHOP 
Screen 3 
HIPHOP 
Screen4 Total 
1 14 9 9 8 12 33 
2 15 5 1 5 4 33 
3 22 10 18 14 16 58 
4 16 6 11 14 14 40 
5 15 6 5 10 8 35 
6 15 9 8 11 8 38 
7 14 5 6 2 4 26 
8 3 3 3 7 10 21 
Table 8.4 Contribution of pateamine screen data to MCODE clusters. 
 
Figure 8.25 Synthetic lethal and negative genetic interactions present in the SGD database 
for yeast eIF4A encoding genes TIF1 and TIF2 and the closely related FAL1. Edges between 
red nodes correspond to synthetic lethal or negative genetic interactions; edges between green 
and red nodes correspond to pateamine hypersensitive homozygous diploid gene deletions in HOP 
screens 1, 3 and 4 and haploid gene deletions strains hypersensitive to 16 µM pateamine. 
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Genetic interaction type Description 
Synthetic Rescue A genetic interaction is inferred when mutations or 
deletions of one gene rescues the lethality or growth defect 
of a strain mutated or deleted for another gene. 
Positive Genetic Positive epistatic interaction, defined by genome-wide 
SGA. 
Synthetic 
Haploinsufficiency 
A genetic interaction is inferred when mutations or 
deletions in separate genes, at least one of which is 
hemizygous, cause a minimal phenotype alone but result in 
lethality when combined in the same cell under a given 
condition. 
Negative Genetic Synthetic-sick or lethal interactions, defined by genome-
wide SGA. 
Dosage Lethality A genetic interaction is inferred when over expression or 
increased dosage of one gene causes lethality in a strain that 
is mutated or deleted for another gene. 
Synthetic Lethality A genetic interaction is inferred when mutations or 
deletions in separate genes, each of which alone causes a 
minimal phenotype, result in lethality when combined in 
the same cell under a given condition. 
Phenotypic 
Enhancement 
A genetic interaction is inferred when mutation or over-
expression of one gene results in enhancement of any 
phenotype (other than lethality/growth defect) associated 
with mutation or over expression of another gene. 
Synthetic Growth Defect A genetic interaction is inferred when mutations in separate 
genes, each of which alone causes a minimal phenotype, 
result in a significant growth defect under a given condition 
when combined in the same cell. 
Dosage Rescue A genetic interaction is inferred when over-expression or 
increased dosage of one gene rescues the lethality or growth 
defect of a strain that is mutated or deleted for another gene. 
Phenotypic Suppression A genetic interaction is inferred when mutation or over-
expression of one gene results in suppression of any 
phenotype (other than lethality/growth defect) associated 
with mutation or over expression of another gene. 
Dosage Growth Defect A genetic interaction is inferred when over expression or 
increased dosage of one gene causes a growth defect in a 
strain that is mutated or deleted for another gene. 
Table 8.5 Descriptions of genetic interactions used in network analysis. Downloaded from 
The BioGRID database (http://grid.princeton.edu/help.php). 
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Physical interaction type Description 
Two-hybrid Bait protein expressed as a DNA binding domain (DBD) 
fusion and prey expressed as a transcriptional activation 
domain (TAD) fusion and interaction measured by 
reporter gene activation. 
Affinity Capture-RNA An interaction is inferred when a bait protein is affinity 
captured from cell extracts by either polyclonal antibody 
or epitope tag and associated RNA species identified by 
Northern blot, RT-PCR, affinity labeling, sequencing, or 
microarray analysis. 
PCA A protein-protein interaction assay in which a bait protein 
is expressed as fusion to one of the either N- or C- 
terminal peptide fragments of a reporter protein and prey 
protein is expressed as fusion to the complementary N- or 
C- terminal fragment of the same reporter protein. 
Interaction of bait and prey proteins bring together 
complementary fragments, which can then fold into an 
active reporter. 
Reconstituted Complex An interaction is detected between purified proteins in 
vitro. 
Affinity Capture-MS An interaction is inferred when a "bait" protein is affinity 
captured from cell extracts by either polyclonal antibody 
or epitope tag and the associated interaction partner is 
identified by mass spectrometric methods. 
Affinity Capture-Western An interaction is inferred when a Bait protein affinity 
captured from cell extracts by either polyclonal antibody 
or epitope tag and the associated interaction partner 
identified by Western blot with a specific polyclonal 
antibody or second epitope tag. This category is also used 
if an interacting protein is visualized directly by dye stain 
or radioactivity. Note that this differs from any co-
purification experiment involving affinity capture in that 
the co-purification experiment involves at least one extra 
purification step to get rid of potential contaminating 
proteins. 
Far Western An interaction is detected between a protein immobilized 
on a membrane and a purified protein probe. 
Biochemical Activity An interaction is inferred from the biochemical effect of 
one protein upon another, for example, GTP-GDP 
exchange activity or phosphorylation of a substrate by a 
kinase. The "bait" protein executes the activity on the 
substrate "hit" protein. 
Protein-peptide An interaction is detected between a protein and a peptide 
derived from an interaction partner. This includes phage 
display experiments. 
FRET An interaction is inferred when close proximity of 
interaction partners is detected by fluorescence resonance 
energy transfer between pairs of fluorophore-labeled 
molecules, such as occurs between CFP (donor) and YFP 
(acceptor) fusion proteins. 
Co-fractionation Interaction inferred from the presence of two or more 
protein subunits in a partially purified protein preparation. 
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If co-fractionation is demonstrated between 3 or more 
proteins, one is chosen as the bait and binary interactions 
are recorded between that protein and the others. 
Protein-RNA An interaction is detected between and protein and an 
RNA. 
Co-crystal Structure Interaction directly demonstrated at the atomic level by 
X-ray crystallography. Also used for NMR or Electron 
Microscopy (EM) structures. If a structure is 
demonstrated between 3 or more proteins, one is chosen 
as the bait and binary interactions are recorded between 
that protein and the others. 
Co-localization An interaction is inferred from co-localization of two 
proteins in the cell, including co-dependent association of 
proteins with promoter DNA in chromatin 
immunoprecipitation experiments. 
Co-purification An interaction is inferred from the identification of two or 
more protein subunits in a purified protein complex, as 
obtained by classical biochemical fractionation or affinity 
purification and one or more additional fractionation 
steps. 
Affinity Capture-
Luminescence 
An interaction is inferred when a bait protein, tagged with 
luciferase, is enzymatically detected in 
immunoprecipitates of the prey protein as light emission. 
The prey protein is affinity captured from cell extracts by 
either polyclonal antibody or epitope tag. 
Table 8.6 Descriptions of physical interactions used in network analysis. Downloaded from 
The BioGRID database (http://grid.princeton.edu/help.php) 
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